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Abstract
The anticancer drug cisplatin is a small inorganic molecule that forms
several types of covalent adducts on DNA. There is evidence that at least
some of the consequences of this genetic damage are mediated by proteins
that bind to the cisplatin-DNA cross-links or influence cellular pathways in
response to the genotoxic stress. In either case, such factors can regulate the
processing of the cisplatin lesions and thereby affect cellular sensitivity to the
drug. Identification of these proteins and exploration of their cellular
functions has implicated multiple systems including several classes of DNA
repair, transcription, cell cycle and cell death responses. Chapter one reviews
the current information of how components of these pathways respond to
cisplatin-DNA adducts and contribute to the cytotoxic mechanism of action.
Chapters two and three explore the capacity of one cellular defense
mechanism, the nucleotide excision repair pathway, to remove cisplatin-
DNA damage, and factors that can modulate this activity were examined.
The cisplatin intrastrand cross-links are all excised by human nucleotide
excision repair, however removal of the minor interstrand cross-link was not
detected. Experiments performed with a reconstituted system of purified
nucleotide excision components demonstrated that structural differences
among the types of cisplatin-DNA lesions affect the relative excision repair
rates. Attempts to correlate the repair capacity of human tissue with cisplatin
sensitivity were unsuccessful, however the use of several model systems
suggest that there are cellular factors that can modulate the removal of the
cisplatin-DNA adducts. Members of the HMG-domain family of proteins
specifically blocked the in vitro repair of the 1,2-intrastrand cross-links, an
effect that was observed with a single HMG-domain polypeptide, and in the
reconstituted repair assay. These results suggest that the ability of HMG-
domain proteins to recognize cisplatin-modified DNA could affect cellular
removal of the lesions, and that HMG-domain proteins with a selective
expression pattern could contribute to cisplatin sensitivity. In particular, the
testis-specific proteins tested were the most effective at inhibiting repair,
which may be relevant to the favorable clinical response of testicular tumors
to cisplatin-based chemotherapy. No repair inhibition by a mismatch repair
protein was detected, although binding to cisplatin-DNA adducts was
observed.
4Another factor that could explain the efficacy of cisplatin in treating
testicular cancer is that, unlike other human neoplasms, a low frequency of
mutations in the p53 tumor suppressor gene are observed in this tumor type.
Previous studies have investigated the relationship between p53 status and
cisplatin sensitivity, but have provided conflicting results. The p53-mediated
responses in murine testicular teratocarcinoma cells exposed to cisplatin were
examined in chapter four. Cisplatin exposure of cells with a wild-type p53
gene resulted in accumulation of p53 protein through posttranscriptional
mechanisms; induction of p53-target genes was also observed. Drug
treatment resulted in rapid apoptosis in p53-wild-type cells but not in a p53-'-
teratocarcinoma line. In the latter cells, cisplatin exposure caused prolonged
cell cycle arrest in the G1/early S phase, accompanied by induction of the p21
gene. Clonogenic assays demonstrated that the p53 mutation did not confer
resistance to cisplatin. These experiments suggest that cisplatin inhibits
cellular proliferation of testicular teratocarcinoma cells by two possible
mechanisms, p53-dependent apoptosis and p53-independent cell cycle arrest.
In the final chapter, the role of HMG-domain proteins in the
mechanism of cisplatin cytotoxicity was further investigated. A human
cervical carcinoma cell line was constructed which ectopically expressed a
testis-specific protein, tsHMG, under the control of an inducible promoter.
Examination of tsHMG, expression and cisplatin-induced apoptosis on a
cellular level revealed that the nuclear protein can modulate the cytotoxic
consequences of cisplatin. However, the effects of tsHMG depend on the drug
treatment conditions and the extent of cell death. The results may be relevant 4
to the clinical requirement of achieving a balance between the antineoplastic
and toxic properties of cisplatin. A model proposed to explain the
observations will provide a basis for future studies of cellular factors that can
affect cisplatin sensitivity, and for the design of more comprehensive
antineoplastic therapies. 4
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Chapter One
Introduction: The Responses of Cellular Proteins to Cisplatin-Damaged DNA
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Introduction (1, 2)
The chemotherapeutic agent cis-diamminedichloroplatinum(II), or
cisplatin (Figure 1.1A), can form covalent adducts with many cellular
macromolecules, but there is convincing evidence that its cytotoxic properties are
a consequence of bifunctional-DNA adduct formation (3, 4). Platinum binds to
the N(7) position of purine nucleotides (Figure 1.1B), resulting predominantly in
1,2-d(GpG) and 1,2-d(ApG) intrastrand, but also in 1,3-d(GpNpG) intrastrand,
interstrand and protein-DNA cross-links (5, 6). The 1,2-intrastrand cross-links,
which comprise 90% of the DNA adducts, are not formed by the clinically inactive
trans-DDP because of geometric constraints, and attention has therefore focused
on these adducts as the active lesions in the anticancer activity of the drug.
Numerous studies, carried out to determine how ligation of platinum
affects the conformation and stability of normal B-DNA, revealed significant
destabilization of the double helix (reviewed in 7; see also 8). More detailed
information has been provided by recent structural analyses of the 1,2-d(GpG)
intrastrand cross-link in duplex DNA (Figure 1.2), performed both by X-ray
crystallography (9, 10) and NMR spectroscopy (11-13). Although these structures
differ in some details, they all reveal that the platinum induces a roll of 260-500
between the guanine bases involved in the cross-link, displacement of platinum
from the planes of the guanine rings, and a global bend of the helix axis towards
the major groove. In addition, hydrogen-bonding within the 5'-coordinated GC
base pair is severely perturbed, resulting in enhanced solvent accessibility. The
cisplatin cross-link also unwinds the duplex and induces a widening and
flattening of the minor groove in the vicinity of the adduct. These structural
features strikingly resemble those observed in some DNA-protein complexes (14),
the consequences of which will be discussed below.
d
4
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NMR solution structures of two cisplatin-DNA decamers containing
interstrand cross-links demonstrated that this minor adduct also has characteristic
structural features (15, 16). In particular, the platinum atom lies in the minor
groove, the complementary cytosines are extrahelical, and there is a switch in the
double helix to a left-handed form localized at the site of the adduct. These
distortions bend the helix axis towards the minor groove by approximately 20*-40*
and unwind the duplex by 76*-80*. More detailed descriptions of Pt-DNA
complexes may be found in other chapters in this volume.
The unusual conformations at the sites of cisplatin-DNA adducts suggest
that they might serve as recognition elements for proteins that bind to and process
damaged DNA. Studies with cell-free extracts, designed to test this hypothesis,
demonstrated the presence of factors that bind DNA modified with cisplatin but
not trans-DDP (17-19). Concomitant gel mobility shift assays revealed the binding
activity of one of these proteins to be specific for the 1,2-intrastrand cross-links
(17). The possibility that these cisplatin-damage recognition proteins play a role in
the cytotoxic mechanism of the drug was supported by studies revealing that some
proteins in this class are overexpressed in cell lines having acquired cisplatin
resistance (19-22). In addition, several damage recognition proteins could be
induced in cultured cells exposed to cisplatin (21, 23).
The purpose of this chapter is to review the types of proteins that interact
with or respond to cisplatin-damaged DNA and to discuss how these proteins can
modulate cellular sensitivity to the drug through their participation in various
biochemical pathways (Figure 1.3). Included are proteins dedicated to dealing with
genotoxic stress, such as components of the DNA repair and p53-regulated
pathways, but also proteins affected by the DNA structural distortions induced by
cisplatin adduct formation, such as transcription factors and architectural proteins.
The manner by which such proteins affect the processing of cisplatin-DNA
20
adducts can determine whether a cell attempts to repair the damage or activates
an irreversible cell death program. These proteins most likely contribute to the
anticancer activity of this drug. Moreover, differential protein expression and
activity may explain why certain types of tumors, such as testicular, ovarian, and
head and neck, are successfully treated by cisplatin whereas others are resistant (24,
25). Because many factors are involved in the mechanisms of action and
resistance, we make no attempt to cover this field comprehensively. Topics
beyond the scope of this review include oncogene activation, replication bypass
and mutagenesis, reactions with sulfur-containing molecules, and mechanisms of
drug uptake and export (26-28).
0
DNA Repair Pathways
Nucleotide Excision Repair
There are numerous sources of DNA damage in the environment,
including both naturally and artificially introduced substances. To limit genetic
mutations and prevent the ensuing malignant transformation that might arise
from exposure to such agents, there are a variety of cellular defense mechanisms
that remove lesions from DNA and correct any unwanted changes. One of the
most versatile systems is nucleotide excision repair (NER). In this pathway, many
types of DNA lesions are excised as a small, single-stranded oligonucleotide
fragment, and new DNA is synthesized to fill the resulting gap (Figure 1.4; for
reviews see 29, 30). The study of NER has been facilitated by several genetic
diseases associated with DNA repair deficiencies including xeroderma
pigmentosum (XP), an inherited disorder characterized by unusual sensitivity to
sunlight and a predisposition to neurological abnormalities and cancer (31). Most
of the essential mammalian excision repair factors have been cloned by
complementation studies with such human XP (XPA-XPG) or rodent (ERCC1-
4
0
21
ERCC11) mutant cell lines. Experiments with purified proteins demonstrated that
14-16 polypeptides are necessary to reconstitute fully the dual incision activity if
the excinuclease (Table 1.1) (32-34).
Recognition of DNA Damage by NER Proteins
If cisplatin-DNA adducts are substrates for NER, they should be recognized
specifically by proteins involved in the first, and possibly rate-limiting, damage
recognition step (29). The zinc finger protein XPA plays a central role in sensing
genetic damage and recruiting the excinuclease to the site of the lesion (35). Gel
mobility shift and nitrocellulose binding assays demonstrated that XPA binds to
cisplatin-modified DNA, although the affinity for the damaged over undamaged
DNA was fairly modest, only a factor of 5 or less (36-38). Another essential
component of the excision nuclease, the human single-stranded binding protein
RPA, was detected in a complex with cisplatin-modified DNA isolated from cell
extracts (39, 40). XPA binds tightly to RPA in vitro (29), so it is likely that together
they recognize DNA damage with an increased specificity of binding. Recent work
with purified repair factors, however, did not detect specific binding of the two
proteins to a damaged substrate (41). Rather, it was suggested that XPA/RPA may
bind DNA lesions weakly, and that recruitment of TFIIH and XPC, as well as ATP-
dependent DNA-unwinding, are all required to form the first stable complex in
the NER pathway (41, 42).
Another DNA-damage binding activity was found to be deficient in some
XPE cells (43). This activity is expressed at higher levels in some human tumor
cells selected for cisplatin resistance, accompanied by enhanced levels of repair
(20). In another study, the small subunit of the putative XPE protein was induced
by cisplatin and its induction was greater in resistant cell lines. The diminished
cisplatin sensitivity was attributed to replicative bypass, however, not to excision
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repair (44, 45). Further investigation of the XPE phenotype, which presents with
only mild XP symptoms and partial reduction in repair capacity, demonstrated
that the damaged-DNA binding activity is absent in cells from only a few XPE
patients (reviewed in 29). Moreover, the purified protein does not complement
the repair activity of XPE extracts and it is not required to reconstitute the
excinuclease completely (32, 33). It is therefore impossible at present to delineate
what role this protein might play in excision repair or the cytotoxic activity of
cisplatin.
Repair of Cisplatin-DNA Adducts
It is now certain that cisplatin-DNA cross-links are removed by the excision
repair pathway (4). In fact, one of the original pieces of evidence indicating that
cisplatin-damaged DNA is cytotoxic was the enhanced sensitivity of bacterial
mutants deficient in components of the UvrABC excision nuclease (46, 47).
Parallel studies in mammalian cells revealed the abnormal cisplatin sensitivity of
human XPA and XPF cell lines (48-50) and of a Chinese hamster ovary cell line
lacking ERCC1 (51). The sensitivity of these cells was attributed to defective
9
adduct removal from genomic DNA. This conclusion was supported by work
with an in vitro repair synthesis assay that measures the formation of new DNA
patches following removal of the platinum adducts by the excinuclease. The
signal was diminished in extracts from XPA cells when compared to extracts from
normal lymphoid cells (52, 53).
Experiments were also performed with an alternative assay that makes use 6
of a linear DNA substrate containing a site-specific lesion positioned close to a
radioactive phosphodiester group. Incubation with cell-free extracts and
resolution of the DNA by denaturing gel electrophoresis afforded small
oligonucleotides containing the adduct and the label (54). By using this excision
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assay, it was revealed that both cisplatin 1,2-d(GpG) and 1,3-d(ApG) intrastrand
cross-links are substrates for the mammalian excinuclease (55, 56). The minor 1,3-
d(GpTpG) cross-link is removed much more efficiently, however (Table 1.2). The
relative rates of repair of the various cisplatin-DNA adducts by the mammalian
excinuclease (GTG >> GG) agree with prokaryotic excinuclease recognition of
DNA adducts formed by a diaminocyclohexane platinum compound (57, see
however 58) and reflects the degree of unwinding caused by the different adducts
(59). The correlation between helix-destabilization and relative rates of repair is
not surprising given that components of the damage-recognition complex (XPA
and RPA) preferentially bind single-stranded over double-stranded DNA (35).
Although cisplatin interstrand cross-links also significantly distort DNA
(see above), it is unclear whether they are repaired by NER. Study of a psoralen
interstrand cross-link suggested that the excinuclease recognizes this type of
damage, but with an unusual outcome (60). Two cleavage sites were identified,
both 5' to the damage, such that the adduct was not removed from the DNA. It
was suggested that the ensuing gap might serve as a recombinogenic signal to
activate subsequent removal of the cross-link through a different repair pathway.
When a cisplatin interstrand adduct was incubated with mammalian cell-free
extracts, however, no such reaction products were detected (56). Cells from
Fanconi's anemia patients (FA) are very sensitive to cross-linking agents but
proficient in NER (61). The unusual sensitivity of this cell type to cisplatin is
associated with an inability to remove interstrand adducts from the DNA (49, 50),
indicating that the adducts are repaired by an alternative pathway. There is some
evidence to suggest that mammalian repair of interstrand cross-links requires a
few proteins that are also components of excision repair (62). The repair synthesis
signal arising from a cisplatin-modified plasmid enriched for the interstrand
cross-link was larger than that detected for randomly-modified DNA (63), and this
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activity was absent in extracts made from XPA cells. Although these experiments
provide some information about the repair of cisplatin interstrand cross-links, the
detailed mechanism still remains to be elucidated.
Cisplatin is also a carcinogen (3), at least in part because mutations across
from its DNA adducts are generated during replicative bypass (6). Studies of a
cisplatin 1,2-d(GpG)-containing substrate revealed that a thymine across from the
adduct enhanced the excinuclease activity when compared with the correct
complementary bases (64, 65). This effect probably reflects the superimposition of
structural distortions. The action of an excinuclease on the Pt-damaged strand of
such a compound lesion would permanently fix the mutation in the genome. A
compound lesion would also be recognized by the mismatch repair proteins, the
consequences of which are discussed below.
The Role of NER in the Anticancer Activity of Cisplatin
Over the years, it has become apparent that the antitumor activity of
cisplatin is a consequence of several different cellular phenomena (26, 28). DNA
repair has been investigated as one factor that could influence cisplatin sensitivity,
since failure to remove DNA lesions would allow them to persist and interfere
with essential cellular systems. Several early studies provided evidence that
trans-DDP was ineffective because its DNA adducts were repaired more efficiently
than those of the cis isomer (6). This result might be a consequence of differential
recognition of the platinum adducts by the repair enzymes or by some other factor
that modulates repair. In addition, in contrast to previous reports (reviewed in 5),
recent evidence suggests the trans-DDP forms predominantly monofunctional
and interstrand DNA cross-links (66), which might be processed in a different
fashion than intrastrand adducts.
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Sublines with reduced sensitivity to cisplatin have been produced in vitro
by first exposing cells to low levels of the drug and then increasing the
concentration in a stepwise fashion as the cells adapt to its presence. Enhanced
DNA repair has been implicated as a mechanism of drug tolerance in a variety of
model systems, including murine leukemia (67-69), rat colon adenocarcinoma
(70), human ovarian carcinoma (71), and human testicular tumor cell lines (72,
73). In some cases, it was evident that other factors were involved since the
increase in DNA repair was not proportional to the level of resistance. In
addition, the resistance phenotype may be caused by mutations that reverse a
DNA repair deficiency in the parental cells. For example, the murine leukemia
L1210/0 cell line has been used in many studies of acquired resistance to cisplatin.
A recent investigation revealed the parental cell line to be deficient in nucleotide
excision repair, due to an XPG genetic defect. In the course of selection for drug
resistance, the XPG function was restored, probably by a platinum-induced
mutation (74). Whatever the explanation, the possibility that increased DNA
repair could confer resistance to cisplatin led to studies of agents that inhibit repair
(7, 27). Although the results seem to depend on cell type, many of the compounds
identified in this manner produced a synergistic response with cisplatin in vitro,
and provided promising leads for clinical evaluation.
In E. coli, RNA polymerases stalled at sites of DNA damage are recognized
by the coupling factor TCRF, which recruits repair factors (29). In mammalian
cells, the coupling factor has not been clearly identified, but mutations in the two
genes responsible for Cockayne's syndrome, another repair-related disease, result
in defective transcription-coupled repair. Various types of DNA damage
including cisplatin adducts are removed more rapidly from actively transcribed
genes (75), and intrastrand adducts in particular are preferentially removed from
the transcribed strand (76). Transcription-coupled repair of the major cisplatin-
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DNA adducts has not been linked to drug sensitivity. In contrast, enhanced gene-
specific repair of the cisplatin interstrand cross-link was detected in several cell
lines with acquired cisplatin resistance (77, 78), but its repair mechanism has not
been delineated.
A reduced capacity to repair cisplatin-DNA adducts may be responsible for
the clinical effectiveness of the drug in the treatment of certain types of cancer.
Cell lines derived from human testicular tumors are hypersensitive to a variety of
DNA-damaging agents, including cisplatin (79). In comparison to relatively
resistant bladder cancer cell lines, testis tumor cells have lower levels of
platinum-adduct removal from the whole genome (80). This result was
reproduced when the repair of both the actively transcribed N-ras gene and the
inactive CD3D gene was analyzed. In particular, immunochemical analysis of the
different cisplatin-DNA adducts demonstrated a deficiency in the repair of the 1,2-
intrastrand cross-links (81, 82). The biological basis for this effect has not yet been
established. Possible explanations include a defect in the nucleotide excision
repair pathway, lower expression levels of the repair proteins, the absence of some
excinuclease-activating signal, or the presence of a repair-inhibiting factor. 9
Further work is required to ascertain whether DNA repair is the major
determinant of cisplatin sensitivity in testicular cancer.
In vitro experiments with cultured cell lines have provided a wealth of 9
information about the biological mechanism of cisplatin. Although there is some
correlation between the sensitivity of these cells and related tumors (83), it is
likely that they provide only a limited representation. An extreme case is a
murine mammary tumor that acquired cisplatin resistance in vivo but seemed to
lose drug tolerance when cultured in a monolayer in vitro (84). Reimplantation
in vivo restored cisplatin resistance, demonstrating the importance of cellular
0
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context when examining drug sensitivity. For this reason, the mechanism of
action of cisplatin should be examined in human tissue when possible.
By using leukocytes from chemotherapy patients with squamous cell
carcinoma of the head and neck region, it was demonstrated that damage removal
from DNA was related to cisplatin resistance (85). This type of study assumes the
profile of adduct formation and repair to be the same in peripheral and tumor
tissue. The hypothesis was supported by several early studies that employed
either atomic absorption spectroscopy or immunochemical techniques to
demonstrate a relationship between DNA adduct formation in blood cells and
disease response (86-91). Subsequent work revealed, however, that cisplatin-DNA
adduct levels do not always correlate with survival (92) and can vary substantially
between individuals (93).
DNA repair components have been analyzed in a few tumor samples.
Elevated levels of RNA for ERCC1 and XPA were detected in the tumors of
ovarian cancer patients who were clinically resistant to cisplatin chemotherapy
when compared to the responders (94, 95). In these studies, the tissue was
harvested before drug treatment, the higher levels of expression of the NER
components providing a biochemical basis for inherent cisplatin resistance in
some of the patients. The mechanism of acquired resistance was investigated in a
malignant oligodendroglioma by examining tissue both before and after failed
cisplatin therapy (96). The level of repair of cisplatin-DNA adducts, as determined
by a host cell reactivation assay, was higher in the tumor procured after therapy
and associated with increases in DNA polymerase P and ligase activity.
Clearly, the NER proteins play a major role in the biological processing of
cisplatin-DNA adducts. As a consequence, it is likely that they can modulate
cellular sensitivity to cisplatin. So far, however, there is only limited information
about the relative repair capacities of malignant and normal tissue. To determine
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whether DNA repair contributes to tumor responses during cisplatin
chemotherapy, it is necessary to quantitate directly the DNA repair activity from
the tissue. Recent studies of human tissue demonstrated a significant variability
in the repair capacity of tumors from different patients (97). When the levels of
repair in extracts from different organs were compared, no correlation with
cisplatin toxicity was observed (98). Such experiments are difficult to evaluate,
however, since current methods involve the preparation of crude extracts, which
must be normalized to one another, and the use of in vitro repair assays which
are complicated by inherent variability (99). Improved technical protocols, along
with a better understanding of the intricacies of neoplastic transformation, should
make it easier to study the excinuclease activity in the context of the complex
cellular environment.
Mismatch Repair
Normal DNA processing activities are inherently error-prone, and the
existence of several mechanisms to remove genetic misinformation indicates
how disastrous the propagation of mutations can be. The consequences of such 9
negligence was made evident by the discovery that almost all cases of hereditary
nonpolyposis colon cancer as well as a variety of sporadic tumors arise from
defects in the mismatch repair pathway (100). In addition to the maintenance of
genetic integrity (for reviews on mismatch repair, see 100-102), however, it is
becoming apparent that mismatch repair may also mediate the cytotoxicity of a
variety of clinically effective drugs, including cisplatin (103, 104). A connection
between cisplatin sensitivity and mismatch repair was made with the discovery
that repair-deficient cell lines were resistant to cisplatin and carboplatin, but not to
all DNA-damaging agents (105, 106). Furthermore, some ovarian cancer cell lines 9
selected for cisplatin resistance lose the ability to express hHML1 (107-109), one of
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the essential components of the mismatch repair machinery (101, 102). In a model
proposed to explain drug tolerance associated with defects in mismatch repair, it is
assumed that replication bypass of cisplatin-modified bases produces mutations
(Figure 1.5A). During mismatch repair, the strand to be corrected is nicked, an
oligonucleotide containing the mismatch is excised, and new DNA is synthesized.
The mismatch repair proteins always replace the incorrect sequence in the
daughter strand through some as yet undetermined signal, which would leave
the exogenous platinum damage unrepaired. This activity initiates a futile cycle.
During DNA synthesis to replace the excised oligonucleotide, the polymerases
would again incorporate mutations, which would be followed by attempts to fix
them. The repeated breaks in DNA formed at each ineffective cycle of repair
could trigger a cell death response.
A more direct association was made by experiments showing that cisplatin-
modified DNA is recognized by mismatch repair proteins. The MutSa
heterodimer, a putative mismatch recognition factor, binds to a 32-bp
oligonucleotide containing one 1,2-d(GpG) cisplatin intrastrand cross-link but
only poorly to 1,2-d(ApG) and 1,3-d(GpTpG) adducts and not at all to a trans-DDP
1,3-intrastrand cross-link (110). Further work demonstrated that hMSH2, a
component of MutSa, binds specifically to DNA globally modified with cisplatin
but not with other, clinically ineffective platinum compounds (111). This protein
also displays a weak selectivity for a single 1,2-d(GpG) adduct in 100-bp probe
compared to the corresponding unmodified DNA.
The binding of mismatch repair proteins to cisplatin-modified DNA in the
absence of mutations could activate cell death indirectly, by initiating the same
futile cycle described above. Alternatively, recognition of DNA adducts by the
repair apparatus could trigger cell cycle arrest and/or apoptosis by some
mechanism (Figure 1.5B), such as activation of the JNK or c-Abl signaling
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pathways (112). The absence of a functional complex to detect damage would
increase cellular tolerance for cisplatin-DNA adducts and explain the drug
resistance associated with diminished expression of these proteins. This
hypothesis is interesting in light of the recent connection between mismatch
repair and PCNA, a replication factor that has been implicated in a cell cycle
checkpoint (113, 114), and the observation that hMLH1-deficient cells do not
exhibit the prominent G2-arrest usually observed following cisplatin exposure
(109).
Cellular sensitivity to different platinum compounds and the recognition
of the platinum DNA adducts by mismatch repair protein complexes appear to be
linked (105). It may also be significant that hMSH2 is expressed to higher levels in
testicular and ovarian tissue than in other organs such as heart, liver and colon
(111). Whether or not mismatch repair plays a general role in the anticancer
activity of cisplatin still remains debatable, however. Mismatch repair proteins
bind to cisplatin-DNA adducts in vitro with weak specificity (111, 115). Although
specificity is enhanced when a platinum lesion is combined with a mutation (115),
it is still less than the affinity of these proteins for the unplatinated mutation (65,
110).
Mismatch repair mutants are more likely to afford a mechanism for
acquired cisplatin resistance (107-109). Exposure to cisplatin can select for
mismatch repair deficiency both in vitro (116, 117), and in vivo (109), and deleting
MSH2 produces a small but significant level of cisplatin resistance in xenografts
(116). The fact that several ovarian carcinoma cultured cell lines develop a defect
in this pathway during the acquisition of resistance to cisplatin is intriguing,
because the growth of resistant tumors is a significant problem in the treatment of
ovarian cancer (118). The importance of overcoming resistance in cancer
chemotherapy should further stimulate investigation of this area.
0
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HMG-Domain Proteins and Cisplatin
As mentioned in the introduction, preliminary studies demonstrated the
existence of cellular proteins that specifically recognize and bind to cisplatin-
modified DNA. To determine what role these proteins might play in the cytotoxic
mechanism of cisplatin, it was necessary to learn their identity and study them
individually. To achieve this goal, a cDNA encoding one of these SSRPs
(structure-specific recognition proteins) was isolated by expression library
screening (119, 120), and a data base search with the predicted amino acid sequence
revealed homology with the non-histone chromosomal protein HMG1 (120). The
region of highest identity (47%) was an 80-amino acid DNA-binding motif known
as the HMG domain, which occurs in a variety of proteins. In a complementary
study, HMG1 and HMG2 were detected among a small group of nuclear proteins
isolated from HeLa cell extracts by fractionation on cisplatin-modified DNA
cellulose (121). Gel mobility shift assays demonstrated that HMG1 binds
specifically to DNA treated with cisplatin, but not to DNA modified with trans-
DDP (122), and the use of site-specifically modified probes revealed that it is the
1,2-intrastrand adducts that induce binding. These results stimulated a much
more extensive study of the family of HMG-domain DNA-binding proteins.
The canonical HMG domain is a positively charged, predominantly O-
helical 71 amino acid polypeptide (123-125). This L-shaped peptide occurs in a
wide variety of minor groove DNA-binding proteins having little or no
homology outside of the HMG domain. Members of this protein family lie on a
continuum between two modes of DNA recognition. At one end are proteins that
bind to a defined, AT-rich, consensus sequence. These proteins have only a single
domain, usually function as transcription factors and regulators of cellular
differentiation, and include the lymphoid enhancer binding factor LEF-1, the
testis-determining factor SRY, and the Sox family of proteins. At the other
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extreme are proteins such as HMG1 and 2, which contain more than one HMG-
domain and display no DNA sequence specificity (for a review on HMG1/HMG2
see 125). The exact cellular function of these proteins is unknown, but because
they bend DNA and recognize pre-bent DNA structures like other HMG-domain
proteins, it has been proposed that they act as architectural factors during nucleic
acid processing. In this role, the HMG-domain protein would facilitate the
assembly of multi-protein complexes responsible for activities that include the
maintenance of chromatin structure, DNA recombination, replication,
transcription and repair.
The sequence homology between HMG-domains is quite low, identity
typically being on the order of 25%, but recent modeling experiments indicate that
the tertiary structure is highly conserved (126). This result may explain why
HMG-domain proteins are all able to bind specifically to distorted DNA structures
such as four-way junctions. Recent solution structures of the SRY and LEF-1
HMG-domains in complexes with their target sequences revealed a pronounced
bend in the DNA accompanied by unwinding of the helix and widening of the
minor groove (127, 128). Similar features have been observed in structures of
DNA duplexes containing the cisplatin 1,2-d(GpG) intrastrand cross-link (10-13).
Accordingly, cisplatin-DNA adducts might provide an optimal framework for
specific recognition by this DNA-binding motif.
Binding to Cisplatin-DNA Adducts
Most of the HMG-domain proteins examined have the capacity to bind
specifically to DNA cross-linked with cisplatin; Table 1.3 summarizes studies with
site-specifically modified DNA (see also 121, 129-133). The binding affinity of these
proteins to a site-specific 1,2-d(GpG) cisplatin intrastrand cross-link was 9
determined by using gel mobility shift and other assays. The differences in
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experimental conditions employed, the method for calculating Kd, components of
the reaction solutions, and the DNA probes themselves, prohibit any quantitative
comparison of the results. Several points of interest have emerged from these
studies, however. First, there is no doubt that these polypeptides bind to a single
1,2-intrastrand cross-link with higher affinity than to the corresponding
unplatinated DNA; the specificity ratio (p) ranges from 3-235. The higher
specificity occurs with smaller DNA substrates, which is not surprising given that
longer stretches of undamaged DNA provides more opportunity to form non-
specific complexes with any DNA-binding protein.
The second observation is that isolated HMG-domains recognize the
cisplatin lesion, establishing that it is this motif which confers such an unusual
activity on the family of proteins (but see 134). That the domains do not bind to
the cisplatin-DNA adducts with the same affinity and specificity as the whole
proteins supports the fact that regions outside the domain influence the DNA-
binding activity ((135) and references within).
Finally, the sequence context of the Pt-DNA adduct can have a significant
impact on the strength of the protein-DNA interaction (136). In a study of a series
of 15 bp platinated probes, changing the identity of the two nucleotides flanking a
1,2-d(GpG) cisplatin-DNA adduct modulated the binding affinity by more than 2
orders of magnitude. In particular, a striking effect was apparent for the base-pair
3' to the lesion, a position which has unusual minor groove accessibility and
considerable hydrogen bond disruption (Figure 1.2) (10, 131, 137). It has not been
determined whether this modulation of binding is due to differences in the
structures of the cisplatin-modified duplexes, changes in the stability and
flexibility of the duplex DNA, base-specific protein-DNA contacts or some
combination thereof.
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A recent study demonstrated that HMG1 can also apparently bind to DNA
containing cisplatin interstrand cross-links (130). As described above, the duplex-
DNA distortions induced by the interstrand cross-link are quite different from
those resulting from a 1,2-intrastrand adduct, suggesting that there is no
correlation between the bending or unwinding angles and HMG recognition. The 0
authors propose that the proteins recognize fixed distortions in DNA, but that if
the DNA is too denatured or flexible, as is the case following trans-DDP
modifications, binding is inhibited. To date, this is the only reported example of
such an interaction, and to appreciate its importance, a comparison of substrates
containing the different types of cisplatin adducts will be required.
In addition to binding structural distortions in DNA, the ability to bend 9
linear DNA is a common feature of this protein family (123). Thus HMG-domain
proteins could effect the mechanism of cisplatin by further distorting DNA at the
site of the lesions (138). Circular permutation assays demonstrated that HMG-
domain proteins amplify the bend in a 1,2-d(GpG) site-specifically platinated probe
(139). In addition to determining the bend angles, which ranged from 500 to 900,
these experiments also revealed that the platinum was near the center of the bend
locus. The enhanced bending of the cisplatin-modified DNA suggests one reason
why the interaction with HMG-domain proteins is favored. As described above,
the roll between guanine bases is such that the platinum is under considerable
strain, which could be released if the bend angle were increased to ~ 900 through
the formation of a protein-DNA complex (139).
The Role of HMG-Domain Proteins in Modulating the Cisplatin Sensitivity of
Cells.
The binding of cisplatin-modified DNA by HMG-domain proteins, a
9
consequence of features in common with the natural DNA targets, may
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fortuitously play a role in the drug cytotoxicity. It is clear that HMG-domain
proteins do respond to cisplatin, since both HMG1/2 and hUBF relocalize in cells
exposed to the drug (140, 141). Interruption of the gene for Ixrl, a yeast HMG-
domain protein, resulted in a 2-6 fold desensitization of the cells to the drug (142,
143), which correlated with a decrease in the number of platinum-DNA adducts
(142). In addition, a recent report suggests that overexpression of HMG2 can
sensitize cells to cisplatin (144).
If HMG-domain proteins function as a determinant of cisplatin cytotoxicity,
the levels of these proteins would be expected to reflect cellular drug sensitivity.
This issue is difficult to address, however, because it is not known whether only
one member of this family, and if so, which one, or all HMG-domain proteins
should be examined. Nevertheless, several studies have searched for a
connection between the quantity of expressed HMG-domain protein and cellular
response to cisplatin. No correlation was detected between hSSRP1 expression
and the cisplatin sensitivity of several cell lines and tissue types (120). In contrast,
elevated levels of HMG1/2 bound to cisplatin-modified DNA cellulose were
detected in nuclear extracts from HeLa cells with acquired cisplatin resistance
(145). HMG1 was also expressed in higher levels in human hepatocellular
carcinomas than in the healthy tissue (146). Clearly, further research is needed to
determine the importance of HMG-domain proteins sensitizing tumors to
cisplatin.
Several models have been proposed to explain what specific role HMG-
domain proteins could play in the cisplatin mechanism of action. When the
ability of this family to recognize cisplatin-modified DNA was first detected, it was
suggested that HMG-domain proteins might be factors that communicate the
presence of the genetic damage to the repair pathways (119), but no evidence to
date supports such a hypothesis.
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In another potential scenario, the formation of tens to hundreds of
thousands of genomic platinum lesions following a chemotherapeutic dose of
cisplatin (88, 92) could titrate HMG-domain proteins away from a much smaller
number of natural binding sites (Figure 1.6A). Both hUBF and SRY bind with
similar affinity to the 1,2-d(GpG) intrastrand adduct and to their target sequences
(Table 1.3) (147, 148). Furthermore, the addition of cisplatin-modified DNA to an
in vitro ribosomal RNA transcription assay inhibited the hUBF-based activity
(149). If gene regulation by an HMG-domain protein were essential for cell
viability, then such a diversion could result in cell death. This hypothesis was
tested in yeast by taking advantage of the function of Ixrl (150), also known as
Ord1 (151), which represses the transcription of Cox5b, an isoform of subunit V of
cytochrome c oxidase. If cisplatin-DNA adducts can titrate Ixrl away from its
recognition sequence, the transcription of genes regulated by Ixrl should increase
specifically in the wild-type cells exposed to cisplatin when compared with ixrl
mutants. No cisplatin-induced increase was observed either in the mRNA levels
of the Cox5b gene or in the activity of a reporter gene placed downstream of the
Ixr1 promoter. Thus, in this system at least, titration of Ixrl cannot be invoked to
explain the cisplatin resistance of cells with a mutant HMG-domain protein. It is
possible, however, that transcriptional upregulation of Ixrl-controlled genes was
not detected due to cisplatin-DNA adducts which blocked RNA polymerase
activity, since a decrease in Cox5b mRNA was detected at the higher
concentrations of cisplatin employed.
There is more experimental evidence to support an alternative, possibly
synergistic but not exclusive, model (Figure 1.6B), which proposes that HMG-
domain proteins bind tightly to cisplatin-DNA adducts and block repair complexes
from removing the damage. Such repair shielding would enhance the
o
cytotoxicity of the drug by allowing the lesions to persist in the cell. Gel mobility
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shift assays demonstrated that the binding of HMG1 to cisplatin-modified DNA
occurs slightly faster than binding by the repair factor RPA, and that a preformed
HMG1-DNA complex is not disturbed by RPA (40). Moreover, addition of HMG-
domain proteins to the in vitro repair assay specifically inhibited excision of the
1,2-d(GpG) but not the 1,3-d(GpTpG) intrastrand cisplatin-DNA cross-links (55, 56,
148). In vivo evidence for this model was provided by yeast double mutants. In
this system the differential cisplatin sensitivity caused by inactivation of Ixrl was
directly related to damage recognition and formation of the excision repair
complex (143).
The endogenous HMG-domain proteins in HeLa cell-free extracts do not
seem to affect the relative rates of repair of cisplatin-DNA adducts (56, 64).
Nevertheless, the hypothesis that HMG-domain proteins can enhance cellular
sensitivity to cisplatin by blocking repair of the DNA adducts is still viable.
Several HMG-domain proteins are specifically expressed in the testes ((148) and
references cited therein), two of which, tsHMG and hSRY, inhibit the in vitro
excision of cisplatin-DNA adducts at lower protein concentrations than any of the
other HMG-domain proteins tested (56, 148). Selective expression of these or
other such proteins in testicular tumors would provide an explanation for the
unusual cisplatin sensitivity of this tumor type and the reduced repair of
cisplatin-DNA adducts observed in testicular cell lines (discussed above).
Platinum Inhibition of Transcription
The formation of cross-links on DNA has the potential to affect directly two
essential cellular processes, replication and transcription. Early work
demonstrated that cisplatin could inhibit replication under conditions that did
not block transcription or translation (3). Adducts formed by trans-DDP can also
inhibit DNA polymerases (6), however, and it has become evident that cisplatin
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lesions are not absolute blocks for replication (see the review by Villiani, this
book). Furthermore, cisplatin commonly causes an arrest in the G2 phase of the 6
cell cycle (152), suggesting that inhibition of gene expression, and not replication,
determines whether the cell will live and divide, or undergo apoptosis.
Accordingly, some effort has been devoted to studying the effects of
cisplatin on transcription. In vitro experiments with RNA polymerases
demonstrated that productive elongation activity was prematurely terminated by
the whole spectrum of cisplatin-DNA adducts, but not by the trans-DDP 1,3-
intrastrand adducts (153-155). Selective bypass of trans-DDP adducts was also
demonstrated in XPA cells, suggesting that repair of the DNA lesions did not
contribute to differential transcription inhibition by the platinum compounds
(156). In vivo, hormone-induced chromatin remodeling and subsequent
transcription from the MMTV promoter was specifically inhibited by cisplatin
(157). In this case, platinum adducts seemed to cause a decrease in the DNA
binding of one of the transcription factors, NFL. Several chromatin-associated
proteins, such as the linker histone protein H1 or HMG1/2, could have produced
through their known affinity for cisplatin-DNA adducts (158), however this I
possibility was not thoroughly investigated and it was suggested that NF1 is
inhibited from binding by the cisplatin-induced distortions. This mechanism of
cisplatin cytotoxicity could be countered by mutations that eliminate hot-spots for
platinum binding, as observed in SV40 viruses selected for drug resistance (159).
It is possible that cisplatin cytotoxicity arises from more subtle effects than
just general inhibition of transcription. The expression of some genes with a
strong promoter is inhibited more in cultured cells by cisplatin than bulk RNA
synthesis, and this differential sensitivity was not observed for trans-DDP (160,
161). On the other hand, the induction of several weak promoters by cisplatin is
reminiscent of the bacterial SOS response (161, 162). Since the inhibition or
4
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activation of RNA polymerase II-mediated transcription by cisplatin is gene-
specific and modulated by the promoter region, the end result would not be to
shut down the cellular machinery so much as to create an imbalance. The
selective inhibition, or induction, of gene expression by cisplatin is particularly
relevant with respect to the expression of oncogenes, several of which have been
implicated in cisplatin resistance (26).
As mentioned above, one consequence of stalled RNA polymerase II at a
DNA adduct is activation of transcription-coupled repair (29). This effect may
depend on the type of polymerase, however, since the removal of some types of
DNA damage is slower from RNA-polymerase I transcribed ribosomal DNA than
from a nuclear gene (163). The lower level of repair in the nucleolus could also
reflect the influence of other transcription factors, such as the HMG-domain
protein UBF, which binds to cisplatin-modified DNA (147). When HeLa cells
were exposed to cisplatin at concentrations that did not seem to affect nuclear
transcription, inhibition of rDNA gene expression was associated with the
redistribution of UBF, along with other factors responsible for rRNA transcription
(141). These observations indicate how cisplatin might exert a combination of
effects. Transcription is stopped due to titration of essential factors by the
platinum-DNA adducts, and the same proteins could shield the lesions from the
repair activity.
p53 and the Cellular Response to Cisplatin
To avoid the propagation of mutations leading to malignant
transformation the cell has two options. It can arrest the cell cycle and attempt to
repair the lesions or, if the damage is too extensive, it can initiate a suicide
program. One of the major factors required for maintenance of genomic stability
is the product of the p53 tumor suppressor gene, a nuclear protein that exerts its
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effects through transcriptional regulation (for reviews see 164-166). Upon
exposure to genotoxic compounds, p53 is induced by several post-transcriptional
mechanisms, resulting in the activation or repression of a variety of downstream
genes. The loss of p53 activity removes a crucial barrier to unrestrained neoplastic
growth. More than 50% of solid human tumors have mutations in this gene,
usually in highly conserved regions such as exons encoding the DNA-binding
domain. In addition, the status of the p53 gene in a tumor can be an important
prognostic indicator (167, 168). A non-functional p53 could confer resistance to
chemotherapy by protecting tumor cells from drug-induced apoptosis, or it could
sensitize the cells owing to the absence of p53-dependent growth arrest and repair.
p53 and Cisplatin Sensitivity
Given the importance of p53 in cancer, it is not surprising that many
researchers have tried to establish a connection between p53 and cisplatin
sensitivity, but unfortunately a consensus has not been attainable. Introduction of
a wild-type p53 gene by viral transfer into both a human non-small cell lung
cancer line and an ovarian cancer cell line selected for cisplatin resistance resulted
in sensitization of the cells to cisplatin-induced apoptosis (169, 170). Similarly,
ovarian carcinoma cell lines selected for cisplatin resistance had non-functional
p53, associated with lower levels of apoptosis (171-173). In contrast, a comparison
of nine human ovarian cell lines did not demonstrate any correlation between
p53 and cisplatin-mediated growth inhibition, suggesting that p53-independent
pathways were responsible for cisplatin cytotoxicity (174). In addition, in human
breast cancer or foreskin fibroblast cells, which do not favor an apoptotic
mechanism of cell death, inactivation of p53 sensitized the cells to cisplatin (175,
176). Finally, in a recent comparison of the drug sensitivity of 57 different human
cell lines (177), on average p53-mutant cells were slightly less sensitive to
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cisplatin-induced growth inhibition, but there was a large range of responses,
depending on the cell line. These results confirm the importance of cell type and
cellular context in studying p53-mediated responses to cisplatin (168).
Testicular cancer is particularly interesting with respect to cisplatin because
the addition of this drug to the chemotherapeutic regimen has had such a
dramatic effect on patient survival (178, 179). In addition, testicular tumors are
unusual because they rarely have mutations in the p53 gene (180-185). High
expression levels of the p53 protein, usually a characteristic of a genetic mutation,
are also observed in testicular tumors (184-187), although a recent study of mouse
testicular teratocarcinoma cells suggested that the protein is not transcriptionally
active until the cells are exposed to a DNA-damaging agent (188). It is possible
that the extreme sensitivity of testicular cancer cells to cisplatin is due to the
induction of p53-regulated responses, such as apoptosis, but several in vitro
studies failed to support this hypothesis. In an investigation of 4 testicular germ
cell tumor cell lines, the p53 status was not a determinant of cisplatin sensitivity
and p53-independent apoptosis was observed (189, 190). Similarly, although
cisplatin-induced apoptosis observed in several murine testicular teratocarcinoma
cell lines was dependent on a functional p53, the activation of a p53-independent
cell cycle arrest resulted in comparable long term survival for p53-normal and
p53-mutant cells (191).
As discussed above, it is important to confirm in vitro results with in vivo
studies. In an examination of several germ cell tumors from male patients who
failed cisplatin-based therapy, either because of inherent or acquired resistance,
mutations in the p53 gene were found in a subset of these tumors (192). Defects in
p53 could potentially cause some of the clinical resistance, due to the lack of an
apoptotic response, but the majority of the resistance observed was not explained
by p53 mutations. Together with the cell culture results, the clinical data suggest
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that p53 is not a key determinant of cisplatin cytotoxicity in testicular cancer.
Ovarian cancer is another type of malignancy that is managed with cisplatin
chemotherapy, but patient survival is significantly limited by the development of
resistance (118). For this type of tumor, p53 expression, either mutant or wild
type, seems to be a marker for poor prognosis, which should be considered when
planning the therapy regimen (for example, see (193-195) and references therein).
p53-Mediated Responses to Cisplatin
There are multiple pathways for p53 induction (166), but the specific
mechanism for the activation of p53-mediated responses by cisplatin is still
obscure. Details about the DNA-damage signal transduction pathway could be
important for the mechanism of cisplatin resistance and must be provided by
future research. In contrast, quite a lot is known about the downstream effects of
p53. Several of these p53 activities have been implicated in the modulation of
cellular sensitivity to cisplatin (Figure 1.7).
Apoptosis
One of the consequences of p53 induction is apoptosis, a cellular response
that is activated by many DNA-damaging agents including cisplatin (152).
Members of the Bcl-2 protein family, some of which are controlled by p53, can
either accelerate or inhibit the programmed cell death pathway (196). For
example, the p53-regulated bax protein usually promotes cell death, but its effects
can be neutralized by Bcl-2. In several cases, cisplatin sensitivity was associated
with the functional status of p53 and levels of the Bcl-2 proteins. In two different
ovarian carcinoma cell lines, cisplatin resistance was acquired in vitro together
with loss of p53-mediated transactivation of bax and initiation of apoptosis (172,
197). The introduction of a wild-type p53 gene resulted in an increase in bax
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expression and cisplatin-induced apoptosis (170), whereas exogenous Bcl-2 delayed
the activation of programmed cell death (198). A comparison of human testicular
and bladder tumor cell lines, the latter of which are more resistant to cisplatin,
revealed higher levels of apoptosis induced by the DNA-damaging agent
etoposide in the testicular cancer cell lines (199). Programmed cell death was
associated with functional p53 and high levels of Bax, whereas in most of the
bladder cancer cells p53 was non-functional and the Bax:Bcl-2 ratio was much
smaller.
DNA Repair
A connection between p53 and DNA repair was observed in p53-deficient
cells that exhibited less global DNA repair (200-202) but see (203), as well as a
reduced capacity to reactivate cisplatin- and UV-damaged reporter plasmids (175,
204, 205). Furthermore, pretreatment with low levels of UV activated a protective
response in which the levels of repair activity were elevated, an effect not
observed in p53-deficient cells (204, 206). It is possible that the p53 protein is
directly involved in removing DNA damage since the protein recognizes both
irradiated DNA and mismatches (164). There is also evidence that p53 can interact
with several components of the excinuclease, including RPA and the TFIIH-
associated factors XPB and XPD (207, 208). So far, however, there is no evidence to
demonstrate an integral role for p53 in the excision repair pathway.
It is more likely that p53 influences repair in a regulatory capacity. One link
between p53 and NER was made with the observation that the p53-regulated
Gadd45 binds to PCNA, a component of both replication and repair (209).
Overexpression of Gadd45 provided a small level of protection from cisplatin
(210), whereas Gadd45 antisense DNA sensitized human colon carcinoma cells to
cisplatin, an effect that was associated with a decrease in repair (205). It was
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hypothesized that the Gadd45 protein could interact directly with the repair
proteins because it stimulated repair synthesis in nuclear extracts (209); however,
this result could not be reproduced under a variety of experimental conditions
(211, 212). Thus, it seems likely that there are still some as yet unidentified factors
which link p53 and the excision repair pathway.
The cyclin-dependent kinase inhibitor p21 is another downstream effector
of p53 (164-166). There is evidence for p53-independent induction of p21 (164),
and under these conditions the protein may be responsible for cisplatin-induced
apoptosis (213, 214). The p21 protein usually plays a protective role in response to
cisplatin (215, 216), however, an effect that correlated with enhanced repair of a
damaged reporter plasmid (215-217). These observations are consistent with the
hypothesis that DNA-damage induced p53 activates a G1 cell cycle arrest through
p21, affording the cell time to repair the lesions and precluding the genetic
instability produced by replication of damaged DNA. In accord with this model,
the addition of p21 to cell-free extracts blocked DNA replication but not excision
repair (218), although, since p21 does interact with PCNA, it has the potential to
block the repair activity of PCNA in addition to its activity in replication (219).
In E. coli, DNA-damaging agents produce what is known as the SOS
response, a coordinated up-regulation of genes which contribute to cell survival at
least in part by repairing the DNA (29). The p53 protein could provide a signal in
a eukaryotic version of this type of general defense mechanism. The binding and
activation of p53 by small oligonucleotides such as those generated by NER (164)
suggests the existence of a feedback loop connecting DNA repair and p53-regulated
gene expression. A p53-dependent increase in repair capacity has been reported
for a variety of cell lines exposed to low levels of genotoxic agents (220). Similarly,
in a recent study a dinucleotide, mimicking a signal produced by UV-DNA
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damage, elicited a protective response to UV irradiation involving activation of
the p53 pathway and enhanced repair (221).
Thus there is substantial evidence to suggest that p53 plays a central role in
the cellular response to DNA-damage. It is also clear that p53 can control the
processing of Pt adducts. Additional experiments are needed to clarify exactly
which function p53 fulfills in the management of the DNA repair pathway.
HMG1
Finally, a surprising finding that might connect cisplatin and p53 was made
with the discovery that HMG1 enhances both p53 binding to DNA and its
transactivation activity (222). In particular, HMG1 was suggested to play an
architectural role promoting the cooperative formation of protein complexes
containing p53 at the site of transcriptional regulation. Although no direct
interaction between p53 and cisplatin-modified DNA has yet been reported, the
protein recognizes other types of DNA lesions and has been detected in
association with some repair factors (164, 207, 208). It is therefore feasible that
HMG1 and p53 could encounter each other at the sites of cisplatin-DNA adducts
in response to cellular exposure to the drug.
Another intriguing scenario is that cisplatin-DNA adducts could modulate
p53 activity by some manifestation of the titration hypothesis (Figure 1.6A). For
example, if p53 and HMG1 were to interact in vivo as they do in vitro, HMG1
could mediate the specific binding of this complex to cisplatin-modified DNA,
keeping the p53 protein away from its natural targets. At least some of the p53-
regulated activities are enhanced by treatment with cisplatin, however, providing
evidence against this theory. In an inverse situation, cisplatin-induced p53 might
attract HMG1 away from the platinum adducts, preventing it from shielding the
lesions from repair. This hypothesis provides another possible link between p53
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and repair. More detailed information about such an interaction in vivo is
required before any conclusions can be drawn about how it may contribute to the
cisplatin mechanism of action.
Other Nuclear Proteins and Cisplatin-Modified DNA
DNA-PK
Several other proteins can bind cisplatin-modified DNA and hence might
influence cellular processing of the damage. One example is the DNA-dependent
protein kinase, DNA-PK. This protein plays a role in the repair of DNA double
strand breaks, a product of ionizing radiation as well as V(D)J recombination (223,
224). There are two components of this complex. The first is the Ku heterodimer,
a DNA-binding protein that specifically recognizes the ends of duplex DNA as
well as single strand-to-double strand transitions, nicks, and hairpins. The second
factor is the catalytic subunit, DNA-PKcs, which functions as a kinase only when
associated with DNA-bound Ku. Multiple phosphorylation substrates have been
identified in vitro, including itself, p53, RPA, c-Jun, HMG1, and a variety of other
transcription factors. DNA-PK might modulate cisplatin activity indirectly, since
cells with a DNA-PK defect were sensitive not only to double-strand break
inducing agents, but also to cisplatin and UV radiation (225). These cells exhibited
lower levels of nucleotide excision repair, which was restored by transfection with
the wild-type DNA-PK gene. In an in vitro assay, however, the levels of repair
synthesis were unaffected by addition of purified DNA-PK, or by clearing the
extracts by immunoprecipitation. No complementation was observed when two
extracts with deficiencies in different components of DNA-PK were mixed
together. It was suggested that DNA-PK must play a regulatory role in the
excision repair pathway, possibly activating the cell to the presence of DNA-
damage by phosphorylating transcription factors.
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DNA-PK can directly bind to cisplatin-modified DNA, but the interaction
does not enhance its phosphorylation activity (226). In fact the presence of the
platinum adducts on the DNA substrates significantly decreased the
phosphorylation activity when compared with undamaged DNA (226, 227). It is
not immediately apparent how these results can be reconciled with the hypothesis
discussed above, but only a few substrates were investigated, so it is possible that
the full range of effects of cisplatin-DNA adducts on activity are still not known.
In addition, since the affinity for damaged DNA was slightly less than for
undamaged DNA, the significance of this interaction in the cisplatin mechanism
of action may be minimal.
Histone HI
The histone H1 protein has higher affinity for cisplatin-modified DNA
than for DNA damaged by trans-DDP or undamaged DNA (228). This interaction
is similar to that of other abundant chromosomal proteins, HMG1 and HMG2,
and may reflect common functions involving the organization and maintenance
of chromatin structure. Like HMG1/2, H1 preferentially binds to altered DNA
structures, including supercoiled DNA and four-way junctions (229). This lysine-
rich protein is associated with the linker DNA of chromatin, and may bind to the
DNA where it crosses itself as it enters and exits the core particles. H1 interacts
with HMG1 in vitro, and it has been suggested that HMG1 functionally replaces
H1 during the remodeling of chromatin that occurs during replication,
transcription or repair (229, 230). It is feasible that this protein could effect
cisplatin cytotoxicity in the same manner as the HMG-domain proteins. This
hypothesis is made more attractive by the existence of tissue specific histone
proteins, including testis-specific variants of H1 (229).
48
TBP
Another protein that binds to cisplatin-modified DNA is the TATA box-
binding protein TBP (231, 232). The addition of either UV- or cisplatin-damaged
DNA inhibited transcription in an in vitro assay, and activity was restored by the
addition of the basal transcription factor TBP both in a reconstituted system and in
whole cells. TBP activity might be titrated away by the presence of cisplatin-DNA
lesions, as postulated for HMG-domain protein (Figure 1.6A). Structural
similarities were noted between the TBP-bound DNA target and the crystal
structure of the 1,2-d(GpG) cisplatin intrastrand adduct, including the DNA bend
as well as an opening and flattening of the minor groove. This correspondence
may promote the formation of similar protein-DNA complexes, since TBP bound
to the two types of DNA generated comparable DNase 1 footprints (232), and the
transcription factor was not associated with DNA modified with other
compounds, such as trans-DDP. These experiments suggest that TBP has the
potential to play a major role in the mechanism of action of cisplatin.
Telomeres/Telomerase
The ends of chromosomes are protected from fusion, degradation or
rearrangements by a repetitive DNA sequence known as the telomere (233). In
humans, telomeres comprise 500 to > 2000 tandem repeats of the 6 bp sequence
TTAGGG. Such a G-rich strand provides an attractive target for cisplatin. A
recent study of cisplatin-treated HeLa cells suggested that a low dose of the drug
causes telomere shortening due to incomplete replication of the chromosome
ends, followed by induction of the programmed cell death pathway (234).
Whether such DNA adducts are important in the cytotoxic mechanism of
cisplatin remains to be determined, but the unique telomere sequence does
present a novel target for designing new platinum-based antitumor agents.
4
4
49
Telomeres also protect the cell from losing important genetic information
due to the shortening of the chromosome ends at each replicative cycle. Since the
telomeric sequence is finite, however, after a certain number of cellular divisions
a critical length is reached and the cells enter senescence and die (235). To avoid
such a crisis, some cells maintain the telomere structure through the activity of
the ribonucleoprotein telomerase, which synthesizes new repeats at the ends of
the DNA. Telomerase activity has been detected in the majority of human
cancers, but not in most normal tissue, implicating this enzyme in cellular
immortality and suggesting novel approaches to cancer therapy (236, 237).
Inhibition of telomerase activity by an antisense vector increased the sensitivity of
a malignant glioblastoma cell lines to cisplatin-induced apoptosis (238). A recent
study investigated whether telomerase activity can be blocked by cisplatin.
Exposure of testicular cancer cell lines to the drug inhibited telomerase activity, an
effect not observed with bleomycin, doxorubicin or trans-DDP (239). The authors
suggest that cisplatin-DNA adducts can specifically inhibit the transcription of the
G-rich gene for the RNA component of the enzyme.
Concluding Remarks
Cells exposed to cisplatin can respond either by attempting to fix the
damage or, if the injury is too extensive, committing suicide. It is unlikely that
any one factor in the cell controls this crucial decision and thereby the clinical
efficacy of the drug. Much is known about proteins that interact with cisplatin-
DNA adducts. We are beginning to understand how cisplatin-induced DNA
distortions provide a structural basis for protein recognition, and the identity and
cellular function of many factors which mediate cisplatin cytotoxicity are now
being defined. However, these proteins are involved in a complex, interwoven
set of pathways. Many of the details of these systems, particularly the methods of
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communication between critical cellular mechanisms, are still obscure and must
be delineated in order to understand how the processing of the DNA lesions
differs in sensitive and resistant tissue. The information on these diverse cellular
responses should provide the basis for new therapeutic protocols and rational
drug design.
A recent experiment with radiolabeled cisplatin has afforded new insight
into its pharmacology. When radioactive [191Pt]cisplatin was administered to
cancer patients, gamma camera imaging revealed selective accumulation of
platinum in tumor tissue as well as in several organs such as the liver, kidney,
bladder, gastrointestinal tract, uro-genital region and the neck (Figure 1.8) (240).
What distinctive features of the tissue produce this platinum localization? It is
likely that differential delivery to the tissue as well as efficient uptake by the cells
could have a significant role. It is also possible, however, that some of the
proteins discussed above prevent rapid removal of the Pt-DNA adducts, allowing
detectable levels of platinum to accumulate in the tissue. At this time, the
relative importance of these two possibilities, uptake into the tissue versus
intracellular processing, is unclear, but these preliminary studies suggest that this
issue is worthy of further pursuit.
a
a
a
a
6
4
6
I
I
4
a
51
References
1. This work will be published in a slightly different form. See reference 2.
2. Zamble, D. B. & Lippard, S. J. (1999) in 30 Years of Cisplatin - Chemistry and
Biochemistry of a Leading Anticancer Drug, Ed. Lippert, B. (VHCA-Wiley,
Basel), pp. In press.
3. Rosenberg, B. (1985) Cancer 55, 2303-2316.
4. Zamble, D. B. & Lippard, S. J. (1995) Trends Biochem. Sci. 20, 435-439.
5. Lepre, C. A. & Lippard, S. J. (1990) in Nucleic Acids and Molecular Biology,
Eds. Eckstein, F. & Lilley, D. M. J. (Springer-Verlag, Berlin), Vol. 4, pp. 9-38.
6. Comess, K. M. & Lippard, S. J. (1993) in Molcular Aspects of Anticancer
Drug-DNA Interactions, Eds. Neidle, S. & Waring, M. (Macmillan,
London), pp. 134.
7. Bloemink, M. J. & Reedijk, J. (1996) in Metal Ions in Biological Systems, Eds.
Sigel, A. & Sigel, H. (Marcel Dekker, Inc., New York), Vol. 32, pp. 641-685.
8. Poklar, N., Pilch, D. S., Lippard, S. J., Redding, E. A., Dunham, S. U. &
Breslauer, K. J. (1996) Proc. Natl. Acad. Sci. USA 93, 7606-7611.
9. Takahara, P. M., Rosenzweig, A. C., Frederick, C. A. & Lippard, S. J. (1995)
Nature 377, 649-652.
10. Takahara, P. M., Frederick, C. A. & Lippard, S. J. (1996) J. Am. Chem. Soc.
118, 12309-12321.
11. Yang, D., van Boom, S. S. G. E., Reedijk, J., van Boom, J. H. & Wang, A. H.-J.
(1995) Biochemistry 34, 12912-12921.
12. Gelasco, A. & Lippard, S. J. (1998) Biochemistry 37, 9230-9239.
13. Dunham, S. U., Dunham, S. U., Turner, C. J. & Lippard, S. J. (1998) J. A m.
Chem. Soc. 120, 5395-5406.
14. Werner, M. H., Gronenborn, A. M. & Clore, G. M. (1996) Science 271, 778-
784.
52
15. Huang, H., Zhu, L., Reid, B. R., Drobny, G. P. & Hopkins, P. B. (1995) Science
270, 1842-1845.
16. Paquet, F., Perez, C., Leng, M., Lancelot, G. & Malinge, J.-M. (1996) J. Bio mol.
Struct. Dyn. 14, 67-77.
17. Donahue, B. A., Augot, M., Bellon, S. F., Treiber, D. K., Toney, J. H., Lippard,
S. J. & Essigmann, J. M. (1990) Biochemstry 29, 5872-5880.
18. Andrews, P. A. & Jones, J. A. (1991) Cancer Commun. 3, 93-102.
19. Bissett, D., McLauglin, K., Kelland, L. R. & Brown, R. (1993) Br. J. Cancer 67,
742-748.
20. Chu, G. & Chang, E. (1990) Proc. Natl. Acad. Sci. USA 87, 3324-3327.
21. Chao, C. C.-K., Huang, S.-L., Lee, L.-Y. & Lin-Chao, S. (1991) Biochem. J. 277,
875-878.
22. McLaughlin, K., Coren, G., Masters, J. & Brown, R. (1993) Int. J. Cancer 53,
662-666.
23. Hibino, Y., Kusahio, E. & Sugano, N. (1995) Biochem. Mol. Biol. Int. 36, 617-
625.
24. Loehrer, P. J. & Einhorn, L. H. (1984) Ann. Intern. Med. 100, 704-713.
25. McEvoy, G. K. (1994) in American Hospital Formulary Service (American
Society of Hospital Pharmacists, Bethesda, MD).
26. Scanlon, K. J., Kashani-Sabet, M., Tone, T. & Funato, T. (1991) Pharmac.
Ther. 52, 385-406.
27. Timmer-Bosscha, H., Mulder, N. H. & de Vries, E. G. E. (1992) Br. J. Cancer
66, 227-238.
28. Chu, G. (1994) J. Biol. Chem. 269, 787-790.
29. Sancar, A. (1996) Annu. Rev. Biochem. 65, 43-81.
30. Wood, R. D. (1997) J. Biol. Chem. 272, 23465-23468.
4
a
6
a
6
a
4
53
31. Cleaver, J. E. & Kraemer, K. H. (1989) in The metabolic basis of inherited
disease, Eds. Scriver, C. R., Beaudet, A. L., Sly, W. S. & Valle, E. (McGraw
Hill, New York), Vol. 2, pp. 2949-2971.
32. Aboussekhra, A., Biggerstaff, M., Shivji, M. K. K., Vilpo, J. A., Moncollin,
V., Podust, V. N., Protic, M., Hubscher, U., Egly, J.-M. & Wood, R. D. (1995)
Cell 80, 859-868.
33. Mu, D., Park, C.-H., Matsunaga, T., Hsu, D. S., Reardon, J. T. & Sancar, A.
(1995) J. Biol. Chem. 270, 2415-2418.
34. Mu, D., Hsu, D. S. & Sancar, A. (1996) J. Biol. Chem. 271, 8285-8294.
35. Cleaver, J. E. & States, J. C. (1997) Biochem. J. 328, 1-12.
36. Asahina, H., Kuraoka, I., Shirakawa, M., Morita, E. H., Miura, N.,
Miyamoto, E., Okada, Y. & Tanaka, K. (1994) Mutat. Res. 315, 229-237.
37. Jones, C. J. & Wood, R. D. (1993) Biochemistry 32, 12096-12104.
38. Kuraoka, I., Morita, E. H., Saijo, M., Matsuda, T., Morikawa, K., Shirakawa,
M. & Tanaka, K. (1996) Mutat. Res. 362, 87-95.
39. Clugston, C. K., McLaughlin, K., Kenny, M. K. & Brown, R. (1992) Cancer
Res. 52, 6375-6379.
40. Patrick, S. M. & Turchi, J. J. (1998) Biochemistry 37, 8808-8815.
41. Mu, D., Wakasugi, M., Hsu, D. S. & Sancar, A. (1997) J. Biol. Chem. 272,
28971-28979.
42. Evans, E., Moggs, J. G., Hwang, J. R., Egly, J.-M. & Wood, R. D. (1997) EMBO
J. 16, 6559-6573.
43. Chu, G. & Chang, E. (1988) Science 242, 564.
44. Vaisman, A. & Chaney, S. G. (1995) Biochemistry 34, 105-114.
45. Vaisman, A., Keeney, S., Nichols, A., Linn, S. & Chaney, S. G. (1996) Oncol.
Res. 8, 7-12.
46. Beck, D. J. & Brubaker, R. R. (1973) J. Bacteriol. 116, 1247-1252.
54
47. Beck, D. J., Popoff, S., Sancar, A. & Rupp, W. D. (1985) Nucl. Acids Res. 13,
7395-7412.
48. Poll, E. H. A., Abrahams, P. J., Arwert, F. & Eriksson, A. W. (1984) Mutat.
Res. 132, 181-187.
49. Plooy, A. C. M., van Dijk, M., Berends, F. & Lohman, P. H. M. (1985) Cancer
Res. 45, 4178-4184.
50. Dijt, F. J., Fichtinger-Schepman, A. M. J., Berends, F. & Reedijk, J. (1988)
Cancer Res. 48, 6058-6062.
51. Lee, K. B., Parker, R. J., Bohr, V., Cornelison, T. & Reed, E. (1993)
Carcinogenesis 14, 2177.
52. Hansson, J. & Wood, R. D. (1989) Nucl. Acids Res. 17, 8073-8091.
53. Szymkowski, D. E., Yarema, K., Essigmann, J. M., Lippard, S. J. & Wood, R.
D. (1992) Proc. Natl. Acad. Sci. USA 89, 10772-10776.
54. Huang, J.-C. & Sancar, A. (1994) J. Biol. Chem. 269, 19034-19040.
55. Huang, J.-C., Zamble, D. B., Reardon, J. T., Lippard, S. J. & Sancar, A. (1994)
Proc. Natl. Acad. Sci. USA 91, 10394-10398.
56. Zamble, D. B., Mu, D., Reardon, J. T., Sancar, A. & Lippard, S. J. (1996)
Biochemistry 35, 10004-10013.
57. Page, J. D., Husain, I., Sancar, A. & Chaney, S. G. (1990) Biochemistry 29,
1016-1024.
58. Visse, R., van Gool, A. J., Moolenaar, G. F., de Ruijter, M. & van de Putte, P.
(1994) Biochemistry 33, 1804-1811.
59. Bellon, S. F., Coleman, J. H. & Lippard, S. J. (1991) Biochemistry 30, 8026-
8035.
60. Bessho, T., Mu, D. & Sancar, A. (1997) Mol. Cell. Biol. 17, 6822-6830.
61. Fujiwara, Y., Tatsumi, M. & Sasaki, M. S. (1977) J. Mol. Biol. 113, 635-649.
62. Larminat, F. & Bohr, V. A. (1994) Nucl. Acids Res. 22, 3005-3010.
0
11
55
63. Calsou, P., Frit, P. & Salles, B. (1992) Nucl. Acids Res. 20, 6363-6368.
64. Moggs, J. G., Szymkowski, D. E., Yamada, M., Karran, P. & Wood, R. D.
(1997) Nucl. Acids Res. 25, 480-490.
65. Mu, D., Tursun, M., Duckett, D. R., Drummond, J. T., Modrich, P. & Sancar,
A. (1997) Mol. Cell. Biol. 17, 760-769.
66. Boudvillain, M., Dalbies, R., Aussourd, C. & Leng, M. (1995) Nucl. Acids
Res. 23, 2381-2388.
67. Eastman, A. & Schulte, N. (1988) Biochemistry 27, 4730-4734.
68. Sheibani, N., Jannerwein, M. M. & Eastman, A. (1989) Biochemistry 28,
3120.
69. Calsou, P., Barret, J.-M., Gros, S. & Salles, B. (1993) Eur. J. Biochem. 211, 403-.
70. Oldenburg, J., Begg, A. C., van Vugt, M. J. H., Ruevekamp, M., Schornagel, J.
H., Pinedo, H. M. & Los, G. (1994) Cancer Res. 54, 487-493.
71. Masuda, M., Ozols, R. F., Lai, G.-M., Fojo, A., Rothenberg, M. & Hamilton,
T. C. (1988) Cancer Res. 48, 5713-5716.
72. Kelland, L. R., Mistry, P., Abel, G., Freidlos, F., Loh, S. Y., Roberts, J. J. &
Harrap, K. R. (1992) Cancer Res. 52, 1710-1716.
73. Hill, B. T., Shellard, S. A., Fichtinger-Schepman, A. M. J., Schmoll, H. J. &
Harstrick, A. (1994) Anti-Cancer Drugs 5, 321-328.
74. Vilpo, J. A., Vilpo, L. M., Szymkowski, D. E., O'Donovan, A. & Wood, R. D.
(1995) Mol. Cell. Biol. 15, 290-297.
75. Jones, J. C., Zhen, W., Reed, E., Parker, R. J., Sancar, A. & Bohr, V. A. (1991)
J. Biol. Chem. 266, 7101-7107.
76. May, A., Nairn, R. S., Okumoto, D. S., Wassermann, K., Stevnsner, T.,
Jones, J. C. & Bohr, V. A. (1993) J. Biol. Chem. 268, 1650-1657.
77. Zhen, W., Jr., L. C. J., O'Connor, P. M., Reed, E., Packer, R., Howell, S. B. &
Bohr, V. A. (1992) Mol. Cell. Biol. 12, 3689-3698.
56
78. Petersen, L. N., Mamenta, E. L., Stevnsner, T., Chaney, S. G. & Bohr, V. A.
(1996) Carcinogenesis 17, 2597-2602.
79. Masters, J. R. W., Osborne, E. J., Walker, M. C. & Parris, C. N. (1993) Int. J.
Cancer 53, 340-346.
80. Kbberle, B., Grimaldi, K. A., Sunters, A., Hartley, J. A., Kelland, L. R. & 6
Masters, J. R. W. (1997) Int. J. Cancer 70, 551-555.
81. Bedford, P., Fichtinger-Schepman, A. M. J., Shellard, S. A., Walker, M. C.,
Masters, J. R. W. & Hill, B. T. (1988) Cancer Res. 48, 3019-3024.
82. Hill, B. T., Scanlon, K. J., Hansson, J., Harstrick, A., Pera, M., Fichtinger-
Schepman, A. M. J. & Shellard, S. A. (1994) Eur. J. Cancer 30A, 832-837.
83. Kelland, L. R., Jones, M., Abel, G., Valenti, M., Gwynne, J. & Harrap, K. R.
(1992) Cancer Chemother. Pharmacol. 30, 43-50.
84. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y., Pfeffer, M. R.,
Crawford, J. W. & Frei, E. (1990) Science 247, 1457-1461.
85. Parker, R. J., Dimeny, . W., Dabhakar, M., Vionnet, J. & Reed, E. (1993) Int.
J. Oncol. 3, 331-335.
86. Reed, E., Yuspa, S. H., Zwelling, L. A., Ozols, R. F. & Poirier, M. C. (1986) J.
Clin. Invest. 77, 545-550.
87. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H. & Poirier, M. C. (1987) Proc.
Natl. Acad. Sci. USA 84, 5024-5028.
88. Reed, E., Parker, R. J., Gill, I., Bicher, A., Dabholkar, M., Vionnet, J. A.,
Bostick-Bruton, F., Tarone, R. & Muggia, F. M. (1993) Cancer Res. 53, 3694-
3699.
89. Dabholkar, M., Bradshaw, L., Parker, R. J., Gill, I., Bostick-Bruton, F.,
Muggia, F. M. & Reed, E. (1992) Environ. Health Perspect. 98, 53-59.
90. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H. & Poirier, M. C. (1988)
Carcinogensis 9, 1909-1911.
4
41
57
91. Reed, E., Ostchega, Y., Steinberg, S. M., Yuspa, S. H., Young, R. C., Ozols, R.
F. & Poirier, M. C. (1990) Cancer Res. 50, 2256-2260.
92. Fisch, M. J., Howard, K. L., Einhorn, L. H. & Sledge, G. W. (1996) Clin.
Cancer Res. 2, 1063-1066.
93. Fichtinger-Schepman, A. M. J., van Oosterom, A. T., Lohman, P. H. M. &
Berends, F. (1987) Cancer Res. 47, 3000-3004.
94. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J. & Reed, E. (1994) J.
Clin. Invest. 94, 703-708.
95. Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Equreaga, C. &
Reed, E. (1992) J. Natl. Cancer Inst. 84, 1512-1517.
96. Ali-Osman, F., Berger, M. S., Rairkar, A. & Stein, D. E. (1994) J. Cell.
Biochem. 54, 11-19.
97. Jones, S. L., Hickson, I. D., Harris, A. L. & Harnett, P. R. (1994) Int. J. Cancer
59, 388-393.
98. Jones, S. L. & Harnett, P. R. (1994) Biochem. Pharmacol. 48, 1662-1665.
99. Chaney, S. G. & Sancar, A. (1996) J. Natl. Cancer Inst. 88, 1346-1360.
100. Modrich, P. & Lahue, R. (1996) in Ann. Rev. Biochem., Eds. Richardson, C.
C., Abelson, J. N. & Raetz, C. R. H. (Annual Reviews Inc., Palo Alto), Vol.
65, pp. 101-133.
101. Friedberg, E. C., Walker, G. C. & Siede, W. (1995) DNA Repair and
Mutagenesis (ASM Press, Washington).
102. Modrich, P. (1997) J. Biol. Chem. 272, 24727-24730.
103. Karran, P. & Bignami, M. (1996) Chem. & Biol. 3, 875-879.
104. Fink, D., Aebi, S. & Howell, S. B. (1998) Clin. Cancer Res. 4, 1-6.
105. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehm6, A., Christen, R. D.
& Howell, S. B. (1996) Cancer Res. 56, 4881-4886.
58
106. Aebi, S., Fink, D., Gordon, R., Kim, H. K., Zheng, H., Fink, J. L. & Howell, S.
B. (1997) Clin. Cancer Res. 3, 1763-1767.
107. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D.,
Christen, R. D., Boland, C. R., Koi, M., Fishel, R. & Howell, S. B. (1996)
Cancer Res. 56, 3087-3090.
108. Drummond, J. T., Anthoney, A., Brown, R. & Modrich, P. (1996) J. Biol.
Chem. 271, 19645-19648.
109. Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P.,
van der Zee, A. G. J. & Anthoney, D. A. (1997) Oncogene 15, 45-52.
110. Duckett, D. R., Drummond, J. T., Murchie, A. I. H., Reardon, J. T., Sancar,
A., Lilley, D. M. J. & Modrich, P. (1996) Proc. Natl. Acad. Sci. USA 93, 6443-
6447.
111. Mello, J. A., Acharya, S., Fishel, R. & Essigmann, J. M. (1996) Chem. & Biol.
3, 579-589.
112. Nehme, A., Baskaran, R., Aebi, S., Fink, D., Nebel, S., Cenni, B., Wang, J. Y.
J., Howell, S. B. & Christen, R. D. (1997) Cancer Res. 57, 3253-3257.
113. Johnson, R. E., Kovvali, G. K., Guzder, S. N., Amin, N. S., Holm, C.,
Habraken, Y., Sung, P., Prakash, L. & Prakash, S. (1996) J. Biol. Chem. 271,
27987-27990.
114. Umar, A., Buermeyer, A. B., Simon, J. A., Thomas, D. C., Clark, A. B.,
Liskay, R. M. & Kunkel, T. A. (1996) Cell 87, 65-73.
115. Yamada, M., O'Regan, E., Brown, R. & Karran, P. (1997) Nucl. Acids Res. 25,
491-495. 0
116. Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T.-P., Nehme, A.,
Christen, R. D., Haas, M., MacLeod, C. L. & Howell, S. B. (1997) Cancer Res.
57, 1841-1845.
a
4
59
117. Fink, D., Nebel, S., Norris, P. S., Aebi, S., Kim, H. K., Haas, M. & Howell, S.
B. (1998) Br. J. Cancer 77, 703-708.
118. Hamilton, T. C., Lai, G.-M., Rothenberg, M. L., Fojo, A. T., Young, R. C. &
Ozols, R. F. (1989) in Drug resistance in cancer therapy, Ed. Ozols, R. F.
(Kluwer Academic Publishers, Norwell), pp. 151-169.
119. Toney, J. H., Donahue, B. A., Kellett, P. J., Bruhn, S. L., Essigmann, J. M. &
Lippard, S. J. (1989) Proc. Natl. Acad. Sci. USA 86, 8328-8332.
120. Bruhn, S. L., Pil, P. M., Essigmann, J. M., Housman, D. E. & Lippard, S. J.
(1992) Proc. Natl. Acad. Sci. USA 89, 2307.
121. Hughes, E. N., Engelsberg, B. N. & Billings, P. C. (1992) J. Biol. Chem. 267,
13520-13527.
122. Pil, P. M. & Lippard, S. J. (1992) Science 256, 234-237.
123. Grosschedl, R., Giese, K. & Pagel, J. (1994) Trends Genet. 10, 94-99.
124. Read, C. M., Cary, P. D., Crane-Robinson, C., Driscoll, P. C., Carrillo, M. 0.
M. & Norman, D. G. (1995) in Nucleic Acids and Molecular Biology, Eds.
Eckstein, F. & Lilley, D. M. J. (Springer-Verlag, Berlin), Vol. 9, pp. 222-250.
125. Bustin, M. & Reeves, R. (1996) in Prog. Nucl. Acid Res. Mol. Biol., Vol. 54,
pp. 35-100.
126. Baxevanis, A. D., Bryant, S. H. & Landsman, D. (1995) Nucl. Acids Res. 23,
1019-1029.
127. Werner, M. H., Huth, J. R., Gronenborn, A. M. & Clore, G. M. (1995) Cell 81,
705-714.
128. Love, A. J., Li, X., Case, D. A., Giese, K., Grosschedl, R. & Wright, P. E. (1995)
Nature 376, 791-795.
129. Billings, P. C., Davis, R. J., Engelsberg, B. N., Skov, K. A. & Hughes, E. N.
(1992) Biochem. Biophys. Res. Comm. 188, 1286-1294.
130. Kasparkova, J. & Brabec, V. (1995) Biochemistry 34, 12379-12387.
60
131. Locker, D., Decoville, M., Maurizot, J. C., Bianchi, M. E. & Leng, M. (1995) J.
Mol. Biol. 246, 243-247.
132. Codony-Servat, J., Gimeno, R., Gelphi, C., Rodriquez-Sanchez, J. L. &
Juarez, C. (1996) Biochem. Pharmacol. 51, 1131-1136.
133. Turchi, J. J., Li, M. & Henkels, K. M. (1996) Biochemistry 35, 2992-3000.
134. Lawrence, D. L., Engelsberg, B. N., Farid, R. S., Hughes, E. N. & Billings, P. C.
(1993) J. Biol. Chem. 268, 23940-23945.
135. Grasser, K. D., Teo, S.-H., Lee, K.-B., Broadhurst, R. W., Rees, C., Hardman,
C. H. & Thomas, J. 0. (1998) Eur. J. Biochem. 253, 787-795.
136. Dunham, S. U. & Lippard, S. J. (1997) Biochemistry 36, 11428-11436.
137. Schwartz, A. & Leng, M. (1994) J. Mol. Biol. 236, 969-974.
138. Berners-Price, S. J., Corazza, A., Guo, Z., Barnham, K. J., Sadler, P., Ohyama,
Y., Leng, M. & Locker, D. (1997) Eur. J. Biochem. 243, 782-791.
139. Chow, C. S., Whitehead, J. P. & Lippard, S. J. (1994) Biochemistry 33, 15124- 6
15130.
140. Chao, J. C., Wan, X. S., Engelsberg, B. N., Rothblum, L. I. & Billings, P. C.
(1996) Biochim. Biophys. Acta 1307, 213-219.
141. Jordon, P. & Carmo-Fonesca, M. (1998) Nucl. Acids Res. 26, 2831-2836.
142. Brown, S. J., Kellett, P. J. & Lippard, S. J. (1993) Science 261, 603-605.
143. McA'Nulty, M. M. & Lippard, S. J. (1996) Mutat. Res. 362, 75-86.
144. Arioka, H., Nishio, K., Ishida, T., Kurokawa, H., Fukumoto, H., Fukuoka,
K., Nomoto, T., Yokote, H. & Saijo, N. (1996) in American Association for
Cancer Research Meeting Abstracts, pp. 2739.
145. Billings, P. C., Engelsberg, B. N. & Hughes, E. N. (1994) Cancer Invest. 12,
597-604.
6
4
4
61
146. Kawahara, N., Tanaka, T., Yokomizo, A., Nanri, H., Ono, M., Wada, M.,
Kohno, K., Takenaka, K., Sugimachi, K. & Kuwano, M. (1996) Cancer Res.
56, 5330-5333.
147. Treiber, D. K., Zhai, X., Jantzen, H.-M. & Essigmann, J. M. (1994) Proc. Natl.
Acad. Sci. USA 91, 5672-5676.
148. Trimmer, E. E., Zamble, D. B., Lippard, S. J. & Essigmann, J. M. (1998)
Biochemistry 37, 352-362.
149. Zhai, X., Beckmann, H., Jantzen, H.-M. & Essigmann, J. M. (1998)
Biochemistry 37, 16307-16315.
150. McA'Nulty, M. M., Whitehead, J. P. & Lippard, S. J. (1996) Biochemistry 35,
6089-6099.
151. Lambert, J. R., Bilanchone, V. W. & Cumsky, M. G. (1994) Proc. Natl. Acad.
Sci. USA 91, 7345-7349.
152. Eastman, A. (1990) Cancer Cells 2, 275-280.
153. Corda, Y., Job, C., Anin, M.-F., Leng, M. & Job, D. (1991) Biochemistry 30,
222-230.
154. Lemaire, M.-A., Schwartz, A., Rahmouni, A. R. & Leng, M. (1991) Proc.
Natl. Acad. Sci. USA 88, 1982-1985.
155. Corda, Y., Job, C., Anin, M.-F., Leng, M. & Job, D. (1993) Biochemistry 32,
8582-8588.
156. Mello, J. A., Lippard, S. J. & Essigmann, J. M. (1995) Biochemis try 34, 14783-
14791.
157. Mymryk, J. S., Zaniewski, E. & Archer, T. K. (1995) Proc. Natl. Acad. Sci.
USA 92, 2076-2080.
158. Zlatanova, J., Yaneva, J. & Leuba, S. H. (1998) FASEB J. 12, 791-799.
159. Buchanan, R. L. & Gralla, J. D. (1990) Biochemistry 29, 3436-3442.
160. Evans, G. L. & Gralla, J. D. (1992) Biochem. Pharmacol. 44, 107-119.
62
161. Evans, G. L. & Gralla, J. D. (1992) Biochem. Biophys. Res. Comm. 184, 1-8.
162. Zoumpourlis, V., Kerr, D. J. & Spandidos, D. A. (1992) Biochem. Pharmacol.
43, 650-654.
163. Stevnsner, T., May, A., Petersen, L. N., Larminat, F., Pirsel, M. & Bohr, V. A.
(1993) Carcinogenesis 14, 1591-1596.
164. Ko, L. J. & Prives, C. (1996) Genes Dev. 10, 1054-1072.
165. Levine, A. J. (1997) Cell 88, 323-331.
166. Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chernova, 0. B. & Stark, G.
R. (1998) J. Biol. Chem. 273, 1-4.
167. Lowe, S. W. (1995) Curr. Opin. Oncol. 7, 547-553.
168. Weller, M. (1998) Cell Tissue Res. 292, 435-445.
169. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W.-W., Owen-
Schaub, L. B. & Roth, J. A. (1994) Cancer Res. 54, 2287-2291.
170. Song, K., Li, Z., Seth, P., Cowan, K. H. & Sinha, B. K. (1997) Oncol. Res. 9,
603-609.
171. Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R. M. &
Brown, R. (1996) Cancer Res. 56, 1374-1381.
172. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D.,
Pierotti, M. A., Miyashita, T., Reed, J. C. & Zunino, F. (1996) Cancer Res. 56,
556-562.
173. Gallagher, W. M., Cairney, M., Schott, B., Roninson, I. B. & Brown, R. (1997)
Oncogene 14, 185-193.
174. De Feudis, P., Debernardis, D., Beccaglia, P., Valenti, M., Graniela Sire, E.,
Arzani, D., Stanzione, S., Parodi, S., D'Incalci, M., Russo, P. & Broggini, M.
(1997) Br. J. Cancer 76, 474-479.
175. Fan, S., Smith, M. L., Rivet II, D. J., Duba, D., Zhan, Q., Kohn, K. W.,
Fornace Jr., A. J. & O'Connor, P. M. (1995) Cancer Res. 55, 1649-1654.
0
a
63
176. Hawkins, D. S., Demers, G. W. & Galloway, D. A. (1996) Cancer Res. 56, 892-
898.
177. O'Connor, P. M., Jackman, J., Bae, I., Myers, T., Fan, S., Mutoh, M., Scudiero,
D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J.
J. & Kohn, K. W. (1997) Cancer Res. 57, 4285-4300.
178. Richie, J. P. (1992) in Campbell's Urology, Eds. Walsh, P. C., Retik, A. B.,
Stamey, T. A. & Vaughan, E. D. J. (W. B. Saunders Company, Philadelphia),
Vol. 2, pp. 1222-1262.
179. Bosl, G. J. & Motzer, R. J. (1997) N. Engl. J. Med. 337, 242-253.
180. Peng, H.-Q., Hogg, D., Malkin, D., Bailey, D., Gallie, B. L., Bulbul, M., Jewett,
M., Buchanan, J. & Goss, P. E. (1993) Cancer Res. 53, 3574-3578.
181. Heimdal, K., Lothe, R. A., Lystad, S., Holm, R., Fossa, S. D. & Borresen, A.-L.
(1993) Genes Chrom. Cancer 6, 92-97.
182. Wei, Y. D., Jiafu, Z., Xi, Q. S., Yongjiang, M., Xiulong, Z., Daizong, L. &
Jianren, G. (1993) J. Urol. 150, 884-886.
183. Fleischhacker, M., Strohmeyer, T., Imai, Y., Slamon, D. J. & Koeffler, H. P.
(1994) Mod. Path. 7, 435-439.
184. Riou, G., Barrois, M., Prost, S., Terrier, M. J., Theodore, C. & Levine, A. J.
(1995) Mol. Carcinog. 12, 124-131.
185. Schenkman, N. S., Sesterhenn, I. A., Washington, L., Tong, Y. A.,
Weghorst, C. M., Buzard, G. S., Srivastava, S. & Moul, J. W. (1995) J. Urol.
154, 617-621.
186. Bartkovi, J., Bairtek, J., Lukis, J., Vojtesek, B., Staskovi, Z., Rejthar, A.,
Kovarfk, J., Midgley, C. A. & Lane, D. P. (1991) Int. J. Cancer 49, 196-202.
187. Lewis, D. J., Sesterhenn, I. A., McCarthy, W. F. & Moul, J. W. (1994) J. Urol.
152, 418-423.
188. Lutzker, S. G. & Levine, A. J. (1996) Nature Med. 2, 804-810.
64
189. Burger, H., Nooter, K., Boersma, A. W. M., Kortland, C. J. & Stoter, G. (1997)
Int. J. Cancer 73, 592-599.
190. Burger, H., Nooter, K., Boersma, A. W. M. & Stoter, G. (1998) Br. J. Cancer
77, 1562-1567.
191. Zamble, D. B., Jacks, T. & Lippard, S. J. (1998) Proc. Natl. Acad. Sci. USA 95,
6163-6168.
192. Houldsworth, J., Xiao, H., Murty, V. V. V. S., Chen, W., Ray, B., Reuter, V.
E., Bosl, G. J. & Chaganti, R. S. K. (1998) Oncogene , 2345-2349.
193. Levesque, M. A., Katsaros, D., Yu, H., Zola, P., Sismondi, P., Giardina, G. &
Diamandis, E. P. (1995) Cancer 75, 1327-1338.
194. Righetti, S. C., Della Torre, G., Pilotti, S., Menard, S., Ottone, F., Colnaghi,
M. I., Pierotti, M. A., Lavarino, C., Cornarotti, M., Oriana, S., B6hm, S.,
Bresciani, G. L., Spatti, G. & Zunino, F. (1996) Cancer Res. 56, 689-693.
195. Marx, D., Meden, H., Ziemek, T., Lenthe, T., Kuhn, W. & Schauer, A. (1998)
Eur. J. Cancer 34, 845-850.
196. White, E. (1996) Genes Dev. 10, 1-15.
197. Jones, N. A., Turner, J., McIlwrath, A. J., Brown, R. & Dive, C. (1998) Mol.
Pharmacol. 53, 819-826.
198. Eliopoulos, A. G., Kerr, D. J., Herod, J., Hodgkins, L., Krajewski, S., Reed, J.
C. & Young, L. S. (1995) Oncogene 11, 1217-1228.
199. Chresta, C. M., Masters, J. R. W. & Hickman, J. A. (1996) Cancer Res. 56,
1834-1841.
200. Ford, J. M. & Hanawalt, P. C. (1995) Proc. Natl. Acad. Sci. USA 92, 8876-8880. 0
201. Ford, J. M. & Hanawalt, P. C. (1997) J. Biol. Chem. 272, 28073-28080.
202. Ford, J. M., Baron, E. L. & Hanawalt, P. C. (1998) Cancer Res. 58, 599-603.
203. Ishizaki, K., Ejima, Y., Matsunaga, T., Hara, R., Sakamoto, A., Ikenaga, M.,
Ikawa, Y. & Aizawa, S. (1994) Int. J. Cancer 58, 254-257.
a
4
65
204. Smith, M. L., Chen, I.-T., Zhan, Q., O'Connor, P. M. & Fornace Jr., A. J.
(1995) Oncogene 10, 1053-1059.
205. Smith, M. L., Kontny, H. U., Zhan, Q., Sreenath, A., O'Connor, P. M. &
Fornace Jr., A. J. (1996) Oncogene 13, 2255-2263.
206. McKay, B. C., Francis, M. A. & Rainbow, A. J. (1997) Carcinogenesis 18, 245-
249.
207. Dutta, A., Ruppert, J. M., Aster, J. C. & Winchester, E. (1993) Nature 365, 79-
82.
208. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.-M.,
Wang, Z., Friedberg, E. C., Evans, M. K., Taffer, B. G., Bohr, V. A., Weeda,
G., Hoeijmakers, J. H. J., Forrester, K. & Harris, C. C. (1995) Nature Genet. 10,
188-195.
209. Smith, M. L., Chen, I.-T., Zhan, Q., Bae, I., Chen, C.-Y., Gilmer, T. M.,
Kastan, M. B., O'Connor, P. M. & Fornace Jr., A. J. (1994) Science 266, 1376-
1380.
210. Smith, M. L., Kontny, H. U., Bortnick, R. & Fornace Jr., A. J. (1997) Exp. Cell
Res. 230, 61-68.
211. Kazantsev, A. & Sancar, A. (1995) Science 270, 1003-1004.
212. Kearsey, J. M., Shivji, M. K. K., Hall, P. A. & Wood, R. D. (1995) Science 270,
1004-1005.
213. Kondo, S., Barna, B. P., Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura,
T., Kaakaji, R., Peterson, J. W., Werbel, B. & Barnett, G. H. (1996) Oncogene
13, 1279-1285.
214. Kawasaki, T., Tomita, Y., Bilim, V., Takeda, M., Takahashi, K. &
Kumanishi, T. (1996) Int. J. Cancer 68, 501-505.
215. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace Jr., A. J. & O'Connor, P.
M. (1997) Oncogene 14, 2127-2136.
66
216. Ruan, S., Okcu, M. F., Ren, J. P., Chiao, P., Andreeff, M., Levin, V. & Zhang,
W. (1998) Cancer Res. 58, 1538-1543.
217. McDonald III, E. R., Wu, G. S., Waldman, T. & El-Deiry, W. S. (1996) Cancer
Res. 56, 2250-2255.
218. Shivji, M. K. K., Grey, S. J., Strausfeld, U. P., Wood, R. D. & Blow, J. J. (1994)
Curr. Biol. 4, 1062-1068.
219. Pan, Z.-Q., Reardon, J. T., Li, L., Flores-Rozas, H., Legerski, R., Sancar, A. &
Hurwitz, J. (1995) J. Biol. Chem. 270, 22008-22016.
220. Smith, M. L. & Fornace Jr., A. J. (1997) Proc. Natl. Acad. Sci. USA 94, 12255-
12257.
221. Eller, M. S., Maeda, T., Magnoni, C., Atwal, D. & Gilchrest, B. A. (1997) Proc.
Natl. Acad. Sci. USA 94, 12627-12632.
222. Jayaraman, L., Moorthy, N. C., Murthy, G. K., Manley, J. L., Bustin, M. &
Prives, C. (1998) Genes Dev. 12, 462-472.
223. Jeggo, P. A., Taccioli, G. E. & Jackson, S. P. (1995) BioEssays 17, 949-957.
224. Lees-Miller, S. P. (1996) Biochem. Cell Biol. 74, 503-512.
225. Muller, C., Calsou, P., Frit, P., Cayrol, C., Carter, T. & Salles, B. (1998) Nucl.
Acids Res. 26, 1382-1389.
226. Turchi, J. J. & Henkels, K. (1996) J. Biol. Chem. 271, 13861-13867.
227. Turchi, J. J., Patrick, S. M. & Henkels, K. M. (1997) Biochemistry 36, 7586-
7593.
228. Yaneva, J., Leuba, S. H., van Holde, K. & Zlatanova, J. (1997) Proc. Natl.
Acad. Sci. USA 94, 13448-13451.
a
229. Zlatanova, J. & van Holde, K. (1996) in Prog. Nucl. Acid Res. Mol. Biol., Eds.
Cohn, W. E. & Moldave, K. (Academic Press, San Diego), Vol. 52, pp. 217-
259.
4
a
0
40
67
230. Wolffe, A. (1995) Chromatin Structure and Function (Academic Press,
London).
231. Vichi, P., Coin, F., Renaud, J.-P., Vermeulen, W., Hoeijmakers, J. H. J.,
Moras, D. & Egly, J.-M. (1997) EMBO J. 16, 7444-7456.
232. Coin, F., Frit, P., Viollet, B., Salles, B. & Egly, J.-M. (1998) Mol. Cell. Biol. 18,
3907-3914.
233. Wellinger, R. J. & Sen, D. (1997) Eur. J. Cancer 33, 735-749.
234. Ishibashi, T. & Lippard, S. J. (1998) Proc. Natl. Acad. Sci. USA 95, 4219-4223.
235. Autexier, C. & Greider, C. W. (1996) Trends Biochem. Sci. 21, 387-391.
236. Shay, J. W. & Bacchetti, S. (1997) Eur. J. Cancer 33, 787-791.
237. Kim, N. W. (1997) Eur. J. Cancer 33, 781-786.
238. Kondo, Y., Kondo, S., Tanaka, Y., Haqqi, T., Barna, B. P. & Cowell, J. K.
(1998) Oncogene 16, 2243-2248.
239. Burger, A. M., Double, J. A. & Newell, D. R. (1997) Eur. J. Cancer 33, 638-644.
240. Areberg, J., Bj6rkman, S., Einarsson, L., Frankenberg, B., Lundqvist, H.,
Mattsson, S., Norrgren, K., Scheike, 0. & Wallin, R. (1998) Acta Oncologica
In press.
241. Moggs, J. G., Yarema, K. J., Essigmann, J. M. & Wood, R. D. (1996) J. Biol.
Chem. 271, 7177-7186.
242. Chow, S. C., Barnes, C. M. & Lippard, S. J. (1995) Biochemistry 34, 2956-2964.
243. Ohndorf, U. M., Whitehead, J. P., Raju, N. L. & Lippard, S. J. (1997)
Biochemistry 36, 14807-14815.
68
Table 1.1. Components of the excinucleasea.
Mammalian Protein
XPA
Yeast Homolog
Rad14
Role in Repair
Damage recognition
RPA/HSSB Rpa Damage recognition, also involved in
repair synthesis
XPB/ERCC3
XPD/ERCC2
p62
p52/Cdk7
p4 4
p3 4
p38/CycH
Rad25/Ssl2
Rad3
Tfb1
Tfb2
Ssll
Tfb4
Ccl1
Contains helicases and DNA-
dependent ATPase activity
Required for formation of
preincision complex and
transcription-repair coupling
XPC
hHR23B
XPG/ERCC5
XPF/ERCC4
ERCC1
Rad4
Rad23
Rad2
Rad1
RadiO
Stabilization and protection of
preincision complex, not required for
repair of some lesions
Binds XPC
3' endonuclease
Subunit of 5' endonuclease
Subunit of 5' endonuclease
aProteins required for repair
ligase. bS. cerevisae
synthesis include RFC, PCNA, RPA, DNA polymerase s or 8 and DNA
TFIIH
includes:
01
(I
a
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Table 1.2. Site-specific cisplatin-DNA adducts repaired by mammalian NER
Adduct Repair detected Reference
GG + (55)
AG + (56)
GTG +++ (55, 241)
GC ICL (56)
GG mismatch ++ (64, 65)
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Table 1.3. HMG-domain protein binding constants for cisplatin-DNA adducts.
aThe HMG1 peptides
mtTFA and hUBF peptides were from human.
0
Proteina
HMG1
HMG1 domain B
HMG domain Ad
Ixrl
tsHMGd
tsHMG domain Ad
hSRYd
hSRY domain
mSRY domain
LEF-1 domain
mtTFA
hUBF"
hUBF*
nucleotides are listed as well as the probe length. CSpecificity of binding ratio for
DNA compared with unmodified probe. dDetermined by competition assays.
quantitative DNaseI protection assays. nd: not determined
cisplatin-modified
*Determined by
0
6
41
probe'
TGGT-100mer
TGGT-100mer
AGGC-92mer
TGGT-20mer
AGGT-15mer
CGGC-15mer
AGGA-15mer
CGGC-15mer
AGGC-92mer
TGGT-20mer
TGGT-20mer
TGGT-20mer
SRY-20mer
TGGT-100mer
SRY-100mer
TGGT-20mer
SRY-20mer
AGGC-92mer
AGGC-92mer
AGGC-92mer
TGGT-100mer
rRNA promoter
were from rat, tsHMG
kd (M)
3.7 ±2.0 x 10-7
3 x 10-7
4 x 10-7
5 x 10-7
4.8 ±0.9 x 10-8
1.3 ±0.2 x 10-6
6.8 ±0.8 x 10-9
5.2 ±0.6 x 10-7
2.5 0.1 x 10-7
3.0 0.5 x 10-8
5.9 3.4 x 10-7
1.2 0.2 x 10-7
5.0 1.0 x 10-8
4 ±1 x 10-9
3 0.7 x 10-9
4 0.7 x 10-9
3 0.4 x 10-9
=10-6
=10-7
=10-7
6 x 10-11
1.8 x 10-11
PCp
= 100
= 3-4
= 2.5
> 4
nd
nd
235
=3
=8
= 230
-20
20
40
=5
nd
=5
10
nd
nd
nd
nd
nd
and mSRY peptides were from mouse, hSRY, Lef-1,
bThe cisplatin-modified (underlined) and the flanking
Reference
(122)
(242)
(242)
(242)
(136)
(136)
(136)
(136)
(150)
(243)
(243)
(148)
(148)
(148)
(148)
(148)
(148)
(139)
(139)
(139)
(147)
(147)
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H3N\ C1
Pt
H3N Cl
Cisplatin
cis-diamminedichloroplatinum(II)
Carboplatin
H3N\ /C1
Pt
C/ \NHCl NH 3
trans-diamminedichlororoplatinum(II)
0 2 CH 3
H3N\ tC1
H2N /
0 2CH3
JM-216
B
/H
H
Figure 1.1. Relevant structures. (A) Therapeutically active platinum
compounds, cisplatin, carboplatin and JM-216, and the inactive
isomer trans-diamminedichloroplatinum(II). (B) Watson-Crick DNA
base-pairs. Arrows indicate the N7 position of the purine bases, in
the major groove, where the covalent Pt adducts form.
A
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Figure 1.2. DNA distortions caused by a 1,2-d(GpG) cisplatin-intrastrand adduct in
a double-stranded deoxyoligonucleotide with the sequence d(CCTCTG*G*TCTCC).
(A) Major groove of normal B-DNA. (B) DNA bend caused by the cisplatin-DNA
cross-link. (C) Minor groove of normal B-DNA. (D) Widening of the minor
groove by the cisplatin-DNA cross-link. The cisplatin-DNA figures are from an
NMR solution structure (12).
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proteins
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Figure 1.3. Effects of cisplatin-DNA adducts on some of the proteins in the
nucleus that interact with the lesions.
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XPA, RPA ATP ADP+Pi
TFIIH
(XPB, XPD)
XPC
XPC)
I
5' nick
ITN
oligo
Exinuclea
Polymerases
dNTPs, ATP PC?
Ligase
4C
XPG
XPF
ERCC1
3' nick
0:
Figure 1.4. Nucleotide excision repair pathway. XPA and RPA are putative damage
recognition factors, but the first stable complex is formed after ATP hydrolysis and
the recruitment of TFIIH and XPC. This complex unwinds the DNA helix
surrounding the lesion. The addition of XPG and the departure of XPC results in the
next detectable preincision complex, and dual incision occurs after the final addition
of XPF/ERCC1. The damaged oligonucleotide is excised and then most of the
excinuclease dissociates and is replaced by PCNA in an ATP-dependent process,
followed by repair synthesis by DNA polymerase 8 or e and DNA ligases.
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Figure 1.5. Possible roles for mismatch repair in the cytotoxicity of cisplatin.
A) During replicative bypass, a mismatch is incorporated across from the
cisplatin-DNA adduct. This compound lesion is recognized by the mismatch
repair proteins, which cut the DNA on the strand opposite to the platinum.
Repair synthesis reproduces the same mismatch, resulting in a futile cycle
and possible the accumulation of DNA strand breaks which would activate
apoptosis. B) Alternatively, the mismatch repair complex binds to the
cisplatin-DNA adduct alone and generates a signal that triggers apoptosis.
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Figure 1.6. Models for HMG-involvement in the cisplatin mechanism of action.
A) When a cell is exposed to a lethal dose of cisplatin, 104-105 DNA adducts are
formed on the genome. If HMG-domain proteins bind with similar affinity to
these lesions and to their natural target sites, the protein would be titrated away
from their transcriptional regulatory function. B) The HMG-domain proteins
block access of the excision repair complex and shield the adducts from repair.
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Figure 1.7. Downstream effects of cisplatin-induced p53
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Figure 1.8. Whole body gamma camera image (anterior to the left, posterior
to the right) of a testis cancer patient 1 h after the end of a [191Pt]cisplatin
infusion. The platinum was still clearly detectable after 65 h but only
weakly visible 7 days after the infusion. Chemotherapy was performed
following surgery, so no macroscopic tumor tissue remained in the testis.
In a different patient, however, platinum was detected in a metastatic tumor
of the neck.
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Chapter Two
The Repair of Cisplatin-DNA Adducts by the Mammalian Excinuclease
80
Introduction (1-3)
Covalent adducts on genomic DNA are generated by cellular exposure to a
variety of agents, including external sources such as sunlight and cigarette smoke, as
well as internal sources such as oxidative metabolism. The presence of DNA lesions
can promote mutagenesis, resulting in permanent genetic changes and neoplastic
transformation (4). Alternatively, genotoxic stress can cause arrest in the cell cycle,
inhibit essential cellular processes, and activate cell death pathways such as apoptosis
(5). This second consequence of DNA damage is not always disadvantageous, and
can be exploited to benefit an organism by eliminating malignant cells. A case in
point is the current application of the toxic DNA-cross-linking agent cis-
diamminedichloroplatinum(II) (cisplatin) in the clinical setting. This drug is used to
treat a variety of human cancers, and is particularly effective against metastatic
testicular and ovarian tumors (6, 7).
Cisplatin binds to many of the macromolecules found in the cell, but it is
generally accepted that the drug exerts its effects through the formation of DNA
adducts (8). The 1,2-intrastrand d(GpG) and d(ApG) cross-links account for 90% of
all of the lesions formed, minor adducts include 1,3-d(GpNpG) intrastrand and DNA-
interstrand cross-links (9, 10). It is not clear if any one type of cross-link is the active
lesions in the anticancer activity of cisplatin, although the prevalence of the 1,2-
intrastrand adducts, as well as the fact that they are not formed by the inactive isomer
trans-DDP due to geometric constraints, makes them attractive candidates for this
role. Early gel electrophoresis experiments (11, 12), as well as more recent high
resolution structural analysis (13-18), established that all of the adducts induce
significant and distinctive distortions in the DNA double helix. Thus, it is likely that
they can be distinguished by cellular proteins that respond to and process the DNA
damage generated by cisplatin.
4
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Due to the disastrous consequences of genotoxic stress, the cell contains many
defense mechanisms to remove flaws from its DNA (19). One of the most versatile
pathways is nucleotide excision repair (NER), in which a multi-protein complex
cleaves the DNA on either side of a lesion. Excision of the damage in a small, single-
stranded, oligonucleotide fragment is followed by new DNA synthesis to fill the
ensuing gap (19, 20). The substrate range of NER is very broad, extending from large,
DNA-distorting adducts to mismatches (19), but the catalytic efficiency varies
depending on the lesion. There is substantial evidence to suggest that cisplatin-DNA
adducts are repaired by the NER pathway. Both mammalian and bacterial cells
deficient in the excinuclease activity are unusually sensitive to the drug (21-26), an
effect that was attributed to poor repair of the cisplatin-DNA cross-links.
Furthermore, the repair synthesis assay, which monitors the ATP-dependent
incorporation of a radioactive nucleotide into the repair patches of damaged DNA,
was used to demonstrate that a plasmid globally modified with cisplatin was
repaired in extracts from normal human lymphoid cell lines but not NER-deficient
cell lines (27). Attempts to use this assay in the study of the repair of the 1,2-d(GpG)
intrastrand adduct, however, were unsuccessful (28).
Unfortunately, as with other chemotherapeutic agents, the clinical success of
cisplatin is impeded by its inherently poor activity against some types of cancer as
well as the development of resistance after only a short term remission (29). DNA
repair has been implicated as a mechanism for both acquired and inherent cisplatin
resistance in several model systems (30). In particular, testicular tumor cell lines have
a reduced capacity to repair cisplatin-DNA adducts when compared to relatively
resistant bladder cancer cell lines (31-33). At this time, there is limited information on
the correlation between cisplatin sensitivity and DNA repair in human tissue. An
examination of the blood leukocytes of cancer patients undergoing cisplatin
chemotherapy revealed an inverse relation between adduct removal and clinical
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response (34). Clinical cisplatin resistance has been observed in tumors expressing
elevated levels of the mRNA for several of the excinuclease components (35, 36), or
exhibiting enhanced repair capacity as determined by a host cell reactivation assay
(37). Reports of DNA repair activity in extracts made from mammalian tissue
demonstrated significant variability in the repair capacity of the extracts but no
correlation with the clinical profile of the drug (38-40).
None of these previous studies have directly examined the mammalian
excision repair activity on the individual cisplatin-DNA adducts. Elucidation of the
differential processing of the cisplatin-DNA cross-links, which may be crucial to the
biological mechanism of the drug, is essential in order to design new therapies which
overcome the limitations of cisplatin. In the present study, the in vitro nucleotide
excision repair of several different kinds of cisplatin-DNA adducts was observed and
the activity of the excinuclease on the cross-links was compared. Furthermore, the
influence of extraneous cellular proteins on the excision of the cisplatin-DNA lesions
was determined by using purified repair factors. Finally, repair activity was
examined in extracts prepared from several cell types as well as human tissue.
Materials and Methods
Materials. Cisplatin was obtained as a gift from Johnson-Matthey. T4
polynucleotide kinase and T4 DNA ligase were purchased from New England
Biolabs (Beverly, MA) or Boehringer Mannheim. Glycogen, type XI from oysters, and
piperidine were purchased from Sigma. DMS and hydrazine were purchased from
Aldrich. Yeast tRNA, calf thymus DNA, and pBR322 plasmid DNA were purchased
from Gibco BRL. Protease inhibitors and proteinase K were purchased from
Boehringer Mannheim. The [y-32P]ATP was purchased from Amersham or Dupont,
NEN. The pET-15b/XPAC plasmid containing the gene for XPAC with a 6-histidine
tail was a gift from R. Wood (ICRF, UK) (41). The purified repair components were
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prepared by D. Mu (University of North Carolina) as described (42). The cisplatin-
modified 123 bp fragment was a gift from J. P. Whitehead (M.I.T.).
Cell-Free Extracts (CFEs). The HeLa S3 cell line was from the Lineberger
Comprehensive Cancer Center (University of North Carolina) or was supplied by P.
A. Sharp (M.I.T.). The wild-type rodent cell line (AA8), the xeroderma pigmentosum
complementation group F (XPF) rodent cell line (CHO-UV41), the XPG rodent cell
line (CHO-UV135), the F9 cell line, and the Nulli-SCC1 cell line were obtained from
the American Type Culture Collection Repository (Rockville, Maryland). Whole cell-
free extracts (CFEs) from, all cell lines were prepared by the method of Manley et al.,
stored at -80' and used through only two freeze/thaw cycles (43). The AA8, XPF and
XPF CFEs were prepared by J. T. Reardon (University of North Carolina).
Purification of XPAChs 6. The pET-15b/XPAC plasmid was transformed into E.
coli and the cells were grown and induced as previously described (41), except that 75
.tg/ml of ampicillan was used. All subsequent steps were performed at 4*C. Thawed
cells were resuspended in lysis buffer (20 mM Tris, pH 8, 200 mM NaCl, 0.5 mM
EDTA, 0.1% NP-40, 10% glycerol, 10 mM MgCl 2, 8 gg/ml aprotinin, 0.5 mg/ml
pefabloc) and lysed by two passages through a French press at 1500 psi. Following
centrifugation at 40 000 rpm for 45 min in an ultracentrifuge, the supernatant was
filtered through a 0.45 gm syringe filter, and then loaded onto a His-bind column
(Novagen). XPACiS was eluted according to the manufacturer's specifications. The
protein started coming off the column at about 70 mM imidazole. XPACis was
detected on Coomassie stained 12% SDS-polyacrylamide gels. The fractions
containing XPACis6 were pooled, 1 mM DTT and 8 jg/ml aprotinin were added, and
the resulting solutions were loaded onto a DNA cellulose column (Pharmacia)
equilibrated in buffer A (25 mM Hepes, pH 7.5, 1 mM EDTA, 10 mM p-
mercaptoethanol, 10% glycerol) containing 100 mM KCl. The protein was eluted with
a linear gradient of 100 mM to 1 M KCl in buffer A. It eluted in a broad peak at
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around 600 mM KC1. The fractions containing protein were concentrated in
Centriprep-10 concentrators (Amicon), dialyzed against storage buffer (25 mM
Hepes, pH 7.9, 100 mM KCl, 12 mM MgCl 2, 0.5 mM EDTA, 2 mM DTT, 16.5%
glycerol) and stored at -20'C. The purity of the protein was estimated to be >95% by
Coomassie staining of SDS-polyacrylamide gels.
Mobility Shift Assays with XPAC. A radioactively labeled 123-bp DNA
fragment globally modified with cisplatin (44), or the site-specifically modified repair
substrates, were incubated with the indicated amounts of protein and chicken 0
erythrocyte DNA in binding buffer (4% glycerol, 10 mM MgCl 2, 50 mM KCl, 1 mM
EDTA, 1 mM spermidine, 0.05% NP-40, 200 gg/ml BSA, 10 mM Hepes, pH 7.9) for
20-30 min on ice. The mixtures (10 pl) were combined with 0.6 p1 of gel-loading
solution (30% glycerol, 0.25% (w/v) bromophenol blue and 0.25% (w/v) xylene
cyanol) and loaded onto pre-run, pre-equilibrated (4*C) 6 or 8% native
polyacrylamide gels (29:1 acrylamide:N,N'-diallyltartardiamide). The gel was run in
0.5X TBE (45 mM Tris, 45 mM boric acid, 1.25 mM EDTA, pH 8.3) at 4*C, 300 V for 2-3
h and visualized by autoradiography with Kodak X-Omat film at room temperature.
Platinated Oligonucleotides. Oligonucleotides were synthesized on a 1 gmol 9
scale on a Cruachem PS250 DNA synthesizer and deprotected according to standard
methods. All of the oligonucleotides to be platinated were converted to their sodium
salts on a Dowex cation exchange resin (Aldrich) prior to platination.
Site-Specific Intrastrand Adducts. The synthesis of oligonucleotides containing
the 1,2-d(GpG), the 1,2-d(ApG) and the 1,3-d(GpTpG) cisplatin intrastrand cross-links
was performed as described (12); the 1,2-d(GpG) adduct was a gift from C. S. Chow 4
or U.-M. Ohndorf (M.I.T.). Briefly, cisplatin was allowed to react in aqueous solution
with 1.98 equiv of AgNO3 for 14-16 h at room temperature in the dark. The
precipitated AgCl was removed by centrifugation and the resulting aqueous solution 0
of cis-[Pt(NH 3)2(H2O) 2]2+ was used to treat the DNA at 37*C. Platination was carried
'a
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out using 100-400 gM DNA at a formal platinum:DNA strand ratio of 1.1-1.5. The
reactions were monitored by using reverse phase HPLC, Vydac C4 or C18 analytical
columns, linear gradients of 0-50% CH 3CN in 0.1 M NH 4OAc, pH 6.0. The platinated
oligonucleotides were purified on preparative scale reverse phase HPLC columns.
The purity of the platinated DNA was assessed by HPLC. The amount of DNA
present was estimated by using the calculated extinction coefficient at 260 nm (45),
and the amount of platinum bound per strand was determined by flameless atomic
absorption spectroscopy. The nature of the, platinum adducts was confirmed by
enzymatic digestion of the oligonucleotides before and after platination (46). DNase
1, P1 nuclease and alkaline phosphatase were used to digest the oligonucleotides into
their component nucleosides, which were separated on reverse phase HPLC.
Authentic standards cis-[Pt(NH 3 )2{d(GpG)}]+, c i s-[Pt(NH3)2{d(ApG)}]+ and cis-
[Pt(NH 3)2{d(G)2 }]2+ were employed to assign the products of digestion by HPLC (11).
Site-Specific Interstrand Adduct. The synthesis of the interstrand cross-link was
performed in a manner analogous to that previously described (47,48). Cisplatin was
treated with 0.98 equiv of AgNO3 for 14-16 h in DMF at room temperature in the
dark, and the AgCl formed was removed by centrifugation. Platination was carried
out with 0.4 mM DNA and a four-fold molar excess of platinum-to-oligonucleotide
strand in 10 mM NaClO 4 at 370C. The reaction was stopped after 10 min by making it
0.4 M in NaCl. The monofunctional adduct (20 nt) was purified by ion exchange
FPLC on a Mono Q HR5/5 column (Pharmacia) with linear gradients of 0.25-0.4 M
NaCl in 20 mM Tris, pH 8.0, then concentrated and washed with 0.4 M NaCl at 4*C in
Centriplus-3 concentrators (Amicon). The site of platination was verified by Maxam-
Gilbert sequencing analysis (48, 49). The platinated strand (20 nt) was allowed to
anneal with 0.75 equivalents of its complement (32 nt) in 0.45 M NaCl, 2 mM MgCl2,
20 mM Tris pH 7.4 for 2 h at room temperature and then for 2.5 h at.4*C. The DNA
was washed extensively with 100 mM NaClO 4, 1 mM Mg(N0 3 )2 in Microcon-3
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concentrators (Amicon) at 4*C and then incubated at 37*C for 40 h. The interstrand
cross-link was purified on a Mono Q HR5/5 column with linear gradients of 0.4-0.6
M NaC1 in 10 mM NaOH. The DNA was concentrated in Centricon-3 concentrators
(Amicon) at 4'C, precipitated with ethanol, and stored in 5 mM Tris pH 7.5
containing 50 mM NaClO 4. The presence of the interstrand cross-link was verified by
5'-end labeling with T4 polynucleotide kinase and [y- 32P]ATP followed by analysis
on 15% denaturing polyacrylamide gels. The decreased mobility of the platinated
duplex oligonucleotide, which could be reversed by NaCN treatment (0.2 M, pH 10-
11, 45'C overnight), confirmed the presence of the cross-link. In addition, its location
was determined by 5'-end labeling the monofunctionally platinated 20-mer or its
complementary 32-mer prior to annealing the two strands. The interstrand cross-link
was then isolated on 15% denaturing polyacrylamide gels and analyzed by Maxam-
Gilbert sequencing (see below).
Maxam-Gilbert Sequencing Reactions. The DNA was dried, resuspended in S
water, and the radioactivity was counted. Up to 500,000 cpm were used for the
sequencing reactions.
G specific reaction. The DNA (9 p1) was incubated on ice for 10 min with 190 pl of
dimethyl sulfate (DMS) buffer (50 mM NaCacodylate, pH 7.0, 1 mM EDTA pH 8.0)
and 4 g1 of 1 mg/ml calf thymus DNA (Gibco BRL). DMS was added (5 g1 of 10%
DMS in ethanol) and the reaction was incubated for 10 min at room temperature
before adding 50 g1 of DMS stop solution (1.5 M NaOAc, pH 7.0, 1 M 2-
mercaptoethanol, 250 pg/ml yeast tRNA), 750 pl of ethanol, and 20 pg of oyster
glycogen.
C+T specific reaction. The DNA (20 gl) was incubated on ice for 10 min with 5 pl of 1
mg/ml calf thymus DNA. Hydrazine (30 pl) was added to the DNA and the
reactions were incubated for 5 min at 37'C before adding 200 p1 of hydrazine stop
6
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solution (0.3 M NaOAc, pH 7.0, 0.1 mM EDTA, 100 pg/ml yeast tRNA), 20 jg of
oyster glycogen, and 750 jl of ethanol.
All reactions were incubated at -80*C for at least 2 h and then the DNA was
precipitated by spinning in a microcentrifuge for 30 min at 4*C. The supernatant was
removed, the DNA was washed with 1 ml of cold 70% ethanol, and the DNA was
precipitated again by adding 270 jl of water, 30 l of 3 M NaOAc, 750 pl of ethanol,
and incubating at -80*C for at least 2 h. Following centrifugation at 4C, the DNA
was washed with 100% cold ethanol and then dried. The reaction samples were
incubated overnight in 50 pl of 0.2 M NaCN (pH > 10) at 45'C. The DNA was
precipitated with 15 pg of oyster glycogen, 5 l of 3 M NaOAc, and 130 pl of ethanol,
washed with cold 95% ethanol, then with cold 70% ethanol, and dried. The DNA was
then treated with 1.0 M piperidine for 30 min at 90*C. The reactions were lyophilized
and washed several times with water before counting and loading onto a 20%
denaturing sequencing gel.
Intrastrand Cross-Linked Substrate. Linear 156-bp duplexes were assembled
from three sets of complementary oligonucleotides with overhangs 6 nt long
following 5' end-labeling of the damaged 12-mer with [y-3 2 P]ATP and T4
polynucleotide kinase (2). This procedure introduces a radioactive label at the fifth
phosphodiester bond to the 5' side of the site of damage in the 1,2-d(GpG) and 1,2-
d(ApG) substrates, and at the fourth phosphodiester bond to the 5' side of the
damage in the 1,3-d(GpTpG) substrate. For some of the experiments with CFEs
prepared from tumors or testicular teratocarcinoma cell lines, a 158 bp substrate was
prepared with 3 phosphorothioate linkages and 1 nt overhangs at both of the 3' ends.
Cholesterol Substrate. The cholesterol substrate was analogous to the cisplatin
intrastrand cross-linked substrates. It was a 140 bp duplex with a cholesterol moiety
attached to a propanediol backbone at position 70 of the damaged strand (Operon
Biotechnologies, Almeda, CA). This cholesterol-containing duplex is an efficient
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substrate for the mammalian excinuclease and was prepared as previously described
(50).
Interstrand Cross-Linked Substrate. The interstrand cross-linked substrate was
also assembled from three sets of oligonucleotides except that both strands of the
platinated duplex were 5'-end labeled with [y-32 P]ATP before ligation to the annealed
pairs of arms at 4'C. The ligation products were purified by electrophoresis on 5%
native polyacrylamide gels. The presence of the interstrand cross-link was verified
by comparing the mobility of the substrate before and after NaCN treatment (0.2 M, S
pH 10-11, 45*C overnight) on a 6% denaturing polyacrylamide gel. An impurity was
detected, so the substrate was further purified on a 6% denaturing polyacrylamide
gel. The product was not reannealed following this purification step, but restriction
enzyme digests confirmed that the substrate contained double-stranded DNA (data
not shown).
Excision Assay with CFEs. Whole cell extracts were used to measure excision of
the damaged DNA according to a previously described method (2, 50). The reaction
conditions varied slightly as improvements were made. Briefly, the standard
reactions (25 gl) contained 4-5 gl of reaction buffer (300 mM Hepes pH 7.9, 400 mM 9
KCl, 32 mM MgCl 2, 1 mM EDTA, 20-50 mM ATP, 2 mM DTT), 5 gl of p21 buffer (50
mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 1 mM 2-mercaptoethanol), 20 RM of
each dNTP, 0.2 mg/ml bovine serum albumin (BSA), 50-120 ng of pBR322 as non-
specific competitor DNA, 50-250 pM substrate, and 3-5 l of CFE in storage buffer (25
mM Hepes pH 7.9, 100 mM KCl, 12 mM MgCl 2, 0.5 mM EDTA, 2 mM DTT and 12.5-
16.5% glycerol). Several different types of assay conditions were used, but all
reaction mixtures contained 50-100 jg of CFE and were incubated at 30*C for 45 min
unless otherwise indicated. For the complementation assay, a 50 jI reaction volume
was used containing 20 jl of CFEs from XP complementation groups F or G, a
mixture of the two, or HeLa CFE. For the kinetic studies, 125 pl reaction volumes
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were used containing 25 l of CFE in storage buffer, and aliquots were removed from
the reaction at each time point. The reactions were stopped by making them 0.5% in
SDS and 0.4 mg/mi in proteinase K (Gibco BRL) and heating at 55*C for 15 min.
After two phenol/chloroform/isoamyl alcohol (25:24:1) extractions and an ether
extraction, the DNA was precipitated with 30 gg of oyster glycogen and ethanol,
washed with 70% ethanol, dissolved in formamide loading buffer (80% formamide
(v/v), 10 mM EDTA, 1 mg/ml each xylene cyanol FF and bromophenol blue), and
resolved on a 10% denaturing polyacrylamide gel. When the interstrand cross-linked
substrate was used, reaction products were treated overnight with 0.2 M NaCN, pH
10-11, at 45*C, to remove the DNA-bound platinum, and precipitated with ethanol
prior to resolution on the gel. The gels were vacuum dried on Whatman 3 mm
chromatography paper and exposed to X-ray film (Kodak, X-OMAT AR) at -80*C
with an intensifier screen. The level of excision was quantitated by an AMBIS
Systems scanner, by using a PhosphorImager with ImageQuant software (Molecular
Dynamics), or on a BioRad GS-525 Molecular Imager System.
Reconstituted Excision Assay. The excision assay with highly purified repair
components was performed as previously outlined (42). The reaction buffer
described above was used, except that the pBR322 and dNTPs were omitted and 4
mM ATP (Boehringer Mannheim) was added separately. The purified repair factors
were in 8 I of storage buffer for a 25 1tl reaction, and consisted of 20 ng of XPA, 1-2
ng of TFIIH, 7 ng of XPC, 1-2 ng of XPG, 1-2 ng of XPF/ERCC1 and 250 ng of RPA.
For the kinetic studies 25-50 [d reactions were incubated at 300C and aliquots were
removed at the times indicated.
Cell-Free Extracts from Tumor Tissue. Tumor tissue was obtained from the
Massachusetts General Hospital Pathology Dept. under the direction of Dr. R. Colvin,
or from the Cooperative Human Tissue Network, Western Division. Tumors were
either used fresh (40C) or snap-frozen in N2(1) following surgery, shipped on dry ice
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and stored in N2(1). One of the three following methods for preparing cellular
extracts was used. In some trials, protease inhibitors were added to the
homogenization buffers (1 gg/ml aprotinin, 10 [tg/ml leupeptin, 0.5 mg/ml pefabloc,
10 gg/ml pepstatin and 1 mM benzamidine) and the dialysis buffer (1 pg/ml
aprotinin, 1 pM leupeptin, 100 pM pefabloc, 0.5 gM aprotinin), but this step did not
affect the repair activity of the extracts. The protein concentration of the extracts was
determined by Bradford assay (BioRad or Pierce), with bovine serum albumin used
as a standard.
Manley method. Several methods of breaking up the tissue were tested. Some tissue
samples were pulverized in a mortar and pestle (pre-cooled at -80*C) under N2(1).
Other tissue samples were minced with a razor blade, followed by suspension in
hypotonic solution (10 mM Tris, pH 8, 1 mM EDTA, 5 mM DTT) and homogenization
with 10 s pulses of a polytron (Brinkman Instruments, Kinematica, PCU-2) or with a
Potter-Elvehjem Teflon-glass electric dounce homogenizer (Kontes). Some tissue
samples were pushed through a metal tissue sieve with glass pestle (Thomas
Scientific). Finally, one sample was digested with collagenase according to a
previously described method (51). All work with the tissue was done at 4*C or on
ice. All subsequent steps in the CFE preparation were performed as described (43).
Some extracts were further concentrated either in microcon-3s (Amicon) or in
Biomax-5K Ultrafree centrifugal concentrators (Millipore). Aliquots of the extracts
were frozen in N2(1) and stored at -80'C.
Husain method. This method is slightly modified from a previously described
procedure for the isolation of active topoisomerase 1 from human tumors (52). The
tumor sample was ground in a mortar and pestle (precooled at -80*C) under N 2(1),
suspended in 4 ml of buffer A (10 mM Tris pH 7.5, 10 mM EDTA, 10 mM f-
mercaptoethanol, 0.25% Triton X-100) and homogenized with a Potter-Elvehjem
Teflon-glass electric dounce homogenizer. After incubation on ice for 30 min, 4 ml of
0
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buffer B (buffer A with 2 M NaCI) was added slowly and the mixture was stirred for
30 min at 4*C. The mixture was cleared by centrifugation at 10 000 rpm for 2 h in an
SS-34 rotor. Polyethylene glycol 8000 was added slowly to the supernatant to a final
concentration of 5% (w/v). The mixture was stirred for 30 min at 4*C and then
cleared in a microcentrifuge. The supernatant was dialyzed (20 mM Tris pH 7.5, 50
mM NaCl, 1 mM EDTA, 10% glycerol, 10 mM f-mercaptoethanol) for 2 h and
concentrated in microcon-3 concentrators. Aliquots were frozen in N2(1) and stored at
-800C.
Nuclear extract method., This method is a modification of a previously described
procedure for the isolation of transcriptionally active nuclear extracts from tissue (53,
54). The tissue was minced with a razor blade, suspended in 6 ml of homogenization
buffer (10 mM Hepes pH 7.9, 25 mM KCl, 1 mM EDTA, 2 M sucrose, 10% glycerol, 0.5
mM spermidine, 0.15 mM spermine, 1 mM benzamidine) and homogenized by using
10 sec pulses of the polytron. The homogenate was layered over 1/3 vol
homogenization buffer in a centrifuge tube and centrifuged for 45 min at 26 000 rpm
in a SW Ti4l ultracentrifuge rotor. The pellet was resuspended in 3.5 ml of lysis
buffer (10 mM Hepes pH 7.9, 100 mM KCl, 3 mM MgCl2, 0.1 mM EDTA, 10%
glycerol, 1 mM DTT) by using a dounce homogenizer (pestle A) and 1/10 vol of 4 M
ammonium sulfate was added. The solution was stirred for 30 min on ice and the
precipitate was removed by centrifugation for 1 h at 32 000 rpm in a Ti50.2 rotor.
Solid ammonium sulfate was added to a final concentration of 0.3 g/ml; the solution
was stirred for 30 min on ice and cleared by centrifugation for 30 min at 32 000 rpm.
The protein pellet was resuspended in dialysis buffer (25 mM Hepes, pH 7.9, 40 mM
KCl, 0.1 mM EDTA, 10% glycerol, 1 mM DTT), dialyzed for 2 h, and concentrated in
microcon-3 concentrators; aliquots were frozen in N2(1) and stored at -80*C.
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Results and Discussion
The Binding of XPAC to Cisplatin-Modified DNA. The nucleotide excision repair 0
pathway can be divided into three steps, damage recognition, dual incision and
repair synthesis (19). The isolation and characterization of the individual
excinuclease components were facilitated by cells from patients harboring the human
disease xeroderma pigmentosum (XP), which is a condition arising from defective
nucleotide excision repair (55). This disease is categorized into seven different
complementation groups, each arising from a defect in one of the repair factors. 9
Group A XP patients present with some of the more severe characteristics of this
disorder (55), and the protein that complements the repair deficiency of XPA cells
(XPAC) contains a zinc-finger DNA-binding domain (56). It has been suggested that
XPAC plays a key role in sensing genetic damage, so if cisplatin-DNA cross-links are
removed by NER, the adducts should be recognized by this repair factor. Previous
studies revealed that XPAC does bind different types of DNA lesions, including those 9
found in UV-, osmium tetroxide- and cisplatin-modified DNA (41, 57, 58). The
mobility shift assay presented in Figure 2.1A confirms that XPAC (expressed with an
N-terminal 6-histidine tail, XPACis6) does specifically bind to DNA globally modified 0
with cisplatin. In this experiment, a protein known to specifically recognize cisplatin-
DNA adducts, HMG1 (59), serves as a positive control.
Cellular proteins that specifically recognize cisplatin-modified DNA could
interfere with the excinuclease and modulate the cytotoxicity of the lesions. Thus it
would be informative to study the competition between such proteins and XPAC by
using DNA-binding assays. For this type of experiment, the use of a single, site-
specific, cisplatin-DNA adduct is preferred because some proteins can distinguish
between the types of cross-links. Furthermore, a single adduct should avoid the
complications arising from multiple binding sites. Accordingly, mobility shift assays
were employed to compare the binding of XPAC and HMG1 to a 1,2-d(GpG)
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cisplatin-DNA intrastrand adduct. Specific binding of HMG1 to the substrate
produced a complete shift under conditions in which none of the unmodified DNA
was bound (Figure 2.1B). However, that level of specificity was not achieved with
XPAChis6, even though many different conditions were used (Figure 2.1B and data not
shown). This result is in agreement with previous reports that the affinity of XPAC
for cisplatin-damaged over undamaged DNA is fairly modest (41, 57, 58). It is
possible that XPAC is not the exclusive damage-recognition component of the
excinuclease since the human single-stranded DNA binding protein RPA also
specifically binds to cisplatin-modified DNA (60, 61). Furthermore, the first stable
complex on the excision reaction pathway that can be isolated on substrate DNA
contained XPAC, RPA, as well as several other factors (62). It is likely that XPAC acts
as a DNA damage sensor with only weak specificity, and that tight binding is
realized only upon the recruitment of more excinuclease components to the site of the
lesion. This theory suggests that an in vitro investigation into the effects of cellular
proteins such as HMG1 on excision repair of cisplatin-DNA adducts will require the
use of multi-protein repair complexes.
Repair of the Cisplatin-DNA Intrastrand Adducts by the Mammalian Excinuclease.
To study the repair of cisplatin-DNA adducts in vitro, the excision assay described in
Figure 2.2A was used. A single, site-specific cisplatin-DNA adduct was prepared in a
small oligonucleotide, which was then 5'-end labeled and annealed to a
complementary strand of DNA. Ligation to two pairs of oligonucleotides yields a
156-bp substrate with a radiolabel several bases to the 5' side of the platinum lesion.
When the 1,2-d(GpG) and 1,3-d(GpTpG) intrastrand adducts were incubated with
HeLa CFE, and analyzed on a denaturing polyacrylamide gel, a pattern of small DNA
fragments, 25-31 nt in length, was observed, indicating excision near the damaged
site (Figure 2.3, lanes 1 and 5). Unlike the prokaryotic excinuclease, the mammalian
counterpart does not have a very strict cutting pattern, with most of the variability
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occurring primarily at the 5' incision, resulting in the observed ladder of bands (63,
64). This signal was not detected following incubation with CFEs from cell strains of
XP patients (Figure 2.3, lanes 2, 3, 6 and 7). When extracts from two different
complementation groups, in this case XPF and XPG, were incubated together with the
substrate, repair activity was restored and excision of the damaged DNA was 4
apparent (lanes 4 and 8). This behavior is characteristic of the specific action of the
mammalian excinuclease on damaged DNA (65). Similarly, the second most
abundant cisplatin-DNA lesion, the 1,2-d(ApG) intrastrand adduct, is also repaired 0
by the mammalian excinuclease, resulting in excision of oligonucleotides 25-31 nt
long (Figure 2.4). This ladder of bands was not observed upon incubation of an
unmodified repair substrate with HeLa CFE (data not shown). The lower mobility 0
bands near the top of the gel were present at comparable levels following incubation
of both modified and unmodified probes in CFE (data not shown), suggesting that
they are a product of non-specific nucleases. 0
The observation that the cisplatin-DNA intrastrand adducts are excised by the
mammalian excinuclease expands our understanding of the biological mechanism of
action of cisplatin. A previous report suggested that the 1,2-d(GpG) cross-link was 0
not removed by nucleotide excision repair (28), but the experiments were performed
with the repair synthesis assay. The assay employed here may be more sensitive,
because it measures excision of the radiolabel as opposed to incorporation of
radioactive nucleotides into a damaged substrate, which is difficult to detect above
background. Further work with the repair synthesis assay, with perhaps more
favorable reaction conditions, subsequently confirmed that the 1,2-intrastrand
adducts are repaired by the mammalian excinuclease (66).
Many types of lesions that distort the DNA double helix are repaired by the
mammalian excinuclease, but the efficiency of repair can vary by more than an order 0
of magnitude (19, 67). Furthermore, there is evidence to suggest that the cisplatin-
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intrastrand adducts are structurally distinct (12, 68), which may affect recognition
and repair by the excinuclease and thus the cytotoxicity of the cross-links. The
variations in conformation between the 1,2- and 1,3-intrastrand cross-links are
manifest in the excinuclease activity on the cisplatin-modified substrates. As shown
in Figure 2.3 (and data not shown), the repair of the 1,3-d(GpTpG) intrastrand adduct
in HeLa CFE is significantly more efficient than that of the 1,2-d(GpG) intrastrand
cross-link, a result that was recently confirmed by experiments with the alternative
repair synthesis assay (66).
The relative rates of excision of the two 1,2-intrastrand cross-links were
determined by incubating the site-specifically platinated probes in HeLa CFE for
increasing amounts of time (Figure 2.5). As the incubation time lengthened, the 25-29
nt excision products were digested by non-specific nucleases in the whole cell
extracts, resulting in the detection of additional bands corresponding to material
smaller than 25 nt. The experiment shown in Figure 2.5A was repeated three times,
but differences among the preparations of CFEs caused some variability in the levels
of excision. For this reason, data from each experiment were normalized to the
highest level of repair (consistently the 90 min time point for the AG substrate). The
resulting plot reveals that both of the 1,2-intrastrand adducts are repaired in a similar
fashion (Figure 2.5B). In all of the experiments, however, the 1,2-d(ApG) adduct was
a better substrate for the excinuclease, with the level of excision about 30% higher
than that detected for the 1,2-d(GpG) adduct after 90 min of incubation in HeLa CFE.
The relative rates of repair of the cisplatin-DNA intrastrand cross-links
(GTG>AG>GG) observed in the HeLa CFE agree with studies of prokaryotic repair
(69), but see (70), although that work was performed with a 1,2-diaminocyclohexane
ligand bound to platinum in place of the two ammine groups of cisplatin. Both the
d(GpG) and the (ApG) 1,2-intrastrand adducts bend and unwind the DNA to a
similar extent (11, 12), so the small but reproducible difference in the relative rates of
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repair is not a result of global changes in the DNA structure. These two intrastrand
adducts produce distinct responses in several other biological pathways, however.
For example, the d(ApG) adduct is more mutagenic than the d(GpG) adduct (10, 71),
and it is more readily bypassed by a variety of bacterial DNA polymerases (72). This
disparity must be due to local structural variations in the platinated bases, providing 0
a slightly altered recognition element for the excinuclease or other cellular factors.
Repair of the Interstrand Cross-Linked Substrate. In addition to intrastrand
adducts, cisplatin also covalently cross-links the guanosine nucleosides on opposing S
strands in 5'-d(GpC)-3', sequences (49). Biochemical methods, as well as high
resolution NMR structures, demonstrated that the interstrand cross-links produce
dramatic conformational changes in DNA (13, 16, 73). The DNA distortions include a
bending and unwinding of the duplex, a local reversal to a left-handed helix, and
extrahelical extrusion of the complementary cytosines. Although interstrand cross-
links comprise fewer than 5% of the lesions formed when cisplatin binds to DNA (10,
74), they have been implicated as the cytotoxic lesion (75). Furthermore, removal of
the interstrand cross-links from genomic DNA has been associated with cisplatin
resistance of certain cultured cell lines (31, 76, 77). Thus, it is possible that interstrand 0
cross-links contribute to the mechanism of action of cisplatin.
To test this hypothesis, a site-specific interstrand cross-link was constructed
between two complementary oligonucleotide fragments 20 and 32 nt in length.
Maxam-Gilbert sequencing was used to demonstrate that the platinum was
covalently bound to the guanine bases of the d(GpC) sequence (Figure 2.6); the bond
between the platinum and the N7 of the cross-linked guanines blocks the G-specific
reaction with DMS (48, 49). A radioactive label was introduced on both strands of the
duplex in order to facilitate detection of cleavage sites on either side, and this
complex was ligated with two pairs of oligonucleotides to prepare a 164 bp 0
interstrand cross-linked substrate (Figure 2.2B). The probe was incubated under
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excision assay conditions in the absence of cell extracts, followed by analysis on a
denaturing polyacrylamide gel (Figure 2.7, lane 5). To detect the low levels of
excision repair in the other lanes, the whole gel was overloaded, resulting in the
visualization of very small amounts of impurities surrounding the full length probes.
Nevertheless, it is clear from the reduced mobility of the major band, in comparison
to the intrastrand adduct, that most of the material contains the interstrand cross-link.
Extracts prepared from CHO AA8 cells were employed in the assay for repair
of the interstrand adduct because they provide a high level of excinuclease activity,
but HeLa CFE afforded the same results (data not shown). To detect products arising
from incision on only one strand of the duplex, the platinum adduct was released
after incubation with CFE by treating the DNA with NaCN (49). The 1,2-d(GpG)
intrastrand adduct was run as a positive control to ensure that the extract was active
in nucleotide excision repair (Figure 2.7, lane 3). After NaCN treatment, the pattern
of bands resulting from excision of the control substrate increased in mobility by one
nucleotide (compare lanes 3 and 4), as expected for removal of the positively charged
platinum complex from the excised oligonucleotide fragments. NaCN treatment of
the interstrand cross-linked substrate released two oligonucleotides having slower
mobility than that of the 30 nt marker (lane 6), even after extensive native and
denaturing polyacrylamide gel purification steps. The impurity might arise from
some interstrand cross-linked oligonucleotide ligated to the arms of the probe DNA
only at the ends of the 20-mer; incomplete NaCN reversal would result in the release
of two products, an unmodified 32 nt fragment and a platinated 32 nt fragment. Two
solution structures of cisplatin-modified DNA containing an interstrand cross-link
revealed that the adduct can cause a marked disruption of the B-DNA duplex (13, 16),
which might account for the poor ligation efficiency observed in the present study.
The two new bands were not observed when the substrate was incubated with CFE
prior to cyanide treatment (lane 8), presumably because of nuclease degradation of
98
the impurity. Of greater consequence, however, is that following incubation in cell
extracts no excision products were detected, either before or after NaCN treatment.
Varying the incubation times and the amount of substrate used did not alter this
result (data not shown). Although a faint pattern of bands was observed in the range
between the 30 and 24 nt markers, these features were no more prominent than in 0
other regions of the autoradiograph and are ascribed to non-specific nuclease activity.
In vitro removal of the cisplatin interstrand cross-link by the repair synthesis
assay was previously reported (78). This assay measured the amount of new DNA
synthesized after damage removal in whole cell extracts, however, so the signal could
have been a result of repair other than nucleotide excision. Studies in cell strains
derived from patients with Fanconi's anemia (FA) suggest that NER may not be the 0
primary pathway for removing the cisplatin-DNA interstrand cross-links (23, 25).
Although NER is active in FA cells, they have a deficiency in the repair of interstrand
cross-links, a fact that explains their extreme sensitivity to various DNA cross-linking
agents including cisplatin (79).
A recent investigation of a psoralen interstrand cross-link suggested that the
mammalian excinuclease attempts to repair this type of lesion, but in a different 0
fashion than for any other type of damage (80). The excinuclease hydrolyzed two
phosphodiester bonds about 22-28 nt apart, both 5' to the cross-link and on the same
strand, producing a gap several nucleotides 5' to the cross-link. The cisplatin
interstrand cross-linked substrate used in the study described here contained a
radioactive label at the 10* phosphodiester bond tothe 5' side of the damage on one
side of the duplex and 16 nt to the 5' side of the damage on the other strand. Thus, if 0
nucleotide excision occurred by the standard mechanism, with cleavage sites about 5
nt 3' and 20-24 nt 5' from the adduct, or in the same manner as the psoralen cross-link,
it would be detected in this assay. The fact that we were unable to detect any 0
nucleotide excision products of the cisplatin-interstrand cross-linked substrate might
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be the result of impurities in our probe that obscured its repair. We consider this
possibility to be unlikely, however, and conclude that the cisplatin interstrand cross-
link is not removed by the mammalian NER pathway in the same manner as the
intrastrand adducts, unless the efficiency is so low that it is undetectable in this assay.
This conclusion is in agreement with the recent demonstration that the trans-DDP
interstrand adduct is also refractory to repair by NER (S. S. Marla, personal
communication).
Repair of the Cisplatin Intrastrand Adducts in a Reconstituted System. There are
many cellular proteins that bind to cisplatin-DNA adducts and might, in this manner,
affect their processing (30). Some proteins, such as HMG1 (59), specifically recognize
the 1,2-intrastrand adducts and could selectively block access of the excinuclease to
these lesions. In contrast, the 1,3-intrastrand cross-links are poor targets for
recognition by HMG1 and its analogues, providing a possible explanation for the
more efficient repair of the 1,3-intrastrand adduct observed in the HeLa CFE. To
study the nucleotide excision repair of cisplatin-DNA adducts in the absence of any
potentially interfering factors, the relative rates of repair of the site-specifically
platinated substrates were compared in a reconstituted system of highly purified
repair components (64). The repair signal of all three intrastrand adducts increased
with time over a 3 h period (Figure 2.8). This result differs from the plateau observed
in the whole cell extracts after 40-50 min (Figure 2.5B). The amount of repair detected
was fairly small (0.5-2%) (42).
In the reconstituted system, the most rapidly excised cisplatin-DNA
intrastrand adduct is the 1,3-d(GpTpG) cross-link (Figure 2.8B). The fact that more
efficient repair of the 1,3-intrastrand cross-link compared with the 1,2-intrastrand
adduct was observed both here and in the HeLa CFEs reflects the degree of
unwinding of the platinated DNA (12). Although the difference is more pronounced
in the cell extracts, these results suggest that extraneous cellular proteins in the HeLa
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CFE can only influence the repair of the cisplatin-DNA adducts to a small degree.
Similarly, a comparison of the 1,2-d(GpG) and 1,3-d(GpTpG) intrastrand adducts in 4
the repair synthesis assay revealed a 15-20 fold difference in repair efficiency, and
fractionation of the HeLa cell extracts did not isolate any factors which changed the
relative levels of repair (66). An examination of the rate of incision of cisplatin-DNA 4
adducts by the bacterial UvrABC endonuclease demonstrated the 1,3-d(GpCpG)
intrastrand adduct to be incised less efficiently than the 1,2-d(GpG) intrastrand cross-
link (70). The rate of UvrC binding to the 1,3-d(GpCpG) preincision complex was 4
faster than to the 1,2-d(GpG) preincision complex, however. Thus both mammalian
and prokaryotic excision repair systems can distinguish between the two types of
cisplatin-intrastrand cross-links, even if some divergence between the two pathways 4
is reflected in the relative rates of repair. It should be noted that each adduct was
studied in the context of only a single sequence, which can influence the recognition
by cellular proteins (81).
The relative rates of excision of the two 1,2-intrastrand adducts in the
reconstituted system were indistinguishable over a period of several hours (Figure
2.8), in contrast to the HeLa CFE (Figure 2.5). This result demonstrates that the
slightly faster rate of excision of the 1,2-d(ApG) adduct observed in the whole cell
extracts, compared to the 1,2-d(GpG) adduct, is not caused by differential recognition
of the two adducts by the excinuclease. Instead, it is possible that cellular factors that
can distinguish between the 1,2-intrastrand adducts (discussed above) affect the
relative rates of repair. A recent study of the levels of bifunctional DNA adducts
formed in CHO cells exposed to cisplatin or carboplatin revealed a positive 4
correlation between cytotoxicity and the 1,2-d(ApG) adduct (82). This result might be
explained by differential processing of the adducts, but since the 1,2-d(ApG) cross-
link was repaired at least as efficiently as the 1,2-d(GpG) intrastrand adduct (Figures
4
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2.5 and 2.8), this difference in cytotoxicity between the 1,2-intrastrand adducts cannot
be ascribed to excision repair.
Repair of Cisplatin-DNA Intrastrand Adducts in Murine Testicular Teratocarcinoma
CFEs. The introduction of cisplatin as a chemotherapeutic option has had the largest
impact in the treatment of testicular cancer, which is now one of the most curable
types of solid tumors (83, 84). A significant amount of work on cisplatin has focused
on testicular tumors, in the hope that information about the efficacy of the drug will
lead to better therapies for other types of cancer. Many studies of cisplatin employed
cultured cell lines that retain the relative clinical chemosensitivities of their tumors of
origin. One hypothesis to explain the cisplatin hypersensitivity of testicular tumor
cell lines (85, 86) involves a deficiency in repair of the DNA adducts (33). In
particular, several studies which examined the removal of specific cisplatin-DNA
adducts by immunochemical analysis could not detect any repair of the 1,2-
intrastrand cross-links in some cell lines (31, 32).
To investigate the excision repair of the different site-specific cisplatin-DNA
adducts in testicular tumor cells, CFEs were made from the F9 mouse testicular
teratocarcinoma cell line. Following incubation of the cisplatin-DNA intrastrand
adducts with HeLa or F9 CFEs, the repair products were analyzed on a denaturing
polyacrylamide gel. Figure 2.9 demonstrates that the 1,3-d(GpTpG) cross-link is
excised in a similar manner in both the F9 and HeLa CFEs (compare lanes 7 and 11).
When the 1,2-d(GpG) intrastrand adduct was incubated with F9 CFEs, however, the
signal was different then that generated by HeLa CFEs (compare lanes 1 and 5). The
typical pattern of bands 25-29 nt was barely detectable above the background of non-
specific degradation. Instead, smaller DNA fragments were observed, which are due
to an alternative repair pathway or some other DNA nuclease activity. Similarly,
deficient excision of the 1,2-d(GpG) intrastrand adduct was observed in extracts
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made from the Nulli-SCC1 mouse testicular teratocarcinoma cell lines (data not
shown).
The levels of repair of the 1,2-d(GpG) intrastrand adduct in the F9 extracts
were so low that it was difficult to isolate this signal from the background of non-
specific degradation. To eliminate this problem, each reaction was performed in
duplicate, with or without ATP. In the absence of ATP, the percentage of
radioactivity detected in the region of the excision products was designated as
background and this value was subtracted from the amount of repair detected in the
presence of ATP. This calculation is based on the fact that the excinuclease activity is
ATP-dependent (19), and the assumption that non-specific nucleases are ATP-
independent (87).
Table 2.2 is a summary of the repair of the cisplatin-intrastrand adducts
following incubation with HeLa or F9 CFEs for 30 or 60 min. It is inappropriate to
compare the levels of DNA repair between two different extract preparations because
there are no internal controls to normalize the data. Accordingly, the amount of the
1,2-d(GpG) and 1,3-d(GpTpG) intrastrand cross-links repaired was compared in each
extract preparation. The percent repair was calculated by two different methods.
The data listed in Table 2.2.1 were calculated by assuming that all of the DNA
fragments smaller than about 32 nt were generated by nucleotide excision and
degradation of the excision products. In Table 2.2.2, the data were calculated by 4
assuming that the excision repair products were only about 22-32 nt long (19), and
that smaller DNA fragments were due to non-specific DNA degradation of the repair
substrate. By using either method, the ratio of repair of the 1,3-d(GpTpG) and 1,2-
d(GpG) adducts is much larger in the F9 CFEs than in HeLa, reflecting the poor
repair of the 1,2-intrastrand adduct observed in the mouse testicular teratocarcinoma
cell extract (Figure 2.9).
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A recent report demonstrated that protein recognition of the 1,2-d(GpG)
cisplatin-DNA adduct is influenced by the nucleotides flanking the cross-link (81).
For this reason, a site-specifically cisplatin-modified repair substrate was prepared
with the adduct in a different sequence context than the G*G* substrate used in the
experiments described above (CG*G*C, Table 2.1, the asterisks indicate the sites of
platination). The ratio of repair levels of the CG*G*C substrate in comparison with
the 1,3-d(GpTpG) adduct is smaller in the HeLa CFE than that of the G*G* substrate.
This result is due to a larger level of repair of the CG*G*C substrate in the HeLa CFE
(data not shown). This experiment demonstrates that the sequence context of a
cisplatin-DNA adduct can affect the excinuclease activity. In a similar manner as the
G*G* substrate, however, the CG*G*C substrate was also poorly repaired in the F9
CFEs (data not shown), resulting in a larger G*TG*/CG*G*C ratio of repair in the F9
CFEs than in the HeLa CFEs (Table 2.2). Thus the deficient repair in the F9 extracts is
not limited to the 1,2-d(GpG) intrastrand adduct in a single sequence.
Although these data support the hypothesis that testicular tumor cells are
sensitive to cisplatin due to deficient repair of the major DNA adduct, there are
several caveats such a conclusion. First, the comparison is being made between a
mouse testicular teratocarcinoma cell line and a human cervical carcinoma cell line.
The HeLa CFEs were used because they are known to be proficient in excision repair
of cisplatin-DNA adducts. Future work should focus on human testicular
teratocarcinoma cell lines, and the relative levels of repair in extracts from multiple
cell types should be determined and correlated with cisplatin sensitivity. Second,
there is an inherent variability in the in vitro repair assay (88), most of which
probably arises during extract preparation. As shown in Figure 2.9, the levels of
repair can vary significantly between extract preparations from the same cell type.
The ratio of repair of the 1,2- and 1,3-intrastrand adducts in two HeLa CFE
preparations differs by a factor of 2.5 (compare lanes 7 and 9). It might be possible to
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use some form of internal control to normalize the repair activity of CFEs, however
nothing appropriate has yet been described. Hence, the in vitro repair assay may not
be suited for this type of experiment, and repair of the cisplatin-DNA adducts in
different models may be best monitored in vivo.
Repair of Cisplatin-DNA Adducts in Tumor Tissue CFEs. Although it is clear that 0
the biological activity of cisplatin involves multiple cellular pathways (89, 90), it has
been suggested that cisplatin resistance, either inherent or acquired, is a consequence
of enhanced repair activity (8, 89). Many studies have explored this connection in cell 0
culture, but only one group examined the repair activity of cisplatin-DNA adducts in
extracts made from mammalian tissue (39,40). The repair capacity of ovarian tumors
from different individuals varied by as much as 10-fold (39), and a comparison of
different rat tissue did not reveal any correlation between the levels of repair and the
clinical profile of cisplatin sensitivity (40). In these experiments, DNA randomly
modified by cisplatin was used as a substrate in the repair synthesis assay. Cellular
sensitivity to cisplatin may depend on differences in repair of the cisplatin-DNA
adducts, which would not have been detected. Furthermore, since some DNA
synthesis is observed even with undamaged DNA (27), the origin of this activity is 0
unclear. For this reason, attempts were made to study the repair of the site-specific
cisplatin-DNA adducts in extracts made from human tissue.
Cell-free extracts were prepared from samples of human tissue, either tumor 6
or normal. Several different methods were used to make the extracts (see Materials
and Methods). The Manley method is a procedure that was originally designed for
the isolation of cellular proteins from cultured cells (43). The nuclear extract and 0
Husain methods were successfully applied in the isolation of active transcription
factors and topoisomerase 1, respectively, from human tissue (52, 53). Several
features of these protocols were varied in order to optimize the isolation of excision 6
repair-active proteins. The most consequential factor is the method of breaking up
a
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the tissue to a cellular level. The methods that proved to be successful were either
grinding the frozen tissue in N2(1) or homogenization with a polytron. Ineffective
methods include an enzymatic collagenase digestion (51), pushing the tissue through
a metal sieve with a glass pestle, and an electric dounce homogenizor.
All of the extracts were tested for repair activity by using site-specific cisplatin-
DNA adducts and the excision assay. An example of such an experiment is shown in
Figure 2.10. Out of 63 tissue samples, only 12 extracts were active in repair, and in
most of the extracts the repair capacity was weak such that only the 1,3-d(GpTpG)
cross-link produced a detectable signal. Active extracts were prepared from kidney,
brain, endothelial, and testis tumors, but none from normal tissue. Both active and
inactive extracts were prepared from the same type of tissue. This result has two
possible explanations. One interpretation is that tumor cells from different
individuals have a large variability in the DNA repair capacity. Whereas this
hypothesis may be true, given the success rate in preparing active extracts it is more
likely that the variability in repair activity is due to problems in extract preparations,
as discussed above. Furthermore, the tissue samples were not screened for
homogeneity. Since different cell types in the same organ exhibit variable levels of
repair (91), inconsistencies between the tumors would affect the repair capacity of the
extracts. Attempts were made to correlate repair activity and the presence of proteins
that recognize cisplatin-DNA adducts, by using both Southwestern and Western
assays, but no relationship was detected (data not shown).
Conclusions
These experiments provide some valuable insights into the cellular processing
of genetic damage caused by cisplatin. The three types of major cisplatin-DNA
adducts, the 1,2-d(GpG), the 1,2-d(ApG), and the 1,3-intrastrand cross-links, are all
repaired by the mammalian excinuclease. In a reconstituted system of highly
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purified proteins the 1,3-intrastrand adduct is the most efficiently excised, and the
relative repair rates of the two 1,2-intrastrand adducts are very similar. In whole cell
extracts, the 1,2-d(ApG) cisplatin-DNA adduct is excised at a slightly faster rate than
the 1,2-d(GpG) cross-link. Thus the distinct structures of the cross-links significantly
influence the excinuclease activity, but it is also possible that there are cellular 0
proteins in the extracts that can affect the relative rates of repair of the cisplatin-DNA
adducts. In vitro repair of the 1,2-d(GpG) intrastrand adduct is deficient in murine
testicular teratocarcinoma cell lines, a result that needs to be confirmed in human cell
lines. Finally, it is possible to detect excision repair in extracts made from human
tissue, but difficulties arise because of the low success rate in preparing active
extracts and in normalizing the repair activity between samples. 0
a
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Table 2.1. Sequences of the oligonucleotides used to prepare the site-specific
cisplatin adducts. Only one strand of the interstrand cross-link (ICL) is shown. The
platinated nucleosides are in bold.
Abbreviation
G*G*
A*G*
G*TG*
ICL (GC20)
Sequence (5' to 3')
TCTAGGCCTTCT
TCTTAGTTCTCT
TCTGTGCACTCT
CTCCTCCTTGCTCTCCTCTC
CCTCTCCGGCTCTTCCG*G*C
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Table 2.2.1. Summary of experiments comparing the excision of cisplatin-DNA
intrastrand adducts in extracts made from HeLa or mouse testicular teratocarcinoma
(F9) cells. The reactions were incubated at 30*C for the times indicated prior to
resolution on 10% denaturing polyacrylamide gels. The data was analysed on a
BioRad phosphorimager. The averages of the ratios of percent repair of the different
adducts are listed ± 1 esd.
30 min incubation 60 min incubation
CFE GTG/GGa GTG/CGGCb GTG/GG GTG/CGGC
HeLa 4.8 ± 0.55 2.7± 0.21 3.5 ± 0.58 2.5
F9 13 ±4.8 4.9 ± 0.64 13± 1.3 7.8
nc 3 2 4 1
aThe percent repair was calculated by dividing the signal from all of the products smaller than
appoximately 33 nt by the radioactivity in the whole lane, then the percent repair of the same reaction
performed in the absence of ATP was subtracted. The GTG/GG ratio was calculated by dividing the
percent repair of the 1,3-d(GpTpG) intrastrand adduct by the percent repair of the 1,2-d(GpG)
intrastrand adduct. bThe CG*G*C substrate contains a 1,2-d(GpG) intrastrand adduct in a different
sequence context than the G*G* substrate (see Table 2.1). cNumber of individual experiments.
Table 2.2.2. Summary of experiments as in Table 2.2.1 except that the percent repair
was calculated in a slightly different fashion (see below).
30 min incubation 60 min incubation
CFE GTG/GGa GTG/CGGC GTG/GG GTG/CGGC
HeLa 5.2 ± 0.43 2.5 ± 0.05 4.1 0.59 2.4
F9 22 ±7.7 6.3 ±0.65 31 2.7 11
nc 3 2 4 1
aThe percent repair was calculated by dividing the signal of the products approximately 32-22 nt long
by the signal in the whole lane, and the percent repair of the same reaction performed in the absence of
ATP was subtracted. bThe CG*G*C substrate contains a 1,2-d(GpG) intrastrand adduct in a different
sequence context than the G*G* substrate (see Table 2.1). cNumber of individual experiments.
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Figure 2.1. XPAChis6 binds specifically to cisplatin-modified DNA. (A) The indicated
amounts of HMG1 or XPAChis6 were incubated in a 10 pl reaction with CE DNA and
either 0.2 ng of unmodified or 0.7 ng of cisplatin-modified 123 bp DNA (20 000 cpm)
for 30 min on ice. The reactions were resolved on an 8% native polyacrylamide gel.
(B) HMG1 or XPAChi was incubated for 30 min on ice with the indicated amounts of
CE DNA and 10 000 cpm of the 156 bp site-specific 1,2-d(GpG) intrastrand adduct or
the unmodified control. The reactions were resolved on a 6% native polyacrylamide
gel. The gel was slightly distorted during separation from the plates.
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Figure 2.2. Schematic representation of the in vitro excision repair assay. (A)
A cisplatin-DNA intrastrand adduct is indicated by the half-sphere. (B) The
cisplatin-interstrand cross-linked substrate constructed for the repair assay.
The DNA fragments are not drawn to scale. The asterix indicates the
presence of a 32P radioactive label in the phosphodiester bond.
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30 nt -
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5' TCTAGGCCTTCT 3'
TCTGTGCACTCT 156 bp
Figure 2.3. Excision of the 1,2-d(GpG) and 1,3-d(GpTpG) cisplatin-DNA intrastrand
adducts by the mammalian excinuclease. The substrate indicated was incubated
with HeLa CFE (lanes 1 and 5), or with extracts from XP complementation groups F
(lanes 2 and 6), or G (lanes 3 and 7), or a mixture of the two (lanes 4 and 8), for 75
min at 30*C. The reaction products were resolved on a 10% denaturing
polyacrylamide gel. The bands corresponding to 25-31 nt located just below the
marker are the excision products, as indicated on the scheme below. Only the top
strand of the double stranded substrate is shown, the asterix indicates a 32P
radioactive label in the phosphodiester bond. Lane M, 30 nt marker.
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Figure 2.4. Excision of the 1,2-d(ApG) cisplatin-DNA intrastrand adduct by 6
the mammalian excinuclease. The substrate was incubated with Hela CFE
(lane 1), or with extracts from XP complementation groups F (lane 2), or G
(lane 3), or a mixture of the two (lane 4), for 45 min at 300 C. The reaction
products were resolved on a 10% denaturing polyacrylamide gel. The bands
corresponding to 25-31 nt located between the two markers are the excision I
products, as indicated on the scheme below. The asterix indicates a 32P
radioactive label in the phophosdiester bond. Lane M, 24 and 30 nt markers.
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Figure 2.5. Kinetic studies of excision of the 1,2-d(GpG) and 1,2-d(ApG) cisplatin-
DNA intrastrand adducts in HeLa CFE. (A) Increasing amounts of excision
products with time are revealed on denaturing 10% polyacrylamide gels.
Substrates were incubated with HeLa CFE for the times indicated. (B) Plot of three
excision experiments such as that shown in panel A. The data for each experiment
were normalized to the highest level of repair. Error bars represent ± 1 esd.
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Figure 2.6. Maxam-Gilbert sequencing of the cisplatin-DNA interstrand
cross-link. The radioactive label was put on 5' end of GC20 (lanes 1-12) or
GC32 (lanes 14-19) before the interstrand cross-link was made, as described
in Materials and Methods. All of the sequencing reactions were treated with
NaCN prior to analysis on a 20% denaturing polyacrylamide gel. The
modified guanine nucleotides are indicated (Pt-dG). GC20Pt is a
monofunctional cisplatin adduct on the guanine of the GC20 oligonucleotide.
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Figure 2.7. Excision of the 1,2-d(GpG) intrastrand and interstrand cisplatin-DNA
cross-links by the mammalian excinuclease. The substrates were incubated with
CHO AA8 CFE for one hour at 30*C (lanes 3, 4, 7, and 8) and subsequently
treated overnight with NaCN (lanes 2, 4, 6, and 8) prior to analysis on a 10%
denaturing polyacrylamide gel. The asterixes on the scheme below indicate a 3 2P
radioactive label in the phophodiester bonds. Lane M, 24 and 30 nt markers.
122 6
A GGTime (h 0 1 2 3 4
6
4,,.
3 0 n t. .............
24 nt-
B2 o GG
v e AG
1.5 - V GTG
0 1 2 3 4 5
Time (h
Figure 2.8. Kinetics of excision of the cisplatin-DNA intrastrand adducts by the 0
reconstituted excinuclease. (A) The 1,2-d(GpG) intrastrand cross-linked substrate
was incubated with the purified repair factors at 30*C for the times indicated.
Increasing amounts of excision products with time are revealed on a 10% denaturing
polyacrylamide gel. The 24 and 30 nt markers are indicated. (B) Plot of excision
experiments of the 1,2-d(GpG) (open circles), 1,2-d(ApG) (closed circles), and 1,3- 40
d(GpTpG) (triangles) cross-linked substrates, such as that shown in panel A. Each
data point is an average of two or three experiments, the error bars represent i 1 esd.
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Figure 2.9. Excision of cisplatin-DNA intrastrand cross-links in HeLa and F9 CFEs.
The substrates were incubated with two different preparations of HeLa extracts
(H1 : lanes 1, 2, 7, and 8, H2: lanes 3, 4, 9, and 10) or with a CFE from the F9 mouse
testicular teratocarinoma cells (F9: lanes 5, 6, 11, and 12) for one hour at 30*C.
Half of the reactions were performed in the presence of ATP (lanes 1, 3, 5, 7, 9, and
11). The products were resolved on a 10% denaturing polyacrylamide gel. Levels
of excision in terms of percent repair (calculated as on Table 2.2.1) were 0.9%, 0.8%,
0.3%, 3.1%, 6.6% and 4.3%, lanes 1, 3, 5, 7, 9, and 11, respectively. The ratios of
excision of the 1,3-d(GpTpG) and 1,2-d(GpG) intrastrand adducts (GTG/GG) were
3.4 (H1), 8.2 (H2) and 14.3 (F9). The 24 nt and 30 nt markers are indicated.
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Figure 2.10. Excision repair of the 1,3-d(GpTpG) cisplatin-DNA
intrastrand adduct in extracts prepared from human tissue. The substrate
was incubated with the extracts at 30*C for one hour prior to analysis of
the excision products on a 10% denaturing polyacrylamide gel. The CFEs
used were from HeLa (lane 1), lung tumor (lanes 2, 3), normal lung tissue
(lanes 4, 5), kidney tumor (lanes 6, 7, 10), endothelial tumor (lanes 8, 9),
and normal kidney tissue (lane 11). The reactions in lanes 6-11 were all
performed with the same amount of protein from extracts prepared from
different tissue samples. The 24 nt and 30 nt markers are indicated.
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Chapter Three
The Shielding of Cisplatin-DNA Adducts from Excision Repair in Vitro
126
Introduction (1-4)
The platinum-DNA cross-links through which the anticancer drug cisplatin
exerts its cytotoxic effects significantly destabilize the double helix (5-8). The distinct
conformational changes in the DNA generated by the most prevalent lesion, the 1,2-
d(GpG) intrastrand cross-link, were examined in several recent NMR and X-Ray
crystallography studies (9-13). Some of the global disturbances common to the solid
state and solution structures include bending of the helix axis towards the major
groove, unwinding of the duplex, and widening and flattening of the minor groove.
These properties are very similar to those observed in the DNA of some protein-DNA
complexes (14), and may serve as recognition elements for cellular factors that
process the cisplatin-DNA damage. One of the details revealed by the high-
resolution structural analyses is that the roll between the guanine bases involved in
the cross-link fell within 26-50*. This value is significantly less than the dihedral
angle of 900 required for a stable, square planar complex, and it suggests a putative
driving force behind the formation of protein-DNA complexes at cisplatin-DNA
adducts. Since many DNA-binding proteins induce bends in their target sites (14),
binding at the platinum locus could increase the helical roll and release the 0
considerable strain at the platinum.
One family of proteins that specifically recognize cisplatin-modified DNA are
those which contain the high mobility group (HMG) DNA-binding motif (15-17). The 0
HMG domain is an 80 amino acid polypeptide found in a wide variety of minor
groove-binding proteins. These include transcription factors as well as architectural
components essential for the formation of multi-protein complexes involved in DNA 0
structure, maintenance, and manipulation. Although the homology between all of
these proteins is quite low, they possess common structural features which allow
them to bind to distorted DNA such as that found in four-way junctions, as well as 0
cisplatin-modified DNA (18). In particular, HMG-domain proteins specifically bind
0
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to, and bend, the 1,2-intrastrand adducts of cisplatin, but not the minor 1,3-
intrastrand cross-links or DNA modified with clinically ineffective platinum
compounds (19-21).
Evidence to suggest that HMG-domain proteins play a role in the biological
mechanism of cisplatin was provided by experiments in yeast. Interruption of the
gene encoding the HMG-domain protein Ixrl produced elevated resistance to
cisplatin but not to other DNA-damaging agents (22), an effect which was linked to
an intact excision repair pathway (23). When Ixrl expression was reintroduced to the
knockout cells, the cisplatin resistance decreased (24). Attempts to overexpress the
protein above endogenous levels and enhance sensitivity to the drug were
unsuccessful, however (24). Several non-exclusive models have been formulated to
explain how HMG-domain proteins might affect the cytotoxicity of cisplatin-DNA
adducts (25). The first hypothesis suggests that the protein-DNA complex could
serve as a signal to stimulate repair, but there is no experimental evidence to support
this theory. The second model is based on the fact that some of these proteins have
essential functions, so titration away from their natural binding sites by the cisplatin-
DNA adducts would activate cell death. This potential consequence of cisplatin-
modified DNA was modeled by its ability to disrupt reconstituted ribosomal DNA
transcription, which requires the HMG-containing human upstream binding factor
hUBF for promoter activation (26, 27). Finally, the shielding hypothesis, which is
most consistent with the yeast work, proposes that HMG-domain proteins bind to the
cisplatin-DNA adducts and block cellular defense mechanisms such as repair,
allowing the damage to persist, obstruct vital DNA transactions, and activate cell
death.
In addition to HMG-domain proteins, it is becoming apparent that other
cellular factors specifically recognize the structural distortions of cisplatin-modified
DNA and could affect the processing of the lesions (28). Included are XPAC and RPA
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(29-33), the putative damage recognition components of the nucleotide excision repair
pathway that efficiently removes the cisplatin-DNA lesions (2, 3). Although it is less
certain how any other proteins such as the transcription factor TBP (34, 35), the
histone H1 protein (36), and the mismatch repair protein hMSH2 and its active
complex, MutSa (37, 38) might affect the cytotoxicity of cisplatin, the models
proposed for HMG-domain proteins could also be applied.
In the present study, we explored the shielding hypothesis by using site-
specific cisplatin-DNA adducts and an in vitro excision repair assay. These 6
experiments focus on the effects of the HMG-domain family of proteins on DNA
repair, and particular attention was paid to proteins that may be expressed in
testicular tumors. The results provide insights into the cellular processing of 9
cisplatin-DNA lesions and may be relevant to the unique sensitivity of testicular
cancer to this anticancer drug (39, 40). In addition, the putative role of mismatch
repair proteins in the cisplatin mechanism of action was examined in the context of
excision repair, and no connection was observed. Furthermore, our data reveal that a
mismatch repair deficiency is not required for the development of cisplatin resistance.
Materials and Methods
Materials. Cisplatin was obtained as a gift from Johnson-Matthey. T4
polynucleotide kinase and T4 DNA ligase were purchased from New England
Biolabs (Beverly, MA) or Boehringer Mannheim. The [y- P]ATP was purchased from
Dupont, NEN. The cisplatin-modified 123-bp fragment was a gift from J. P.
Whitehead (M.I.T.). The cisplatin-resistant HeLa and V79 cell lines were grown in the
appropriate concentrations of cisplatin as described (41), and the mismatch repair
capacity of these cell lines was tested in collaboration with P. Modrich (Duke, NC).
The HeLa S3 cell line was from the stock of Lineberger Comprehensive Cancer Center
(University of North Carolina) or was supplied by P. A. Sharp (M.I.T.). Whole cell-
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free extracts (CFEs) were prepared by the method of Manley et al. and stored at -800C
(42).
HMG-domain and Mismatch Repair Proteins. Recombinant rat HMG1 (20),
HMG1 domain B (residues K86-K165) (43), and mouse testis-specific HMG (44), were
expressed and purified as described by K. E. Sandman (M.I.T.), S. A. Kane (M.I.T.),
and U.-M. Ohndorf (M.I.T.), respectively. These proteins were stored in buffer A (50
mM Tris, pH 7.3, 50 mM NaCl, 5 mM 2-mercaptoethanol) at -20'C, and diluted into
p21 buffer (50 mM Tris, pH 7.5, 200 mM NaCl, 1 mM EDTA, 1 mM 2-
mercaptoethanol) immediately prior to use. Recombinant human SRY and HMG-
domain (residues D58-K136) were expressed and purified by E. E. Trimmer (M.I.T.)
as described (4). The hSRY was stored in 20 mM Hepes pH 7.9, 50 mM NaCl, 1 mM
EDTA, 0.5 mM DTT, 5% glycerol. The hSRY HMG-domain polypeptide was
provided in the same buffer as the whole protein except that it contained only 10 mM
NaCl. The proteins were diluted in storage buffer immediately prior to use. Human
MutSac, kindly provided by Dr. Modrich (Duke University, NC), was purified as
described (45). MutSa was stored at -80'C in 50 mM Hepes, pH 7.5, 100 mM KCl, 0.1
mM EDTA, 10% sucrose, 1 mg/ml BSA, and diluted in the same buffer. Once an
aliquot was thawed, it was used up because the protein is not stable through multiple
freeze/thaw cycles. Functional assays for Mutsca activity were not performed in this
laboratory.
Oligonucleotides. The 156-bp oligonucleotides site-specifically modified with
cisplatin were synthesized as previously described (3). The 123-bp DNA fragment
was obtained by digestion of a commercially available 123-bp DNA ladder (Gibco
BRL) with the restriction enzyme Aval; the resulting DNA fragment was purified by
extraction from an agarose gel. The 123-bp fragment was globally modified with
cisplatin as previously described (25), and the platinum/nucleotide ratio was
determined to be 0.02 by using atomic absorption spectroscopy. The DNA was 3'-end
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labeled in a fill-in reaction with the Klenow fragment of DNA polymerase I, [a-
32P]dCTP (Dupont/NEN) and the four deoxynucleotide triphosphates, and purified 0
on a Sephadex G-50 Quick spin column (Boehringer Mannheim).
Mobility Shift Assays with tsHMG. The cisplatin intrastrand cross-linked probes
(5000 cpm) were incubated in a 20 gl volume containing 2 g1 of the excision assay
reaction buffer, 108 ng of pBR322 plasmid DNA, 0.25 mg/ml of BSA, and 5 gl of
tsHMG in dilution buffer, for 30 min on ice. Gel loading solution (30% glycerol,
0.25% (w/v) bromophenol blue and 0.25% (w/v) xylene cyanol FF) was added (0.6
gl) and the reactions were resolved by electrophoresis on pre-run, pre-equilibrated
(40C), 0.5X TBE (45 mM Tris, 45 mM boric acid, 1.25 mM EDTA, pH 8.3), 5% native
polyacrylamide gels (29:1 acrylamide: N,N'-methylene-bisacrylamide, 0.08%
ammonium persulfate). Gels were run at 300 V, 4*C, vacuum dried and exposed to
film (Kodak, X-OMAT AR) at -80'C with an intensifier screen.
Mobility Shift Assays with MutSa. The band shift assays were performed as
previously reported (38). Briefly, the protein was incubated with either 0.3 fmol of
the site-specifically modified oligonucleotides or 1.6 fmol of the randomly platinated
123-bp oligonucleotide. The 20 gl reactions contained 2 gl of MutSca in storage buffer, 9
10 mM Hepes, pH 7.5, 100 mM KCl, 5 mM MgCl2, 1 mM DTT and 0.05 mg/ml BSA,
and 16 fmol or 32 fmol of cold 123-bp unmodified DNA included with the site-
specific or globally platinated probes respectively. After incubation on ice for 20 min, 0
2 g1 of loading solution was added (10 mM Hepes, pH 7.5, and 50% sucrose) and the
reactions were loaded onto pre-run, pre-equilibrated, 6% native polyacrylamide gels.
The gels were run in 0.5 x TBE at 4*C, 300 V, vacuum dried, and exposed to film at - 0
80*C with an intensifier screen.
Inhibition of Excision Repair by HMG-domain and MutSa Polypeptides. The repair
inhibition experiments were performed as previously described with a few
modifications (3). The polypeptides were incubated with the site-specific cisplatin-
4
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DNA repair probes for 10 min at 30*C prior to the addition of HeLa CFE. The volume
of polypeptide added in dilution buffer was kept constant within each experiment.
The reaction conditions varied slightly as improvements were made. Briefly, the
standard reactions (25 gl) contained 1.4-5 gi of protein in dilution buffer, 4-5 l of
reaction buffer (300 mM Hepes pH 7.9, 400 mM KCl, 32 mM MgCl 2, 1 mM EDTA, 20-
40 mM ATP, 2 mM DTT), 5 gl of p21 buffer except when the protein was diluted into
this buffer, 20 gM of each dNTP, 0.2 mg/ml BSA, 50-120 ng of pBR322 plasmid as
non-specific competitor DNA, 50-250 pM substrate, and 3-5 pl of CFE in storage
buffer (25 mM Hepes pH, 7.9, 100 mM KCl, 12 mM MgCl 2, 0.5 mM EDTA, 2 mM DTT
and 12.5-16.5% glycerol). The reactions were incubated at 30*C for the indicated
length of time and then stopped by adding 10 gg of proteinase K, making the reaction
0.5% in SDS and incubating at 55*C for 20 min. The reactions were extracted,
precipitated and resolved on 10% denaturing polyacrylamide gels as previously
described (3). The data were quantitated by using an AMBIS systems scanner or by
Phosphorimager analysis (Molecular dynamics).
Results
Inhibition of Excision Repair by HMG-Domain Polypeptides. Almost all of the
HMG-domain proteins studied to date specifically bind to cisplatin-modified DNA
(46). A recently reported testis-specific HMG-domain protein (tsHMG) was of
particular interest (47), however, since cisplatin is particularly effective in the
treatment of testicular cancer (39, 40). The binding specificity of this protein for
cisplatin-DNA adducts was tested in an electrophoretic mobility shift assay (Figure
3.1). Like HMG1 (20), tsHMG specifically binds to the 1,2-d(GpG) intrastrand adduct,
but not to the 1,3-d(GpTpG) cross-link. One possible consequence of this specific
recognition is that tsHMG could prevent the excinuclease from reaching and
repairing the major cisplatin-DNA adducts. To test this hypothesis, the ability of
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tsHMG to influence the excision repair of cisplatin-modified DNA was examined by
adding the HMG-domain protein to the in vitro excision repair assay. In a reflection
of the specific binding capacity (Figure 3.1), 25-100 nM of tsHMG inhibits repair of
the 1,2-d(GpG) intrastrand adduct, whereas excision of the 1,3-d(GpTpG) intrastrand
adduct was not significantly blocked and a modest stimulation was observed (Figures
3.2 and 3.3A). At these protein concentrations, only the 1,2-intrastrand adduct is
specifically bound (Figure 3.1), but at higher concentrations non-specific binding
observed on both the 1,3-intrastrand substrate and unmodified DNA (data not
shown) inhibits repair of both of the cross-links.
Another testis-specific HMG-domain protein, the human sex-determining
factor hSRY, similarly blocks repair of the major cisplatin-DNA adduct, although at 0
slightly higher concentrations (Table 3.1). Various HMG-domain proteins are capable
of this specific repair inhibition, but none are as effective as the testis-specific proteins
(Table 3.1 and data not shown). For example, 25 nM of tsHMG inhibited the excision 4
of the 1,2-d(GpG) adduct by 35% (Figure 3.3A), whereas 1-2 gM of HMG1 was
necessary to achieve a similar level of inhibition (data not shown). HMG-domain
proteins exhibit very little homology outside of the DNA-binding domain (48), so it is 9
unlikely that the repair inhibition is due to direct interactions with the excinuclease
components. In support of this hypothesis, the isolated HMG-domain of SRY could
inhibit the excision of the 1,2-d(GpG) cisplatin-DNA adduct at concentrations that 0
did not block repair of the 1,3-d(GpTpG) cross-link in HeLa CFE (Figure 3.3B).
The other major cisplatin-DNA adduct, the 1,2-d(ApG) intrastrand cross-link,
is also recognized by HMG1 (20) and is processed in a similar fashion as the 1,2- 0
d(GpG) intrastrand adduct by the mammalian excinuclease (3). To determine
whether HMG-domain proteins also shield the 1,2-d(ApG) adduct from excision
repair, HMG1 was added to the in vitro assay (Figure 3.4). Increasing amounts of
HMG1 caused a decrease in the excision of the 1,2-d(ApG) cross-linked substrate,
4
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inhibition was observed at 0.5 pM HMG1, and 2 gM resulted in a 60% drop in the
level of excision. Similarly, excision of the 1,2-d(GpG) intrastrand adduct, but not the
1,3-d(GpTpG) cross-link, is blocked by comparable concentrations of HMG1 (Table
3.1). Although the exact expression levels of HMG-domain proteins have not been
determined, the isolation of nuclear chromatin yields about 0.8-2.4 million molecules
of HMG1 per cell (49, 50), suggesting that micromolar concentrations of the proteins
are biologically relevant. The phosphorylation status of the HMG-domain
polypeptides employed in these experiments was not determined, and this type of
modification has been shown to influence the DNA-binding properties of members of
the HMG family (51, 52). However, it is not clear how much these proteins are
phosphorylated in their native state, and there is evidence to suggest that the
recombinant proteins are appropriately modified. For example, recombinant tsHMG
exhibits similar DNA-binding and topological activities as protein that was
dephosphorylated and then incubated with extracts from mouse testes supplemented
with protein kinase cofactors (52).
Inhibition of Excision Repair by tsHMG in a Reconstituted System. It is possible
that the repair inhibition by HMG-domain proteins is influenced by interactions with
other factors in the whole cell extracts. To address this issue, the effect on repair was
also tested in a reconstituted system of purified repair factors (53). As in the HeLa
cell extracts, a concentration of tsHMG as low as 25 nM inhibited the excision of the
1,2-d(GpG) intrastrand adduct whereas the repair of the 1,3-d(GpTpG) intrastrand
adduct was slightly stimulated (Figure 3.5).
Binding of Cisplatin-DNA Adducts by MutS a. It was recently demonstrated that
hMSH2, a human homologue of the prokaryotic mismatch recognition repair protein,
specifically binds DNA modified by cisplatin (37). MutSa, the active form of the
same protein in a complex with another 160 kDa polypeptide (45), also binds
specifically to the 1,2-d(GpG) cisplatin intrastrand adduct (38). To examine this
134
behavior, mobility shift assays were performed with MutSC and either random or
site-specific cisplatin-modified DNA. Specific binding of 4-8 nM MutSca to the
cisplatin-DNA adducts is evident with the globally platinated 123-bp DNA fragment
(Figure 3.6A). At higher protein concentrations (>16 nM) several bands due to
complexes with slower mobility were observed for both the modified and
unmodified substrates, presumably due to non-specific binding.
In contrast, although several conditions were tested, only a small variability
was observed in the binding affinity of MutS(x for the 1,2-d(GpG), 1,3-d(GpTpG), and
unmodified substrates (Figure 3.6B and data not shown). The mobility of the only
band specific for the 1,2-d(GpG) adduct was faster than the other bands, and it was
only detected at the lower protein concentrations used (4-8 gM). Additional bands of
slower mobility were produced with all of the substrates and might be made up of a
combination of specific and non-specific binding, since more DNA was shifted by the
1,2-d(GpG) intrastrand adduct. In a previous report, a similar binding pattern of site-
specific lesions was described (54), but the authors designated all of the shifted
material as specific binding products, including the lower mobility bands observed in
reactions with the unmodified DNA. 9
Inhibition of Excision Repair by MutSa. The binding of MutSaX to cisplatin-
modified DNA could be relevant to the cisplatin resistance of some cultured cell lines
that is associated with loss of mismatch repair (55-57). In order to determine whether
this interaction could affect the cytotoxicity of the adducts through modulation of the
excinuclease, MutSc was added to the in vitro repair assay. Figure 3.7A
demonstrates that repair of the 1,2-d(GpG) and 1,3-d(GpTpG) cisplatin-DNA adducts 0
was not influenced by 9.6 nM of MutSx. ATP inhibits MutSa DNA binding activity
(45), so in additional experiments the ATP required for the excinuclease was added to
the reaction only after incubation of MutSa with the substrate and addition of the
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HeLa CFE. Concentrations of MutSa up to 66 nM were employed under these
conditions, and no inhibition of repair was observed (Figure 3.7B).
Discussion
Excision Repair Shielding by HMG-Domain Proteins. The binding of HMG-
domain proteins to the major cisplatin-DNA cross-links is presumably due to a
structural correspondence with the natural target sites. This fortuitous resemblance
has the potential to play a role in the anticancer activity of the drug. Of the multiple
models proposed to explain how HMG-domain proteins could mediate the
cytotoxicity of cisplatin (25), one is refuted and another is supported by the data
presented here. It was originally postulated that HMG-domain proteins could assist
in the excision of platinum damage by binding to the adducts and serving as
recognition elements for repair. The fact that HMG-domain proteins do not stimulate
the in vitro excision of the 1,2-intrastrand adducts is incompatible with this theory,
however. A slight increase in the excision of the 1,3-d(GpTpG) intrastrand cross-link
was detected, but appears to be caused by non-specific binding. Although the HMG-
domain proteins do not activate excision repair, the possibility that the specific
binding of these proteins to the cisplatin lesions could stimulate other cellular
pathways that respond to the DNA damage, such as programmed cell death, cannot
be ruled out.
The fact that all of the HMG-domain proteins tested specifically inhibit
excision of the major cisplatin-DNA adducts supports the alternative repair shielding
hypothesis. This effect is unlikely to be due to any contacts between the HMG-
domain proteins and the excinuclease, since an isolated HMG domain can also block
repair. In addition, the same range of tsHMG concentrations inhibits repair in both
the whole cell extracts and the reconstituted system. This result suggests indirectly
that the inhibition of repair is not regulated by interactions between the HMG-
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domain proteins and any other cellular constituents. The ability of cisplatin-DNA
bound HMG-domain proteins to block the excinuclease raises the possibility that this
complex may also inhibit other DNA-processing pathways. This proposal is
supported by several recent reports demonstrating that HMG1 can inhibit both DNA
replication and helicase activity at the site of a cisplatin-DNA adduct (58, 59). 4
The ubiquitously expressed HMG-domain proteins, such as HMG1, are
present in the HeLa cell extracts used in this assay (20, 60), but the relative repair
rates of the 1,2- and 1,3-intrastrand adducts were similar to those observed in the 4
reconstituted system of purified repair proteins (3). Furthermore, fractionation of
HeLa cell extracts did not affect the relative repair of the cross-links measured with
the repair synthesis assay (61). It should be noted that sequence context can W
significantly influence the strength of the interaction between HMG-domain proteins
and cisplatin-DNA adducts (62), but only one sequence context was employed in
these studies (3, 61). Nevertheless, these results suggest that the levels of HMG-
domain proteins in the extracts were not sufficient to block the repair of the 1,2-
intrastrand adducts. It is likely that, if HMG-domain proteins do play a role in the
cytotoxicity of cisplatin, this property is not an attribute of the whole family of 6
proteins, but rather of certain proteins that have tissue restricted expression (15).
Thus the question of which HMG-domain to examine in an investigation of the
cisplatin mechanism of action can be crucial. 0
Both of the testis-specific HMG-domain proteins investigated here inhibit
repair of the 1,2-d(GpG) intrastrand cisplatin-DNA adduct at concentrations lower
than any other member of this family. The murine tsHMG protein, a nuclear isoform
of mtTFA (63), is expressed in the nuclei of elongating spermatids (47) and may play
a role during chromatin structure transitions (52). Testis-specific isoforms of mtTFA
are abundant in human male germ cells, but no nuclear protein has yet been detected
in human tissue (64). In contrast, hSRY, the human sex-determining factor (65), is
A
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expressed in testicular and prostatic tumor tissue (66). Thus it is possible that SRY, or
other HMG-domain proteins highly expressed in testis tissue (65, 67-70), could
provide the basis for the cisplatin sensitivity of testicular tumors by enhancing the
toxicity of the DNA lesions through repression of repair. This hypothesis is in accord
with several reports that have suggested that the sensitivity of cultured testicular
tumor cell lines is due to poor repair of the major cisplatin-DNA adducts (71-73).
Malignant tissue frequently develops with genetic amplification and changes in
protein expression (74), so the proteins present in tumors cells may be different from
the tissue of origin. It would be of interest to examine the expression levels of HMG-
domain proteins in tumor cells and to determine whether there is any correlation
with cisplatin responsiveness.
The Effects of MutSa on Cisplatin-Modified DNA. In addition to the excinuclease,
there are a variety of cellular mechanisms to correct genetic defects. Errors in DNA
originating from replication, recombination, or deamination, are removed from the
genome by the mismatch repair pathway (75, 76). A predisposition to hereditary
non-polyposis colon cancer, as well as a wide variety of sporadic cancers, have been
associated with mutations in the mismatch repair genes (75, 77). Another
consequence of defects in this pathway is cellular resistance to a variety of
chemotherapeutic drugs (78, 79). Several different mismatch repair-deficient cell
lines exhibit diminished cisplatin sensitivity in comparison with the repair-proficient
controls (80, 81). Similarly, expression of hMLH1, an essential mismatch repair factor
(76), is lacking in multiple ovarian cell lines with acquired cisplatin resistance (55-57).
The connection between cisplatin and mismatch repair was reinforced by the
observation that components of the putative human mismatch recognition complex,
hMSH2 and MutSa (76), also recognize cisplatin-modified DNA (37, 38). This result
is of particular relevance to the cisplatin mechanism of action because hMSH2 is
expressed at elevated levels in testis tissue (37).
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In analogy with HMG-domain proteins, experiments were performed to
examine whether the mismatch repair proteins could shield the cisplatin-DNA
adducts from excision repair. MutSx did not inhibit the excinuclease activity on the
1,2-d(GpG) or 1,3-d(GpTpG) cross-linked substrates. This result was surprising, since
the concentrations of protein added to the in vitro assay (up to 66 nM) should have 9
been sufficient to achieve specific binding of the 1,2-d(GpG) intrastrand adduct (38).
Accordingly, the affinity of MutSa for cisplatin-DNA adducts was re-examined.
Experiments that employed randomly modified oligonucleotides confirmed that
MutSa recognizes DNA, damaged by cisplatin. The specific affinity for the 1,2-
d(GpG) cisplatin-DNA adduct was fairly weak, however, in comparison with the 1,3-
d(GpTpG) cross-linked and unmodified substrates, as previously reported (37, 54). 9
Although the MutSac protein was provided by an outside source and not
independently tested for mismatch repair capabilities, there was no indication that
the protein had lost any DNA-binding activity. The fact that this complex did not
block the excinuclease suggests that it is not strong enough to compete with cellular
factors involved in processing the DNA damage, and that the mismatch repair
pathway must alter cisplatin sensitivity independent of excision repair. 0
MutSa functions in the context of multi-protein complexes, so it is possible that the
native affinity for cisplatin-DNA damage was not achieved. The in vitro excision
assay experiments were performed in extracts prepared from human HeLa cells, 0
however, which are proficient in mismatch repair (J. Drummond, P. Modrich,
personal communication), and should have provided the relevant cellular
components for the formation of the active complexes. Furthermore, a recent study
of excision repair in extracts prepared from both mismatch repair proficient and
deficient cell lines supports the conclusion that there is no functional overlap between
the two pathways (54).
0
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The discovery that cultured cell lines selected for cisplatin resistance have
deficient mismatch repair could have potential clinical relevance. This relationship
has been observed in several ovarian cell lines (55-57) and could explain the severe
problem of acquired cisplatin resistance in many ovarian cancer patients (82). In
addition to the shielding hypothesis, several other models have been postulated to
explain the putative connection between cisplatin-sensitivity and the mismatch repair
pathway (37). One proposal suggests that the mismatch repair proteins bound to the
cisplatin-DNA adducts may be a signal for cell death. Another possibility is that the
enzymes enter a futile cycle of attempted repair and replication bypass, which would
produce endless DNA nicking and activate apoptosis. The latter hypothesis is
supported by the fact that the affinity of the mismatch repair proteins for a cisplatin-
DNA cross-link is strengthened when the adduct is incorporated across from a
mismatch (54, 61, 83). It is important to note, however, that a mismatch repair defect
is not required for the evolution of cisplatin resistance. Two cell lines selected for
cisplatin resistance, a hamster V79 cell line and a human HeLa cell line (41), were
tested for mismatch repair activity in collaboration with the laboratory of P. Modrich.
Both of these cell lines, as well as the parental cells, were proficient in mismatch
repair (data not shown). Furthermore, western analysis was used to examine the
levels of the hMSH2 and hMLH1 proteins, which are frequently deficient in
association with cisplatin resistance (55-57), but equal quantities of both proteins
were expressed in the resistant HeLa clone and the parental cells.
Conclusions
The experiments presented here provide information about how cellular
proteins that recognize cisplatin-DNA adducts could affect the cytotoxicity of the
lesions. HMG-domain proteins specifically block repair of the 1,2-d(GpG) cisplatin-
DNA intrastrand cross-link in an in vitro excision repair assay. This effect was
140
observed in whole cell extracts, a reconstituted repair system, and with an isolated
HMG-domain. The testis-specific HMG-domain proteins are most effective at
inhibiting repair, which may be relevant to the unique sensitivity of testicular tumors
to cisplatin chemotherapy. The mismatch repair protein, MutSa, exhibits weak
selectivity for the major 1,2-d(GpG) cisplatin-DNA adduct and does not inhibit
excision repair of the intrastrand cross-links. Although the mismatch repair pathway
may be a key to the development of drug resistance in certain cell types, it is not an
absolute requirement.
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Table 3.1. Inhibition -of excision of the cisplatin-DNA intrastrand adducts by several
HMG-domain polypeptides. Specific inhibition indicates the concentration of HMG-
domain protein which blocked excision of the 1,2-d(GpG) but not the 1,3-d(GpTpG)
cisplatin intrastrand adducts.
Protein Specific Inhibition Expression Function
(M)
HMG1a 1-4 ubiquitous (?)architectural
HMG1 Domain Bb 0.5-1 factor/transcription
regulation
hSRY 0.1-0.4 embryonal genital sex-determining
hSRY Domain 0.1-0.3 ridge transcription factor
adult testis tissue
tsHMG 0.025-0.1 elongating (?)topological factor
spermatids mtTFA homolog
aThe specificity of inhibition of HMG1 was determined in collaboration with A. Sancar (U. of N.
Carolina) (2). bThe specificity of binding of HMG1 domain B was determined by comparing the
inhibition of a 1,2-d(GpG) intrastrand cisplatin-DNA adduct with the cholesterol repair substrate.
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Figure 3.1. tsHMG specifically binds to the 1,2-d(GpG) cisplatin-DNA intrastrand
adduct. The 1,2-d(GpG) and 1,3-d(GpTpG) site-specific adducts (156 bp) were
incubated with the indicated concentrations of tsHMG for 30 min on ice under
excision assay conditions prior to analysis on a 5% native polyacrylamide gel.
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Figure 3.2. Effect of tsHMG on excision of the 1,2-d(GpG) and 1,3-d(GpTpG)
cisplatin-DNA adducts by the human excinuclease. The 1,2-d(GpG) and 1,3-
d(GpTpG) site-specific cross-linked substrates were incubated with tsHMG
for 10 min at 30*C followed by incubation for an additional 45 min with
HeLa CFE. The reaction products were analyzed on a 10% denaturing
polyacrylamide gel. The 30 nt marker is indicated.
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Figure 3.3. Inhibition of excision repair of the cisplatin-DNA intrastrand adducts
by tsHMG and the HMG domain of SRY. (A) The 1,2-d(GpG) (open circles) and
1,3-d(GpTpG) (closed circles) cross-linked substrates were incubated with tsHMG
for 10 min at 30'C, followed by an additional 45 min incubation with HeLa CFE.
The reactions were analyzed on 10% denaturing polyacrylamide gels. Several
different preparations of HeLa CFE and tsHMG were used to compile the data,
and data points are averages of four or five experiments. (B) The repair substrates
were incubated with the SRY HMG domain for 10 min at 30*C before the addition
of HeLa CFE and further incubation for 50 min. Data points are averages of two or
three experiments. The level of repair in the absence of HMG domain polypeptide
for each experiment is designated 100%. Error bars represent ± 1 esd.
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Figure 3.4. HMG1 blocks excision of the 1,2-d(ApG) cisplatin-DNA cross-link.
The substrate was incubated with HMG1 at the concentrations indicated for
10 min at 30*C followed by incubation for an additional 45 min with HeLa
CFE. The reaction products were analyzed on a 10% denaturing
polyacrylamide gel. The 30 nt marker is indicated.
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Figure 3.5. tsHMG inhibits reconstituted excision repair of the cisplatin-DNA
intrastrand adducts. The 1,2-d(GpG) (open circles) or 1,3-d(GpTpG) (closed
circles) cross-linked substrates were incubated with tsHMG for 10 min at
300C followed by the addition of the purified repair proteins and further
incubation for 110 min. Each data point is an average of three experiments.
The error bars represent ± 1 esd.
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Figure 3.6. Mobility shift assays of cisplatin-modified DNA with MutSa. (A) The
indicated concentrations of protein were incubated with either globally platinated
123 bp DNA (123Pt) or unmodified DNA (123ct) for 20 min on ice followed by
analysis on a 6% native polyacrylamide gel. (B) The 1,2-d(GpG) or 1,3-d(GpTpG)
cisplatin cross-linked or unmodifed 156 bp excision repair substrates were
incubated with the indicated concentrations of protein for 20 min on ice prior to
analysis on a 6% native polyacrylamide gel.
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Figure 3.7. The effects of MutSa on excision of the 1,2-d(GpG) and 1,3-d(GpTpG)
cisplatin-DNA adducts by the human excinuclease. (A) The cisplatin-modified
substrates were incubated with MutSa for 10 min on ice followed by the addition
of HeLa CFE and an additional 50 min incubation. The reactions were resolved
on a 10% denaturing polyacrylamide gel. (B) Inhibition of excision repair of the
1,2-d(GpG) cisplatin-DNA adduct by MutSa. Data from several experiments
such as that shown in panel A are plotted here.
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Chapter Four
p53-Dependent and -Independent Responses to Cisplatin in Mouse Testicular
Teratocarcinoma Cells
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Introduction (1, 2)
Chemotherapeutic agents and radiation are often used in the treatment of 4
cancer to augment surgical procedures, particularly to address metastatic
complications. In most cases, however, chemotherapy has limited success in
conferring long-term patient survival. One notable exception is in the 0
management of testicular cancer, which is the most common malignancy found
in men under 35 years of age (3, 4). Several recent changes in the treatment of this
disease have caused the patient mortality rate to diminish to less than 10 percent, 0
making it one of the most curable solid neoplasms (3). In particular, the largest
effect in the disease response was afforded by the addition of the platinum
compound cis-diamminedichloroplatinum(II) (cisplatin) to the chemotherapeutic 0
regimen (3, 4).
Cisplatin is used to treat a wide variety of cancers in addition to testicular
tumors (5, 6), although its effectiveness is often limited by its inherently poor 0
activity against many tumor types and by the development of resistance (7). The
anticancer mechanism of cisplatin is not clearly understood, but it is generally
accepted that it acts through the formation of DNA adducts (8). The fact that some 0
cells are killed by the DNA damage while others are resistant is most likely 'a
consequence of several cellular pathways (9, 10) which must be unraveled in order
to provide more comprehensive treatment strategies. 0
One response to genotoxic stress involves the p53 tumor suppressor gene
product (11, 12). This nuclear phosphoprotein accumulates following DNA dam-
age and controls cellular proliferation predominantly through its activity as a 0
transcription factor. The expression of downstream genes contributes to tumor
suppression either by activating cell cycle arrest, possibly to give the cell time to
repair the damage and avoid genetic instability, or by initiating apoptosis in the 0
injured cell. The fact that the loss of p53 activity promotes malignant
0
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transformation is confirmed by the high incidence of mutations in this gene in a
wide spectrum of human cancers (13, 14). Moreover, a non-functional p53 might
provide the ensuing tumors with resistance to chemotherapy because of the lack
of drug-induced apoptosis. In this regard, the status of the p53 gene in a tumor
can be an indicator of the clinical prognosis of a cancer patient (15).
Testicular tumors are atypical because the p53 gene is usually not mutated
in this type of cancer (16-18). In addition, testicular tumors express high levels of
the p53 protein, a characteristic that is usually a manifestation of a genetic
mutation (19, 20). Recently, experiments with murine testicular teratocarcinoma
cell lines demonstrated that the elevated levels of p53 protein did not result in
increased transcriptional activity of p53-regulated genes (18), suggesting that the
protein was predominantly inactive. Upon exposure of the cells to the DNA-
damaging agent etoposide, however, their p53-mediated functions were restored,
including activation of the programmed cell death pathway.
Although p53-dependent apoptosis suggests how DNA-damaging agents
such as cisplatin kill neoplastic cells, the relationship between cisplatin sensitivity
and p53 status remains unclear. In support of a role for p53 in the cytotoxic
mechanism of cisplatin, several studies of ovarian carcinoma cell lines
demonstrated that disruption of p53 function afforded drug resistance (21-23),
although recent work has indicated that p53 is not a determinant of cisplatin
cytotoxicity in ovarian cancer cells (24). In addition, non-small cell lung cancer
cells were sensitized to cisplatin-induced apoptosis after the introduction of a
wild-type p53 gene (25). In contrast, cell lines which do not exhibit a predominant
apoptotic response to chemotherapy, such as breast cancer or human foreskin
fibroblast cell lines, were sensitized to cisplatin by the inactivation of p53 (26, 27).
Furthermore, although a screen of human cancer cell lines revealed a trend in
which the p53-mutants were more resistant to cisplatin, there was significant
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variability in drug response (28). Finally, while the present manuscript was in
preparation, a report appeared indicating that the sensitivity of human testicular 0
tumor cell lines to cisplatin-induced apoptosis was independent of p53 status (29).
These investigations reveal that the success of cisplatin-based
chemotherapy may be due in part to apoptosis controlled by wild-type p53, but 0
there is only limited information about the role of this protein in mediating
cisplatin cytotoxicity in testicular cancer cells, the most responsive tumor type.
Moreover, previous work demonstrates the importance of cellular context and 0
cell type in examining the effect of p53 on the cytotoxicity of cisplatin. In the
present study, several mouse testicular teratocarcinoma cell lines, having both
wild-type and mutant p53, were used in order to examine the response of p53- 0
controlled pathways to cisplatin in a relevant cellular background. Experiments
were also performed to determine whether or not p53 is essential for the cytotoxic
activity of this drug. Our results clearly show that, whereas p53 is an important 0
factor in the short-term response to drug treatment, wild-type p53 function is not
an absolute requirement for cisplatin-induced cytotoxicity.
Materials and Methods
Materials. Cisplatin was a gift from Johnson-Matthey. Fresh aqueous stock
solutions were prepared for each experiment. The [a- 3 2 P]dCTP, [y-32P]ATP, 0
[35S]amino acids, and [12 51]Protein A were purchased from Dupont, NEN. Protease
inhibitors and RNase were purchased from Boehringer Mannheim. Igepal CA-
630, DAPI, and cycloheximide were purchased from Sigma. Fixed Staphylococcus 0
aureus (Staph A) was supplied by H. Ploegh (M.I.T.). The anti-p53 monoclonal
antibody mAb421 was obtained from A. J. Levine (Princeton, NJ).
Cells and Cell Culture. F9 (ATCC CRL 1720) and Nulli-SCC1 (ATCC CRL 0
1566) cells were obtained from the American Type Culture Collection, Rockville,
0
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Maryland. The p5 3 mutant teratocarcinoma cell line (EB16) was a gift from A. J.
Levine, Princeton (18), and was derived from a testicular tumor of a p53 knockout
mouse. The teratocarcinoma cell lines were propagated in Dulbecco's modified
Eagle's medium (DMEM) with 2 mM L-glutamine and antibiotic antimycotics
(Sigma) in addition to 10% fetal bovine serum (EB16), 15% fetal bovine serum (F9)
or 10% calf serum (Nulli-SCC1). All plates were coated with a 0.1% (w/v) gelatin
solution (Sigma) for 30 min and washed with PBS before use. The cells were
grown at 37*C in a 5% CO2(g) atmosphere. Unless otherwise indicated, cisplatin
was administered to cells growing in logarithmic phase on 10 cm plates in fresh
media; continuous exposure means that the drug-treated media was not replaced.
p53 Protein Analysis. At each time point, the cells were washed with cold
PBS and then lysed by incubation for 30 min on ice in lysis buffer (50 mM TrisHCl,
pH 8.0, 150 mM NaCl, 0.5% Igepal CA-630, 1 mM DTT, 10 gg/ml each of aprotinin,
leupeptin, and pepstatin, and 0.5 mg/ml pefabloc). The cell lysate was centrifuged,
and the supernatant was stored on ice until use. All subsequent steps were
performed at 4*C with pre-chilled solutions.
Fixed Staph A was washed three times in NET buffer (50 mM TrisHCl, pH
7.5, 150 mM NaCl, 5 mM EDTA, 0.5% Igepal CA-630). Samples containing equal
amounts of protein in the same volume (1-1.5 ml) were pre-cleared with 100 RI of
Staph A and 6 gl each of normal mouse and rabbit sera (Sigma) for 1 h. After cen-
trifugation the supernatant was incubated with 200 gl of mAb421 for 12-16 h.
Staph A (80 pl) was incubated for 45 min in the sample, followed by
centrifugation. The pellet was washed three times in NET buffer, boiled for 5 min
in SDS loading buffer (50 mM TrisHCl, pH 6.8, 100 mM DTT, 2% SDS, 10%
glycerol, 0.1% bromophenol blue), and loaded onto an 8% SDS-polyacrylamide gel.
For western analysis, the proteins were electroblotted onto Immobilon-P
membrane (Millipore) at 450 mA for 100 min, at 4*C, in 20 mM Tris, 200 m M
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glycine, 20% methanol. The blot was blocked with 5% BSA in TPBS (0.05% Tween
20 in PBS), probed with mAb421 diluted 20-fold in TPBS containing 1% BSA. The
blot was then washed, probed with 10 gCi ['25I]Protein A in the same buffer, and
exposed to film at -80*C with an intensifier screen. The data were quantitated by
Phosphorimager analysis (Molecular dynamics). 0
For metabolic labeling, either untreated or cisplatin-treated (24 h) cells were
exposed to methionine/cysteine free media for 30 min and then pulse-labeled for
80 min with 0.3 mCi of [35S]methionine and [35S]cysteine. The cells were then
washed and fed fresh media. Immunoprecipitations were performed as described
above. Following SDS-PAGE analysis, the gel was fixed for 30 min in 25%
isopropanol, 10% acetic acid, then in Amplify (Amersham) for 30 min. The gel
was vacuum dried on Whatman filter paper and exposed to film at -80'C with an
intensifier screen. The data were quantitated as described above.
Northern Assay. Total cellular RNA was isolated by using a single-step acid
guanidinium thiocyanate-phenol-chloroform extraction (Ultraspec II, Biotecx).
Plasmids containing the cDNA needed for probing the p53, p21, mdm-2, cyclin G
and GAPDH genes were provided by T. Jacks (M.I.T.) The DNA was grown in E.
Coli, purified by Quiagen preparation, cut with the appropriate restriction
enzymes, resolved on an agarose gel, and eluted. Total mRNA was resolved on
agarose-formaldehyde gels. The RNA was heated to 65*C for 15 min in 1X MOPS
(40 mM MOPS, pH 7, 10 mM NaAcetate, 1 mM EDTA), 6% formaldehyde and 50%
deionized formamide. The samples were chilled on ice and loading buffer was
added (50% glycerol, 1 mM EDTA, 0.2% bromophenol blue) prior to loading onto 0
an agarose gel containing 6% formaldehyde (Fisher) and 1X MOPS buffer, which
was run in 1X MOPS buffer at 70-90 V. The RNA was transferred to Hybond-N
nylon membrane (Amersham) by using the Schleicher and Schuell turboblotter, 6
cross-linked to the membrane by using a Stratalinker (Stratagene). The blot was
41
161
hybridized to randomly primed cDNA probes (Prime-It II, Stratagene) as
previously described (30). Briefly, the blot was blocked for 1-4 h at 650C (0.5 M
sodium phosphate, pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS), and hybridized for 14-
18 h at 65*C to the radiolabeled cDNA probe in 30% formamide, 0.2 M sodium
phosphate, pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS with 0.1 mg/ml herring sperm
DNA (GibcoBRL) as a non-specific competitor. The blot was washed twice in 40
mM sodium phosphate, pH 7.2, 1 mM EDTA, 1% SDS for 30 min at 650, and
exposed while still damp to film at -80 0C with an intensifier screen. The data were
quantitated by Phosphorimager analysis (Molecular dynamics). Blots were
reprobed after being stripped twice by pouring boiling water onto the membrane
and then incubating at 65'C for 15 min.
DNA Degradation Assay. The cells were treated with cisplatin for 24 h,
harvested, and washed twice in cold TBS (100 mM Tris, pH 7.4, 154 mM NaCl).
DNA from 7.2 x 105 cells was isolated as described previously (18). Briefly, the cells
were resuspended in 200 p1 of PK solution (10 mM Tris, pH 8, 100 mM NaCl, 10
mM EDTA, 0.5% SDS and 0.5 mg/ml proteinase K) and incubated at 37*C for 3 h.
The mixture was extracted once with an equal volume of
phenol:chloroform:isoamyl alcohol (25:24:1) and then once with ether. The DNA
was precipitated with two volumes of isopropanol and then resuspended in TE
containing 50 gg/ml RNase and incubated for 2 h at 37*C. Loading buffer was
added (10% glycerol, 20 mM Tris, pH 7.5, 0.02% SDS, 20 mM EDTA, 0.002%
bromophenol blue and xylene cyanol) and the DNA was loaded onto a 1.1%
agarose gel. The gel was run at 20 mA for 12 h and then stained in 0.5 gg/ml
ethidium bromide for 30 min and destained in deionized water.
Apoptosis Assay. Cells were treated continuously with cisplatin in 24-well
plates (3-5 x 104 cells/well). At each time point, both attached and detached cells
were collected and resuspended in PBS. To check for membrane perforation, an
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aliquot was stained in 0.2% trypan blue and counted on a hemacytometer. The re-
mainder of the cells were fixed in cold methanol, stained with 1 gg/ml of DAPI in
PBS, and mounted on a slide. Chromatin structure was observed under a fluores-
cent light microscope (Axioscope, Zeiss Germany).
FACS Analysis. At each time point, both attached and detached cells were
collected, washed with PBS, fixed by dropwise addition of ethanol, and stored at
4*C. The cells were washed once with PBS followed by resuspension in PBS
containing 50 gg/ml propidium iodide (Sigma) and 0.2 mg/ml RNase. The
samples were incubated, at 37'C for 30-60 min and then analyzed on a Becton-
Dickinson FACScan. Quantitation of cell cycle distribution was performed with
ModFitLT software.
Excision Assay with CFEs. Whole cell-free extracts (CFEs) were used to
measure excision of the damaged DNA according to a previously described
method (31, 32). Extracts were prepared by the method of Manley et al. and stored
at -80' (33). The 1,3-d(GpTpG) cisplatin intrastrand cross-linked substrate
containing a radiolabel four nucleotides to the 5' side of the site-specific adduct
has been described previously (32, 34). The excision assay experiments were
performed as described. Briefly, 125 g1 reactions contained 20 [d of reaction buffer
(300 mM Hepes pH 7.9, 400 mM KCl, 32 mM MgCl 2, 1 mM EDTA, 20-50 mM ATP,
2 mM DTT), 25 g1 of p21 buffer (50 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 1
mM 2-mercaptoethanol), 20 pM of each dNTP, 0.2 mg/ml bovine serum albumin
(BSA), 500 ng of pBR322 as non-specific competitor DNA, 50-250 pM substrate, and
17.5 p1 of CFE in storage buffer (25 mM Hepes pH 7.9, 100 mM KCl, 12 mM MgCl2,
0.5 mM EDTA, 2 mM DTT and 12.5-16.5% glycerol). When comparing two
different CFEs, the same amount of protein was used. The reaction mixtures were
incubated at 30 *C and 25 p1 aliquots were removed from the reaction at each time 0
point. The reactions were stopped by making them 0.5% in SDS and 0.4 mg/ml in
a
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proteinase K (Gibco BRL) and heating at 55 'C for 20 min. The reactions were
extracted, precipitated, and resolved on 10% denaturing polyacrylamide gels as
previously described (34). The data were quantitated by using a PhosphorImager
with ImageQuant software (Molecular Dynamics).
Clonogenic Assays. Dilute cells were plated on 6-well plates (150-200
cells/well) the day before cisplatin treatment. Exposure to drug was either for 2 h,
at which point the cells were washed with PBS and fed fresh media, or
continuous. Colonies were allowed to grow for 5-7 d, stained with 1% methylene
blue (Fluka) in 50% ethanol, and counted.
Results
Cisplatin Induction of the p53 Protein. Previous reports have
demonstrated that DNA-damaging agents induce the p53 protein in testicular
tumor cells (18, 35, 36). In the present study, immunoprecipitation followed by
western blot analysis revealed that continuous treatment of the F9
teratocarcinoma cells with cisplatin resulted in a rapid (2 h) elevation (2-6 fold) in
the steady-state levels of the p53 protein (Figure 4.1). The amount of cellular p53
protein increased over a 6 h period, reaching levels more than 10-fold higher than
in untreated cells, followed by a decrease observed 4 h later (data not shown).
One possible explanation for the cellular accumulation of p53 protein is
drug-induced protein stabilization (18, 37). To test whether such a mechanism is
active in cisplatin-treated cells, the half-life of the p53 protein was determined by
pulse-labeling the F9 cells prior to drug exposure (Figure 4.2). In untreated cells,
the half-life of the p53 protein was 3-4 h, as previously reported (38), and the
requirement for active protein synthesis in p53 degradation was demonstrated by
stabilization of the protein after the addition of cycloheximide to the media
(Figure 4.2A). The 10 gM dose of cisplatin that produced a rapid increase in the
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steady-state levels of p53 did not significantly alter the half-life of the protein,
although a higher dose (50 JM) did stabilize p53. When the cells were exposed to
10 gM cisplatin 24 h prior to the radioactive pulse, many of them died and
detached from the plate, resulting in less total protein for immunoprecipitation
(Figures 4.2B and C). It is clear, however, that a 24 h dose of 10 RM, but not 1 RM, 4
cisplatin stabilized the p53 protein. The mechanism of cisplatin-mediated p53
protein induction in the F9 cells was further examined by northern blot analysis.
No significant changes in the p53 mRNA levels were observed following 0
exposure of the cells to the drug (Figure 4.3).
Cisplatin Activation of p53 Activity. To investigate whether the p53
protein in the cisplatin-treated F9 cells was active, a northern blot containing total 0
RNA was probed for the expression of p21, a transcriptional target of p53 (39). The
p21 message was elevated after a 2 h treatment (data not shown) and continued to
increase over the 10-h period of exposure (Figure 4.3). In addition, the induction
of two other p53-regulated genes, mdm-2 and cyclin G (40, 41), was observed.
Similarly, the RNA of all three genes was induced by cisplatin in another p53-
wild-type teratocarcinoma cell line, Nulli-SCC1. The blots were also analyzed for
expression of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene to
control for gel loading and to demonstrate that cisplatin damage did not enhance
gene expression nonspecifically.
Induction of p53-Dependent Apoptosis in Teratocarcinoma Cells. One of
the p53-regulated responses to genotoxic stress is initiation of the programmed
cell death pathway (12), an effect that could be involved in the cytotoxic
mechanism of cisplatin (42). To determine whether cisplatin kills the testicular
teratocarcinoma cells through an apoptotic pathway, chromatin condensation, an
early indicator of apoptosis (43), was evaluated in cells stained with DAPI (Figure 0
4.4). The nuclear change was observed in a significant number of the p53-normal
0
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cells following a 24 h exposure to 10 pM cisplatin (Figure 4.5A). After treatment
for 2 d, most of the cells (>80%) were apoptotic and had detached from the plate.
The results of the DAPI assays correlate with the loss of viable cells as determined
by a Trypan blue exclusion test (Figure 4.5B), suggesting that at these time points
the teratocarcinoma cells were killed exclusively by apoptosis. The requirement
for functional p53 in the apoptotic response was examined in the EB16 cell line
derived from testicular tumors of mice with a defective p53 gene (18). After 48 h
of drug treatment, the majority of these p53-mutant teratocarcinoma cells
remained attached to the plate and exhibited very little of the altered chromatin
structures (Figures 4.4 and 4.5).
Another feature of programmed cell death is endonuclease digestion of
genomic DNA (43). Resolution of the DNA from cisplatin-treated F9 and Nulli-
SCC1 cells by agarose gel electrophoresis revealed the characteristic ladder of
oligomers (Figure 4.6). Such fragmented DNA was not present upon similar
analysis of the p53-mutant EB16 cells.
Effect of Cisplatin on Cell Cycle. To investigate further the response of the
teratocarcinoma cells to cisplatin, flow cytometry was used to analyze the cell cycle
distribution during exposure to the drug (Figure 4.7 and Table 4.1). A 1 pM dose
of cisplatin allowed the effects of the drug on the cell cycle to be examined without
immediately killing the cells. Treatment of F9 cells with this low dose for 24 h
resulted in an accumulation of cells in the G2 phase. After 2 d of exposure, the
cells were still arrested in G2, although some evidence for cell death (cellular de-
bris) was observed. Significant cell death was apparent after a 1 d treatment with a
higher dose (10 jM) of cisplatin and was complete after 48 h (Figure 4.7), in accord
with the experiments described above (Figure 4.5). The p53-wild-type Nulli-SCC1
cells exhibited similar cell cycle profiles, a low dose of cisplatin activated G2 arrest
and some cell death, whereas a higher dose rapidly killed the cells (Table 4.1).
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Cisplatin-Induced DNA-Repair. It has been suggested that cisplatin-treated
cells arrest in the cell cycle so that attempts can be made to repair the DNA 0
damage (42). In addition, several lines of evidence suggest that p53 modulates the
nucleotide excision repair pathway, either through direct interactions with the
excinuclease components or through transcription-controlled expression of DNA 0
repair factors (44, 45). Pretreatment of human fibroblast or colon carcinoma cells
with UV irradation resulted in an increase in the levels of DNA repair, an effect
not observed in p53-deficient cells (46). To determine whether cisplatin-induction
of the p53 protein was, accompanied by an increase in repair activity in the
teratocarcinoma cells, cell-free extracts (CFEs) were prepared from F9 cells that
were exposed to 10 gM cisplatin for 5 h. The repair capacity of the extracts
prepared from the treated cells was slightly higher than the extracts from
untreated cells (Figure 4.8). This protective response was also observed in cells
which had been exposed to cisplatin for 12 h (data not shown), at which time the
p53-protein levels have subsided, supporting the hypothesis that the p53 protein
is not directly involved in DNA repair, but instead may have a regulatory role.
Cell Cycle Response of p53-Mutant Cells. The effect of cisplatin on the p53- 0
mutant teratocarcinoma cells was also examined. A low dose of cisplatin caused
accumulation of the EB16 cells in the G2 phase of the cell cycle (Figure 4.9 and
Table 4.1). In contrast, the EB16 cells treated with 10 pM cisplatin for 1 d
accumulated in the G1/early S phase of the cell cycle. The block in the cell cycle
was sustained through 4 d of continuous drug treatment and only a small amount
of cellular debris was observed. This result was surprising because one of the 0
mediators of G1 arrest is the p53-regulated p2l gene product (47-49). There is
evidence, however, for a p53-independent pathway of p21 induction and cell cycle
arrest (11, 50). In fact, in our system, northern blot analysis revealed that the p21 0
message was induced during cisplatin treatment of the EB16 testicular
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teratocarcinoma cells, even in the absence of wild-type p53 (Figure 4.3), providing
a possible explanation for the observed G1 arrest. A similar p53-independent
induction of two other p53-regulated genes, mdm-2 and cyclin G (40, 41), was not
observed in the mutant cell line (Figure 4.3).
Cisplatin Cytotoxicity. Colony formation assays were used to determine the
overall sensitivity of the p53-wild-type and p53-mutant mouse testicular
teratocarcinoma cell lines. This type of experiment differs from the apoptosis
assays described above in that it only assesses viable cell division and does not
distinguish between various mechanisms of cell death and/or cell cycle arrest.
Such a limitation was noted in a recent study of human colon cancer cells in
which a p21 mutation sensitized xenografts to y-irradation, an effect not observed
by clonogenic assay (51). However, the response of cell lines tested by this type of
in vitro assay does reflect the differential chemosensitivity of tumors treated in
vivo (36). In the present study, the cells were either treated for 2 h or contin-
uously exposed to cisplatin and grown until visible colonies had formed. Under
both conditions, no significant difference was observed in the sensitivity of the
different cell lines to cisplatin (Figure 4.10), regardless of p53 status. Although the
plating efficiencies of the three cell lines varied, for example in the experiments
shown they ranged from 46-74% (Figure 4.10A) and 13-49% (Figure 4.10B), the p53
mutant cells did not have a consistently lower plating efficiency when compared
to the other cell lines.
Discussion
Previous work investigated the relationship between the status of the p53
gene and cellular sensitivity to cisplatin, with contradictory results (21-29). The
present study addresses the issue of cell type by investigating the p53 response to
cisplatin in murine testicular teratocarcinoma cells. These cell lines resemble
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testicular cancer, for which cisplatin is a particularly effective treatment, in that
the product of a wild-type p53 gene is overexpressed (38, 52).
Treatment of the p53+/+ teratocarcinoma cells lines with etoposide both
induces and activates the p53 protein (18). Similarly, we report here that the p53
protein was elevated and transcriptionally active in the testicular teratocarcinoma 6
cells after a 2 h exposure to cisplatin. One mechanism of p53 cellular
accumulation is inhibition of the protein degradation pathway (28), and in
support of this hypothesis the half-life of the p53 protein was prolonged in
cisplatin-treated cells. In contrast to the rapid protein induction observed at the
same drug concentration, however, protein stabilization was not immediately
apparent and was only manifest after a much longer exposure to the drug (24 h). 0
This result, coupled with the observation that the DNA-damaging agent did not
result in increased levels of p53 mRNA, suggests that the rapid induction of the
p53 protein by cisplatin occurs at least in part through a translational mechanism.
Experiments with human leukemic blast cells also provided evidence for
translational control of p53 expression (53). Cells collected from different patients
with acute myelogenous leukemia displayed variable levels of p53 protein 0
expression, which did not correlate with the levels of mRNA. In addition, a
comparison of leukemia cell lines demonstrated that the p53 mRNA was
preferentially associated with large polysomes in the cell populations with larger 0
ratios of p53 protein to mRNA. In fact, it is possible that p53 is involved in
autoregulatory control of its expression, because the protein binds to, and inhibits
the translation of, its own mRNA (54, 55).
In a similar fashion to other DNA-damaging agents, cisplatin activates the
programmed cell death pathway in the mouse testicular teratocarcinoma cells.
Immediate activation of apoptosis, however, was avoided by the use of a smaller 0
dose of cisplatin, which permitted an investigation of the effects of the drug on
4
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the cell cycle. Both the F9 and Nulli-SCC1 cells accumulated in the G2 phase
during drug treatment. A G2 block is a characteristic effect of cisplatin treatment
and is considered to be a prerequisite for apoptosis induced by cisplatin (42, 56, 57),
or a transient response during which the genetic damage is repaired. In addition,
there is evidence that cisplatin-induced apoptosis depends on the active cell cycle
of proliferating cells, a requirement that was not observed for etoposide (58).
Although there is support for p53 involvement in the G2 /M checkpoint (11), it is
unlikely that the protein participates in the cisplatin-mediated block of the cell
cycle observed here, because some G2 accumulation was evident in the p53-
mutant cells exposed to the low dose. The lack of a functional p53 may be more
relevant to the fate of the cells after cell cycle arrest. Whereas the clonogenic
experiments demonstrate that the cellular proliferation of all of the
teratocarcinoma cells is inhibited by the low dose of cisplatin, preliminary studies
suggest that, in contrast to the p53-wild type cells, the p53-mutant cells do not
undergo programmed cell death (data not shown). Non-apoptotic death
following G2 arrest would be consistent with a report suggesting that cells can die
by a mechanism involving failure to overcome the cell cycle block when treated
with a dose of cisplatin that does not immediately activate apoptosis (59).
The rapid drug-induced apoptosis observed in the F9 and Nulli-SCC1 cells
depends on functional p53, since the characteristic chromatin condensation and
DNA fragmentation were not observed in the p53-mutant cells. Instead, cell cycle
analysis revealed a prolonged block in G1/early S phase in the mutant cells. This
result was unexpected because an effector of the G1 checkpoint is the cyclin-
dependent kinase inhibitor, p21 (47, 49), which is transcriptionally regulated by
p53 (39), and is specifically induced in p53-dependent cellular responses to DNA
damage (48). Exposure to cisplatin caused an elevation in p21 expression in the
p53-mutant teratocarcinoma cells, however, providing an explanation for the
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observed arrest in the cell cycle. Several reports have proposed the existence of
p53-independent G1 arrest and p21 induction (11, 24, 50, 60). This pathway seems
to be selectively activated by different DNA-damaging agents, depending on the
cellular context. For example, UV light, but not ionizing radiation, induced p21
and G1 arrest in p53-deficient fibroblasts from Li-Fraumeni syndrome patients (60),
but G1 accumulation was observed in irradiated p53-/- T lymphoma cells
expressing Bcl-2 (50).
A p53-independent induction of p21 was not detected in human testicular 0
tumor lines exposed ,to cisplatin (29). In' that study, however, similar
chemosensitivities of cells with both functional and non-functional p53 were
observed and attributed to the activation of p53-independent apoptosis.
Therefore, with respect to the lack of p53-involvement in ultimate sensitivity to
drug treatment, the results from the human and mouse testicular tumor cell lines
are consistent, but important differences in cellular mechanisms may exist. The
p53-mutant mouse teratocarcinoma cells did not undergo cisplatin-induced
apoptosis, although clonogenic assays revealed an overall sensitivity similar to
that of the p53-wild-type cell lines. It is conceivable that the p53-mutant cells
experience a permanent cell-cycle arrest mediated by p21, which has been linked
with senescence (61, 62). Preliminary cell viability studies suggest that these cells
eventually die (data not shown), however, making this possibility unlikely.
Whatever the reason for the loss of clonogenic capability, these
experiments demonstrate that, despite the failure of cisplatin to induce
programmed cell death in the p53-mutant cells, this deficiency does not confer 0
resistance. In fact, it is possible that the p53-mutant cells are slightly more
sensitive than the p53-normal cells in this assay (Figure 4.10). A similar decrease
in resistance was observed in fibroblast cells treated with paclitaxel, an anticancer 0
drug that stabilizes cellular microtubules, when the cells were depleted of
4
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functional p53 (63). In contrast, preclinical trials demonstrated that paclitaxel was
effective in the treatment of human tumor xenografts with and without p53
mutations (64). The inconsistency was explained by the observation that paclitaxel
activates the release of tumor necrosis factor a (TNF-a) by murine macrophages.
TNF-a, which would have been induced in the in vivo experiments but not in
the in vitro cell culture experiments, activates p53-independent apoptosis (64).
These experiments, and others (51), demonstrate that it is not always possible to
extrapolate data from cell culture to whole animals. Although the data presented
here suggest that the unusual sensitivity of testicular cancer to cisplatin is not due
solely to a wild-type p53 gene, it is impossible to make such a conclusion without
in vivo evidence. A mutation in the p53-gene is an indicator of poor prognosis in
patients with well or moderately differentiated ovarian cancer (65); however,
overexpression of both wild-type and mutated p53 was found in advanced
ovarian carcinomas refractory to cisplatin-based chemotherapy (66). In light of the
results presented, both here and elsewhere (29), it would be informative to
investigate whether the few testicular cancer patients who fail cisplatin-based
chemotherapy have developed p53 mutations. In a recent study of a small panel
of male germ cell tumors from relapsed patients, a mutant p53 gene was found in
only a subset (<20%) of the specimens (67), supporting the conclusions of the
present study. A much larger screen, however, will be necessary to confirm these
results.
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Cell cycle analysis of teratocarcinoma cells treated with cisplatin. The p53
(F9 and Nulli-SCC1) and p53-mutant (EB16) murine teratocarcinoma cell
lines were treated continuously with cisplat
were collected and analyzed by FACScan as
in. At the time points indicated, the cells
described in Material and Methods.
Dose Time F9 N.S. EB16
(gM) (d)
G1  S G2/M debris G1  S G2/M debris G1  S G2 /M debris
0 0 21 62 17 2 31 51 18 5 43 45 12 1
1 1 2 51 47 2 10 63 27 7 14 40 46 17
1 2 13 5 82 54 9 32 59 19 16 33 51 34
10 1 31 68 1 43 30 40 30 59 100a 0 13
10 2 49 38 13 95 48 29 23 75 100a 0 26
10 4 100a 0 23
a In analysis of the cell cycle of EB16 cells treated with 10 pM cisplatin, the fraction of cells in the G1 or S
phase of the cell cycle could not be confidently determined.
Table 4.1.
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Figure 4.1. Cisplatin induction of p53 in mouse teratocarcinoma cells. F9 cells
were treated with 10 pM cisplatin and whole protein extracts were prepared
at the times indicated. The p53 protein was immunoprecipitated from equal
amounts of total protein with an anti-p53 monoclonal antibody (421) and
resolved on an 8% SDS-polyacrylamide gel. The proteins were transferred to
Immobilon-P membrane, probed with the anti-p53 antibody and then with
[12I]protein A.
9
0
0
179
A
Time (h) 0
0 M 10 M
2 46 2 56
1 AM
^ P '
10 M
0 2 4 6
' ' ' ' ' 
' '
0 1 2 3 4 5 6 7
Time (h)
Figure 4.2. Cisplatin stabilization of p53 protein in mouse teratocarcinoma cells.
The F9 cells were starved for 30 min in methionine/cysteine-free media, pulsed
with [35S]methionine and [35S]cysteine for 80 min, and then washed and
incubated in complete media. The cells were harvested at the indicated time
points. Equal amounts of protein were immunoprecipitated with an anti-p53
monoclonal antibody (421), and analyzed on an 8% SDS-polyacrylamide gel.
(A) The F9 cells were exposed to cisplatin or cycloheximide (chx, 50 ig/ml)
immediately following the radioactive pulse. (B) The cells were exposed to
cisplatin 24 h before the pulse. Less total protein was immunoprecipitated for
the time course of the cells treated with 10 gM cisplatin. (C) Quantitation of the
experiment shown in panel B by phosphorimager analysis. For each cisplatin
concentration, data were normalized to the first time point (0 h).
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Figure 4.3. Cisplatin induction of p21, but not cyclin G or mdm-2, in a p53-
independent manner. The p53-wild-type (F9, Nulli-SCC1), and p53-mutant
(EB16) teratocarcinoma cells were treated with 10 pLM cisplatin. Total RNA
was isolated at the indicated time points; 12 g of RNA was resolved on a
1.1% agarose-formaldehyde gel, transferred to nitrocellulose, and probed
with randomly primed cDNA. Two different blots were prepared from the
same samples of RNA, one blot was probed with the p21, p53, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) genes, the other
with the cyclin G and mdm-2 genes. The asterisk indicates the truncated
p53 gene from the p53-mutant mouse.
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Figure 4.4. Chromatin condensation assay of mouse testicular teratocarcinoma cells
exposed to cisplatin. The F9 (top), EB16 (middle), or Nulli-SCC1 (bottom) cells were
either untreated (left) or exposed to 10 gM cisplatin (right) for 48 h. Following
trypsinization, the cells were fixed in methanol and stained with DAPI.
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Figure 4.5. Induction of p53-dependent apoptosis by cisplatin. Three murine
testicular teratocarcinoma cell lines, the p53-normal F9 (circles) and Nulli-
SCC1 (diamonds) and the p53-mutant EB16 (squares), were treated
continuously with 10 pM cisplatin. At the time points indicated, the cells were
collected and stained with either (A) DAPI to quantitate cells with condensed
chromatin or (B) trypan blue to quantitate cells with permeable membranes.
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Figure 4.6. Cisplatin induction of p53-dependent DNA fragmentation. DNA was
isolated from p53-wild-type (Nulli-SCC1 and F9) or p53-mutant (EB16) mouse
teratocarcinoma cells after 24 h continuous exposure to the concentrations of
cisplatin indicated and resolved on a 1.1% agarose gel.
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Figure 4.7. Cell cycle analysis of p53-normal mouse testicular teratocarcinoma cells
treated with cisplatin. The p53-normal F9 cells were continuously exposed to 0, 1,
or 10 gM cisplatin for the indicated times, fixed in ethanol, stained with propidium
iodide, and sorted according to DNA content. The results of the flow cytometry are
summarized in Table 4.1.
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Figure 4.8. Excison of the 1,3-d(GpTpG) intrastrand cisplatin-DNA adduct in F9
extracts. (A) The substrate was incubated for the indicated amounts of time in
whole cell extracts made either from teratocarcinoma cells exposed to 10 AM
cisplatin for 5 h (F9-Treated) or from untreated cells (F9-Untreated). The
products were resolved on a 10% denaturing polyacrylamide gel. The 24 and 30
nt markders are indicated. (B) Phosphorimager analysis of two experiments
such as that shown in panel A. Error bars represent ± 1 esd.
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Figure 4.9. Cell cycle analysis of p53-mutant mouse testicular teratocarcinoma cells
treated with cisplatin. The p53-mutant EB16 cells were continuously exposed to 0,
1, or 10 gM cisplatin for the indicated times, fixed in ethanol, stained with
propidium iodide, and sorted according to DNA content. The results of the flow
cytometry are summarized in Table 4.1.
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Figure 4.10. Colony formation assays. The p53-wild-type F9 (circles) and Nulli-SCC1
(diamonds) and p53-mutant EB16 (squares) teratocarcinoma cells were treated either
(A) continuously or (B) for 2 h with cisplatin. After incubation for 5-7 days, visible
colonies were stained with methylene blue and counted. For each cell line the
numbers were normalized to the untreated data point. Error bars represent ± 1 esd.
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Chapter Five
The Influence of the Testis-Specific HMG-Domain Protein on the Responses of
HeLa Cells to Cisplatin
4
4
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Introduction
Almost a third of the North American population will develop some type of
cancer in their lifetime (1). Due to the high incidence of this complicated disease,
considerable effort has been devoted to the generation of preventative and curative
measures. One question which needs to be addressed is why the currently available
therapies are often effective against only a subset of tumors. For example, cis-
diamminedichloroplatinum(II) (cisplatin) is an essential component of the successful
chemotherapeutic regimen used to manage testicular tumors (2-4), but it achieves an
appreciable disease response in only a few other types of neoplasms (2, 5). Several
reported properties of testicular cancers could contribute to the selective cytotoxicity
of cisplatin. Included are chromosomal amplification, detected in both sensitive and
resistant male germ cell tumors (4, 6), alternative gene splicing (7), the relative
expression levels of particular proteins (8), or the production of serum tumor markers
which correlate with clinical prognosis (4). Unfortunately, the expression of a specific
cellular component has yet to be definitively associated with the mechanism of action
of cisplatin in any human tumor.
It is generally accepted that the therapeutic effects of cisplatin originate from
the formation of covalent-DNA adducts at the N7 position of purine nucleotides (9,
10). Structural analysis revealed that both the intrastrand and interstrand cross-links
significantly distort B DNA from its normal conformation (11). The distinctive
features of these cisplatin-DNA lesions, such as a local unwinding and bending of the
double helix, are also observed in some protein-DNA complexes (12), so they might
serve as recognition elements for factors that process the DNA damage. Recent
studies have demonstrated that a variety of cellular proteins have the capacity to bind
cisplatin-DNA adducts, although the consequences of this interaction are frequently
unresolved (13). One group of proteins that specifically recognize cisplatin-modified
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DNA are those which contain one or more copies of the high-mobility group (HMG)
DNA-binding motif (14).
The HMG-domain family comprises DNA architectural components and
transcription factors, some of which facilitate the formation of multi-protein
complexes responsible for a variety of DNA transactions (15-17). Despite differences
in sequence specificity, the domain confers certain properties on all of these minor-
groove-binding proteins, including the ability to bend linear DNA and to bind
distorted DNA structures. The affinity for cisplatin-modified DNA provides and a
explanation for why cisplatin treatment stimulated an intracellular redistribution of
several HMG-domain proteins in human lung tumor and cervical carcinoma cells
exposed to the drug (18, 19). This effect was not observed upon exposure to the
clinically ineffective isomer, trans-DDP, the DNA adducts of which are not
recognized by HMG-domain proteins (14). In vivo evidence supporting a role for
HMG-domain proteins in the cytotoxic mechanism of cisplatin was provided by
experiments performed in yeast. Interruption of the gene encoding the HMG-domain
protein Ixrl desensitized the cells to cisplatin but not to other DNA damaging agents
(20). Reintroduction of protein expression in the knockout yeast caused a decrease in
cisplatin resistance, although overexpression of the protein slightly above
endogenous levels did not enhance drug sensitivity (21). Furthermore, a preliminary
report suggested that there was a connection between elevated expression of the non-
histone chromosomal protein HMG2 and the cisplatin sensitivity of a lung
adenocarcinoma cell line (22).
Although many of the mammalian HMG-domain proteins are ubiquitously
distributed in cells of all origins, the expression of some is restricted to certain tissue
types (15). Of relevance to the organotropic response to cisplatin is the fact that
multiple HMG-domain proteins are specifically expressed in testis tissue at various
stages of differentiation (23-30). These proteins include the sex-determining factor
a
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SRY, as well as several of the SRY-related (Sox) proteins that share considerable
homology within their HMG-domains. The recently described murine testis-specific
HMG-domain protein (tsHMG), a nuclear isoform of the mitochondrial transcription
factor mtTFA, is expressed in the spermatocyte nuclei of seminiferous tubules and
elongating and condensing spermatids (26, 30, 31). The function of tsHMG is
currently unknown, although it may mediate chromatin restructuring during
spermatogenesis (31) or sequence-specific regulation of transcription in analogy with
mtTFA (32). Since this protein binds to cisplatin-modified DNA with unusually high
affinity and specificity (33), it could potentially mediate the cisplatin sensitivity of
tumors originating from testicular tissue.
To examine this hypothesis, tsHMG was exogenously expressed in HeLa cells,
and its effect on several different cellular responses to cisplatin was examined. The
experiments revealed that an HMG-domain protein can modulate the cytotoxic
properties of cisplatin, depending on the intensity of drug exposure. These results
suggest that testis-specific HMG-domain proteins such as tsHMG have the capacity
to influence cisplatin cytotoxicity and contribute to the unique sensitivity of testicular
tumors to the drug. Although the expression levels of HMG-domain proteins in
testicular tumors have not yet been quantitated, this information could be used to
develop of a wider range of anticancer strategies.
Materials and Methods
Materials. Cisplatin was a gift from Johnson-Matthey. Geneticin (G418) was
purchased from Gibco BRL. Doxycycline, paraformaldehyde, and 4'-6-diamidino-2-
phenylindole (DAPI) were purchased from Sigma. Tet-system approved fetal bovine
serum was purchased from Clontech. Hygromycin B and protease inhibitors were
purchased from Boehringer Mannheim. All restriction enzymes and T4 DNA ligase
were obtained from New England Biolabs. Pfu polymerase was purchased from
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Stratagene. The mouse mtTFA antiserum (30) was a generous gift from D. A. Clayton
(Stanford, CA).
Construction of tsHMG Vectors. PCR primers were synthesized on an Applied
Biosystems 392 DNA synthesizer, deprotected with NH4 OH, and purified on
denaturing polyacrylamide gels according to standard procedures. Two different
tsHMG-containing plasmids were constructed. To prepare the pTRE-tsHMG vector,
the gene for tsHMG was PCR-amplified out of the pET-15b-tsHMG vector (supplied
by G. Boissonneault, University of Sherbrooke, Quebec (31)). The 659-bp product
was cut with EcoRI and BamHI and cloned into the corresponding sites of the pTRE
expression vector (Clontech). The PCR primers used were 5'-
TGTATTCCGAAGGAATTCTCCAGCATGGGTAGCTATCC-3' and 5'-TGGGCCT-
AATCCGGATCCCAACTCCGTCTTCCATCTTA-3. The pTRE-tsHMG plasmid
expresses the previously reported 199 amino acid tsHMG protein (26) under the
control of an inducible tetracycline response element (TRE) and a minimal CMV
promoter. To prepare the pcDNA3.1-tsHMG vector, the tsHMG gene was cut out of
a pBluescript-tsHMG plasmid (supplied by N. Larsson, Karolinksa Institutet,
Stockholm) with EcoRI and KpnI and cloned into the corresponding sites of the
pcDNA 3.1/neo(-) plasmid (Invitrogen). This plasmid constitutively expresses a
tsHMG protein (215 amino acids) with sixteen additional residues
(MAGAWGLVCIPKCFSS) at the amino terminus of the originally reported sequence
(30), under the control of a complete CMV enhancer promoter. The resulting
plasmids were purified with a maxi-prep Qiagen kit. Restriction mapping and DNA
sequencing (MIT Biopolymers Facility) confirmed the correct orientation and
sequence of the genes.
Cell Culture and Transfections. The HeLa Tet-On cell line (Clontech) is a stable
transfectant of a neomycin resistance gene and the "reverse" Tet repressor, which
activates transcription in the presence of doxycycline. These cells were grown in
0
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DME containing 10% fetal bovine serum, 2 mM glutamine, antibiotic antimycotics
(Sigma), and 100-400 ig/ml G418, at 37 0C in a 5% CO2(g) atmosphere. Transfections
were performed by using the calcium-phosphate precipitation method (34). The
pTRE or pTRE-tsHMG plasmids were linearized with Sspl and 15 gg of DNA was
cotransfected with 0.75 gg of HindIII-digested pTK-Hyg plasmid (containing a
hygromycin resistance gene, Clontech), to provide a selection marker. Following a 16
h incubation with the precipitate, the cells were washed and incubated for 48 h in
fresh media. The cells were then replated at different dilutions and exposed to 200
sg/ml hygromycin. After 14 days selection the drug-resistant colonies were isolated,
expanded, screened for tsHMG production by western analysis, and maintained in
100 gg/ml hygromycin. Unless otherwise indicated, cisplatin was administered to
cells growing in logarithmic phase in fresh media; continuous exposure means that
the drug-treated media was not replaced. Fresh aqueous stock solutions were
prepared for each experiment, and the platinum concentration was confirmed by
using a Varian atomic absorption spectrophotometer AA-1475, equipped with a
graphite tube atomizer.
Western Analysis. Cells growing on 10-cm plates were induced for 24 h with
the indicated concentrations of doxycycline in fresh media, washed with PBS, and
lysed in 250 l of cell lysis buffer (2% SDS in PBS, 10 Jg/ml each of pepstatin,
leupeptin, and aprotinin, 0.5 mg/ml pefabloc). The lysates were passed through a
25G5/8 syringe needle, boiled for 5 min, and the protein concentrations were
determined by using the BioRad DC assay. The proteins (240 pg) were resolved on a
10% SDS-polyacrylamide gel and then electroblotted onto Immobilon-P membrane
(Millipore). The blots were blocked for 1 h in TPBS (0.05% Tween-20 in PBS)
containing 5% BSA, washed, and then incubated for 60-90 min with a-mtTFA
antibody diluted in TPBS with 1% BSA. The membrane was then washed, and
incubated with an a-rabbit IgG whole antibody conjugated to horseradish peroxidase
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(Amersham) diluted 5000-fold in TPBS and 1% BSA. After washing, the blot was
developed with an enhanced chemiluminescent (ECL) detection system. The
membrane was incubated for 1 min in a freshly made solution containing 67 mM Tris,
pH 8, 1.25 mM luminol (Fluka), 0.2 mM p-coumeric acid (Sigma) and 0.009%
hydrogen peroxide, and then exposed to film.
Clonogenic Assays. The cells were exposed to 4.2 gM (2 gg/ml) doxycycline for
2 days, plated onto 6-well plates (400 cells per well) and incubated with doxycyline
for an additional day prior to cisplatin treatment. Exposure to cisplatin was either for
2 h, at which point the cells were washed with PBS and fed fresh media containing
doxycycline, or continuous. Colonies were allowed to grow for 6-7 days, stained with
1% methylene blue (Fluka) in 50% ethanol, and counted.
Immunofluorescence and Apoptosis Assays. In preparation for experiments
involving continuous cisplatin exposure, 5-8 x 104 cells were plated into each well of
6-well plates and treated with 4.2 pM doxycyline for two days prior to drug
treatment. For short drug exposure times, cells growing on 10-cm plates were treated
with doxycycline for 2 days, then replated onto 6-well plates (5-8 x 104 cells per well).
A day later the cells were exposed to cisplatin in fresh media for the indicated length
of time, washed twice with PBS and then incubated in media containing doxycycline.
At the appropriate time point, both the detached and attached cells were collected,
centrifuged onto to Vectabond-treated glass slides (Vector Labs) by using a cytospin,
and air dried. The cells were then fixed with 4% paraformaldehyde in PBS, rinsed
with PBS, and permeabilized with 0.1% Triton-X 100 in 0.1% (w/v) sodium citrate for
2 min at 4*C. The cells were then washed with PBS, incubated for 60 min at 37*C
with terminal deoxynucleotidyl transferase and fluorescein-conjugated dUTP
(Boehringer Mannheim) according to the manufacturer's specifications, and washed
extensively in PBS. The cells were blocked in PBS containing 0.1% Triton X-100 and
5% goat serum (Sigma) for 15 min at RT, incubated for 40 min at 37*C with mtTFA
0
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antiserum diluted 500-fold in blocking buffer, and washed. After incubation for 40
min at 37*C with goat a-rabbit IgG conjugated to rhodamine (Cappel) diluted 1000-
fold in blocking buffer, the cells were washed, stained with 1 gg/ml DAPI in PBS for
5 min, washed and mounted with Mowiol. The cells were then examined with a
fluorescent light microscope (Axioscope, Ziess Germany). The fraction of tsHMG-
expressing and -non-expressing cells that were apoptotic was determined, at least 400
cells were counted on each slide. The significance of the data from each experiment
was determined by using the two-sample unpaired t-test (35). Each experiment was
performed in triplicate, and the mean values and standard deviations (s, eq 1) for the
I(X, -)X
s = (1)
percentage of tsHMG-expressing and non-expressing apoptotic cell was determined.
These values were then used to calculate the population variance (sp2) and t (eq 2 and
3), which was compared with values on a t-table. The means were considered as
significantly different if the probability that the null hypothesis was true (p) was less
than 5%.
2 (N -1)s2 + (N2 -1)s22s2= 1 (2)N1+ N2 -2
t 2 (3)1 1
s, -+-
Transcription Inhibition Assay. This experiment was performed by K. E.
Sandman (M.I.T.). HeLa cells expressing the enhanced green fluorescent protein
(EGFP) under the control of the doxycycline-inducible promoter (36) were transiently
transfected with pcDNA3.1 or pcDNA3.1-tsHMG by the calcium phosphate method,
using 6 pg of circular plasmid per well of 6-well plates. The precipitate was washed
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away after 16 h, and the cells were incubated in fresh media for 48 h. The cells were
then co-treated for 13.5 h with cisplatin and doxycycline in fresh media, and the 0
EGFP expression assay was performed as previously described (37).
Results
tsHMG Expression in HeLa Cells. To investigate whether exogenous HMG-
domain proteins can influence the cytotoxic effects of cisplatin in a cell-based system,
the gene for the mouse tsHMG was placed under the control of an inducible B
promoter, the tetracycline responsive element (TRE). The pTRE-tsHMG vector was
cotransfected into HeLa cells with a hygromycin-resistance gene, and stable clones
were .selected, isolated, and expanded. The HeLa cell line employed expresses a
mutant form of the Tet repressor fused to a VP16 transcriptional activation domain.
This complex activates transcription of TRE-controlled genes in the presence of
tetracycline or a derivative such as doxycycline (Figure 5.1). The HeLa cell line is
derived from a human cervical carcinoma infected with a human papillomavirus
(HPV) which modulates the activity of the wild-type p53 protein (38, 39). Although
the HPV could afford some unusual drug response which is not relevant to the
treatment of uninfected cell types, many of the p53-regulated responses to cisplatin,
including p53 protein relocalization, p21 mRNA induction, and apoptosis, are
observed in this cell type (40-42).
Following induction with doxycycline, clones that inducibly expressed tsHMG
were identified by using a polyclonal antibody for mtTFA in western blot analysis of
whole cell extracts. Murine tsHMG and mtTFA arise from alternative splice variants
such that mtTFA only differs by an extra 44 residues at the amino terminus (30). The
tsHMG protein was detected in multiple clones following a 24 h induction with 4.2
gM doxycycline (Figure 5.2 and data not shown). No significant difference in tsHMG
expression was observed upon induction with a range of doxycycline concentrations
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(2.1-21 RM). The levels of tsHMG expression increased as a function of induction
time up to, but not beyond, 48 h (data not shown). For all subsequent experiments
tsHMG protein expression in the HeLa cells was induced by exposure to 4.2 gM
doxycycline for at least 48 h. Finally, tsHMG was still detectable in the HeLa cells 48
h after doxycycline had been removed from the media (data not shown), possibly
because of a long protein half-life or persistent induction of the response element.
The Effect of tsHMG on Cisplatin Cytotoxicity. Colony formation assays were
used to compare the cisplatin sensitivity of the tsHMG-expressing HeLa cells with
uninduced cells (Figure 5.3). Two sets of conditions were employed, either a two
hour exposure or continuous drug treatment. Some variability in sensitivity was
observed between the different clones, particularly for the longer exposure times. No
reproducible difference in the sensitivity of the induced cells was observed when
compared with that of the uninduced cells, however, under either of the drug-
treatment conditions. The plating efficiencies of the different cell lines varied. For
example, in the experiments shown they ranged from 39-69% (Figure 5.3A) and from
16-38% (Figure 5.3B). When there was a difference between induced and uninduced
cells, the doxycycline-treated cells had a slightly lower proliferative capacity after
plating.
One possible explanation for the absence of any effect of tsHMG on the
sensitivity of the HeLa cells to cisplatin is that the protein localized in the cytoplasm
and did not have access to the drug-damaged DNA. Recent analysis of murine testis-
specific cDNA suggested that tsHMG might be expressed with sixteen additional N-
terminal residues (30), proposed to serve as a nuclear localization sequence (NLS).
The exact location of the translational start site of tsHMG remains uncertain (26, 31),
however, and mutational analysis of several HMG-domain proteins established that
nuclear localization is determined by sequences contained within the HMG domain
(43, 44). To resolve this issue, the subcellular localization of tsHMG in the HeLa cells
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was evaluated with immunofluoresent staining. A high concentration of primary
antibody was employed in these experiments, resulting in a low level of background
fluorescence in all parts of the control pTRE cells, similar in both doxycycline-treated
and -untreated samples (Figure 5.4). The same degree of cellular staining was
observed in an uninduced stable transfectant of pTRE-tsHMG (Figure 5.5). After a 24
h exposure to doxycycline, however, strong immunoreactivity was observed in some
of the nuclei, confirmed by parallel DAPI staining.
Although these experiments demonstrate that tsHMG localizes to the nucleus,
they also suggest why there was no significant effect on cisplatin toxicity in the
clonogenic assays. Examination of the doxycycline-induced HeLa revealed that only
a fraction of the cells contained detectable levels of the HMG-domain protein (Figure
5.5), and the levels of expression of tsHNMG varied from about 20% to 70% of the cells,
depending on the clone.
Sensitization to Cisplatin-Induced Apoptosis. A common cellular response to
cisplatin exposure is the activation of the programmed cell death pathway (45), which
is accompanied by several characteristic transformations including chromatin
condensation and endonuclease digestion of genomic DNA (46). To investigate how
tsHMG affects cisplatin-induced apoptosis in individual HeLa cells, tsHMG
expression was detected with a rhodamine-conjugated secondary antibody. The
number of expressing or non-expressing cells undergoing apoptosis was determined
by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling
(TUNEL) assay (47), which enzymatically incorporates a fluorescein label at the ends
of DNA strand breaks. Low levels of apoptosis were observed in the HeLa cells 48 h
after a 2 h exposure to cisplatin. A representative experiment is shown in Figure 5.6
and listed in Table 5.1. Under these conditions, a larger percentage of tsHMG-
expressing cells exhibited the distinctive nuclear changes than did non-expressing
cells. Although this difference was small, never more than two-fold, it was
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statistically significant, and the effect was reproduced in several tsHMG-expressing
clones, indicating that the HMG-domain protein sensitized the HeLa cells to cisplatin-
induced apoptosis.
Enhanced Transcription Inhibition. A recent study of HeLa cells inducibly
expressing the enhanced green fluorescent protein (EGFP) reporter gene
demonstrated that platinum drugs block transcription to a degree that correlates with
the cytotoxicity of the different compounds (37). In order to study the effect of an
HMG-domain protein on this cisplatin-mediated transcription inhibition, the
pcDNA3.1-tsHMG expression plasmid was transiently transfected into the EGFP-
expressing cells. Induction with doxycycline, followed by fluorescence
measurements and Western analysis, confirmed that tsHMG and EGFP could be
simultaneously expressed (data not shown). Transiently transfected HeLa were then
exposed simultaneously to doxycyline and cisplatin. In the absence of tsHMG,
exposure to low concentrations of cisplatin (1-4 gM) resulted in a slight increase in
the EGFP expression (Figure 5.7), but higher drug doses monotonically reduced the
protein expression, as previously reported (37). This inhibitory effect of cisplatin on
the EGFP expression was enhanced in the presence of tsHMG, such that only a
decrease in fluorescence was observed upon exposure to the drug. Preliminary
experiments revealed that, under the conditions producing the greatest effect of
tsHMG on EGFP expression, significant apoptosis was not detectable (data not
shown).
Protection from Cisplatin-Induced Apoptosis. In order to explore further the
effects of tsHMG on cisplatin-induced apoptosis in HeLa cells, several different drug
treatment conditions were used. When the cells were exposed to cisplatin for two
hours and then incubated for 61 h, instead of 48 h as described above, slightly higher
levels of apoptosis were achieved but tsHMG sensitization of the HeLa cells was no
longer apparent (Table 5.1). Furthermore, when the drug-exposure time was
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extended to 3 h, the increase in apoptosis was accompanied by the opposite effect,
such that tsHMG seemed to be protecting the cells from cisplatin-induced
programmed cell death (Table 5.1). Finally, upon continuous exposure to cisplatin,
the tsHMG-expressing cells were more resistant to cisplatin-induced apoptosis than
the uninduced cells (Figures 5.8, 5.9 and Table 5.1). Some of the signaling pathways
activated during apoptosis involve a controlled activation of proteases (48), so it is
possible that the number of tsHMG-expressing apoptotic cells was artificially low
because the protein was degraded. This explanation is unlikely, however, since the
overall levels of tsHMG ,expression were not significantly reduced in the cisplatin-
treated samples of cells (Table 5.1).
Discussion
The mouse tsHMG protein exhibits strong affinity and specificity for the most
prevalent type of cisplatin-DNA adduct (33, 49), so it has the potential to affect
cellular responses to the platinum-induced genotoxic stress. To explore this
possibility, the influence of ectopic tsHMG expression on cisplatin cytotoxicity was
examined in several stable transfectant clones. No reproducible effect on cisplatin 9
inhibition of colony formation was observed when the HeLa cells were induced to
express tsHMG. Although the clonogenic assay is frequently used to provide
accurate information about the relative chemosensitivities of different cell types (50),
it does not distinguish between two of the possible responses to cisplatin, cell cycle
arrest and death (45). Since arrested cells can recover, the results from this assay do
not always reflect the ultimate consequences of toxic stress (51). Moreover, a closer
examination revealed that the nuclear tsHMG protein was expressed in only a
fraction of the cells, even though all of the clones were each isolated from a single
colony. The high background of non-expressing cells could preclude detection of the
effects of tsHMG on cisplatin cytotoxicity.
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Accordingly, to minimize the limitations of heterogeneous tsHMG expression,
a technique designed for the study of individual cells was used to investigate
cisplatin-induced apoptosis. Under drug treatment conditions that generated low
levels of apoptosis, expression of tsHMG sensitized the HeLa cells to cisplatin.
Furthermore transient transfection of tsHMG into HeLa cells enhanced the cisplatin-
dependent inhibition of the reporter gene expression. These results are consistent
with one of the models proposed to explain how HMG-domain proteins could
modulate the cytotoxicity of the cisplatin-DNA damage (52). The theory is that
HMG-domain proteins bind to the major cisplatin-DNA adducts and block repair or
other DNA-processing pathways. Diminished DNA repair would allow the adducts
to persist in the cell, block essential cellular pathways, such as transcription, and
activate programmed cell death. In support of the shielding hypothesis, the
differential cisplatin resistance of yeast cells lacking a native HMG-domain protein
was dependent on an intact nucleotide excision repair pathway (53). Furthermore,
HMG-domain proteins inhibit repair of the cisplatin-DNA cross-links (49, 54, 55),
replication bypass (56), and helicase activity (57), when added to in vitro assays, and
immunoprecipitation of HMG1/HMG2 from cell extracts enhanced repair synthesis
activity on cisplatin-modified plasmid DNA (58). Since the ubiquitous HMG-domain
proteins that are expressed in HeLa cells did not modulate the repair of cisplatin-
modified DNA (49, 59), it is unlikely that they are responsible for the variability in
disease response to cisplatin. However, many members of this protein family have a
distribution pattern limited to specific tissue types, such as testicular (23-30).
Moreover, the testis-specific proteins tested, tsHMG and hSRY, were the most
effective at blocking the in vitro repair of cisplatin-DNA adducts (49, 55).
The tsHMG-sensitization of HeLa cells to cisplatin was observed at low levels
of apoptosis. Although the difference between induced and uninduced cells was
significant and reproducible, it was not very large. Lengthening the post-treatment
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incubation time, in an effort to amplify this difference, actually diminished the effect.
This result suggests that the cells were sensitized by tsHMG only at the early stages
of apoptosis. It is therefore likely that the ability of the HMG-domain protein to block
repair or replicative bypass of the major cisplatin-DNA adducts is only temporary.
The tendency of DNA-binding proteins to dissociate from and reassociate to their
target site within a period of seconds to hours (for example, see 60-62) would, over
time, provide opportunities for the repair proteins to access and remove the lesions,
allowing the cell to recover from the effects of the damage.
Longer exposure times to cisplatin were also investigated, and under these
conditions tsHMG expression appeared to protect the HeLa cells from cisplatin-
induced apoptosis. This observation supports an alternative model to the shielding
hypothesis described above, which involves the variety of cellular proteins that
specifically recognize cisplatin-modified DNA including transcription factors,
architectural components, and elements of several repair pathways (13, 14). The
genetic damage ensuing from cisplatin exposure may divert these essential proteins
away from their natural target sites and prevent them from accomplishing their
designated functions. For example, it has recently been demonstrated that both the
ribosomal transcription factor, hUBF, and the basal transcription factor, TBP, are
titrated away from in vitro transcription activity by cisplatin-modified DNA (63-66).
Elevated expression of a protein such as tsHMG, which also binds to cisplatin-DNA
adducts, could conceal the lesions and alleviate the lethal consequences, such as
transcription inhibition, arising from the titration of critical cellular factors.
It is also feasible that tsHMG influences cellular responses to cisplatin through
a mechanism that does not involve direct interaction with platinum-DNA adducts.
The function of tsHMG has not yet been established, although the protein modulates
DNA packaging and processing in a topoisomerase I-dependent fashion (31). HMG-
domain proteins act in a variety fundamental pathways through their ability to
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distort DNA conformation and facilitate the assembly of multi-protein complexes (15,
16). Members of this family can functionally interact with nuclear hormone receptors
(67, 68), HOX proteins (69), the DNA-dependent protein kinase (70), TBP (71),
octamer transcription factors (72), and a variety of other general transcription
regulators (73-76). Moreover, several connections have been made between HMG-
domain proteins and the programmed cell death pathway, including interactions
with the tumor suppressor proteins p53 and Rb (77, 78), stimulation of an apoptotic
nuclease activity (79), and modulation of the apoptotic response to cellular stress (80).
Thus, flooding the nucleiof HeLa cells with an HMG-domain protein could intensify
or diminish one of the intrinsic reactions to the cisplatin damage. It should be noted
that these experiments involved ectopic expression of a mouse protein in human
cells. The human homologue of the nuclear tsHMG has not yet been detected (81), so
it is not clear whether the effects of specific protein-protein interactions fully apply to
this system.
The tsHMG protein exerts two different effects on cisplatin-induced apoptosis
in HeLa cells. At the early stages of a low but lethal drug dose, tsHMG enhances cell
death, but the protein plays the opposite role if the drug exposure time is extended.
The importance of drug dose severity on how tsHMG can influence the cellular
response may reflect the clinical usage of cisplatin. As with many other
chemotherapeutic agents, the effectiveness of cisplatin is undermined both by the
development of resistance and by a variety of deleterious side effects (2, 82). The
balance required between toxic and antineoplastic activities results in a fairly
constrained window of acceptable cisplatin doses (83, 84). Small variations in cell
responses within the tumor-specific range, such as that observed in the HeLa cells
expressing tsHMG, could have significant consequences in the potency of the
anticancer therapy. Beyond the tolerable dose, it is possible that other response
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signals become dominant, and cisplatin kills the cells through a different, generally
cytotoxic, mechanism.
The results presented here support the notion that an HMG-domain protein
can modulate cellular responses to cisplatin, but further experiments are required to
resolve the mechanisms underlying the divergent effects. As discussed above, many
HMG-domain proteins are expressed in specific tissue types, and several members of
this family, including the testis-specific SRY, have been detected in human tumors
(85-88). Furthermore, since the process of tumorigenesis frequently involves gene
amplification and changes in protein expression (89), particular HMG-domain
proteins could be expressed in tumors at levels distinct from the tissue of origin. The
experiments presented here and elsewhere indicate that it would be informative to
examine the expression levels of various HMG-domain proteins in normal and
malignant tissue to determine whether or not there is any correlation with cisplatin
sensitivity.
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Table 5.1. Representative examples of cisplatin-induced apoptosis in tsHMG
expressing cells. The HeLa cells were induced with doxycyline for 2-3 days prior to
drug treatment. Immunofluorescence and TUNEL assays were performed as
described in Materials and Methods. Each number is the average of at least 3 data
points ± esd.
Exposure a [Cisplatin] Dox % Apoptotic p % expressing
(jiM) +tsHMG -tsHMG
2h+48h 0 + 1.9 0.79 1.9 ±0.69 32 ±2.4
10 - 10 ± 0.42 0.35 ±0.26
5 + 12 1.8 8.9 ± 0.41 <0.05 32 ±3.0
10 + 14 2.7 8.3 ± 0.83 <0.05 31 ±1.9
2h+61h 0 + 37 ±8.8
10 - 25 ±3.3 2.7 ±0.63
10 + 22 ±3.7 18 ±1.6 <0.2 29 ±0.55
3h+61h 0 + 2.8 ±0.42 3.0 ±0.21 31 ±1.6
5 + 23 ±0.90 23 ±2.20 32 ±4.0
10 + 21 ± 2.06 27 ±0.25 <0.01 31 ± 2.1
24 h 0 + 0.50 ±0.47 0.67± 0.11 38 ±2.3
10 - 33 0.62 3.2 ±0.42
10 + 10±2.22 35 4.4 <0.01 36 ±1.6
37 h 0 + 1.9 ±0.17 2.7 0.89 32 ±3.2
5 - 19 ±2.5 0.41± 0.71
5 + 6.8 ± 2.07 23 ±3.7 <0.01 37± 2.2
10 + 27 ± 4.70 62 ±3.0 <0.001 38 ±2.8
aExposure indicates the drug treatment conditions. In the first three sets of conditions, the cells were
exposed to cisplatin for a short time, washed, and then incubated in fresh media. A single time means
that the cells were treated continuously with cisplatin.
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Figure 5.1. Schematic of gene regulation by the Tet-On system. The "reverse" Tet
repressor (rTetR), fused to the VP16 acivation domain of herpes simplex virus,
binds the tet-responsive element (TRE) in the presence of tetracycline or
doxycycline (Dox). The minimal CMV promoter is silent in the absence of TRE
activation, so tsHMG is only expressed in the presence of Dox.
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Figure 5.2. Inducible tsHIMG expression in HeLa cells. Three different clones of
HeLa cells transfected with pTRE-tsHMG were exposed for the indicated
concentrations of doxycycline (Dox). After a 24 h induction, cell extracts were
prepared, resolved on a 10% SDS-polyacrylamide gel, and transferred to
Immobilon-P membrane. Western blot analysis was performed with the mtTFA
antiserum as described in Materials and Methods.
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Figure 5.3. Colony formation assays. Two different clones of tsHMG-expressing 6
HeLa cells, ts4l (squares) and ts2 (triangles), or HeLa cells transfected with the
control vector, pTRE (circles), were induced with doxycycline (Dox, filled
symbols) for 3 days before either (A) continuous or (B) a 2 h exposure to
cisplatin. For each cell line (induced or uninduced), the numbers were
normalized to the untreated data point. Each experiment was performed in
triplicate, error bars represent ± 1 esd.
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Figure 5.4. Immunofluorescence of HeLa cells transfected with the control pTRE
vector. Transfected cells were either untreated (top) or exposed to doxycycline
(Dox) for 2 days (bottom) while growing on coverslips. Immunofluorescence (left)
was performed as described in Materials and Methods, except the primary antibody
was used at a 50-fold dilution, and the secondary antibody was a fluorescein
isothiocyanate (FITC) conjugate. The cells were also stained with DAPI (right).
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Figure 5.5. Immunofluorescence of HeLa cells transfected with the pTRE-tsHMG
vector. Transfected cells were either untreated (top) or exposed to doxycycline
(Dox) for 2 days (bottom) while growing on coverslips. Immunofluorescence (left)
was performed as described in Materials and Methods, except the primary antibody a
was used at a 50-fold dilution, and the secondary antibody was a fluorescein
isothiocyanate (FITC) conjugate. The cells were also stained with DAPI (right).
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Figure 5.6. The tsHMG protein sensitizes HeLa cells to cisplatin-induced apoptosis.
HeLa cells containing the tsHMG gene were induced with doxycycline for 48 h,
plated onto 6-well dishes, and induced for an additional 24 h. The cells were then
exposed to 10 gM cisplatin for 2 h, washed, and incubated for 48 h. The
immunofluorescence (top left), TUNEL (top right), and DAPI staining (bottom
right), were performed as described in Materials and Methods. The bottom left
panel is an overlay of the rhodamine (immunofluorescence) and fluorescein(TUNEL) pictures. The bar represents 50 gm.
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Figure 5.7. Effect of tsHMG on cisplatin inhibition of EGFP expression in HeLa.
The cells were transiently transfected with 6 gg pcDNA3.1-tsHMG or pcDNA
3.1. Following a 13.5 h induction with doxycycline and concurrent exposure to
the indicated concentrations of cisplatin, the cells were lysed and the EGFP
fluorescence was determined and normalized to total protein content. The
experiment was performed in triplicate, error bars represent ± 1 esd.
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Figure 5.8. The tsHMG protein protects HeLa cells from cisplatin-induced
apoptosis. HeLa cells containing the tsHMG gene were either uninduced
(left) or induced with doxycycline (right) for 48 h prior to treatment with
10 gM cisplatin for 24 h. The immunofluorescence (top) was performed
with a rhodamine-conjugated secondary antibody, TUNEL (middle) was
performed with fluorescein labeled dUTP, and the cells were also stained
with DAPI (bottom), as described in Materials and Methods.
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Figure 5.9. The tsHMG protein protects HeLa cells from cisplatin-induced
apoptosis. HeLa cells containing the tsHMG gene were induced with doxycycline
for 48 h prior to a 24 h exposure 10 gM cisplatin. The immunofluorescence(top
left), TUNEL (top right), and DAPI staining (bottom right), were performed as
described in Materials and Methods. The bottom left panel is an overlay of the
rhodamine (immunofluorescence) and fluorescein (TUNEL) pictures. The bar
represents 50 gm.
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